New Century Healthcare Holding Co. Limited
新世紀醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)
Stock Code: 1518

2021 ANNUAL REPORT

Contents

Corporate Information

DIRECTORS

Executive Directors:

Mr. Jason ZHOU *(Chairman and Chief Executive Officer)*
Ms. XIN Hong *(Senior Vice President and Chief Operating Officer)*
Mr. XU Han *(Senior Vice President and Chief Financial Officer)*

Non-executive Directors:

Mr. GUO Qizhi
Mr. WANG Siye
Dr. CHENG Chi-Kong, Adrian *JP*
Mr. YANG Yuelin
Mr. XIE Qiang

Independent Non-executive Directors:

Mr. WU Guanxiong
Mr. SUN Hongbin
Mr. JIANG Yanfu
Dr. MA Jing

AUDIT COMMITTEE

Mr. SUN Hongbin *(Chairman)*
Mr. GUO Qizhi
Mr. JIANG Yanfu

REMUNERATION COMMITTEE

Mr. WU Guanxiong *(Chairman)*
Dr. MA Jing
Mr. YANG Yuelin

NOMINATION COMMITTEE

Mr. Jason ZHOU *(Chairman)*
Mr. WU Guanxiong
Mr. JIANG Yanfu

AUTHORIZED REPRESENTATIVES

Mr. XU Han
Mr. JIA Xiaofeng

COMPANY SECRETARY

Mr. JIA Xiaofeng

HEADQUARTERS AND PRINCIPAL PLACE OF BUSINESS IN CHINA

56 Nanlishi Road
Xicheng District
Beijing
PRC

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Unit 603A, 6/F, Tower 1
Admiralty Centre
18 Harcourt Road
Hong Kong

REGISTERED OFFICE

c/o Walkers Corporate Limited
190 Elgin Avenue
George Town
Grand Cayman KY1-9008
Cayman Islands

Corporate Information (Continued)

CAYMAN ISLANDS PRINCIPAL SHARE REGISTRAR AND TRANSFER AGENT

Walkers Corporate Limited
190 Elgin Avenue
George Town
Grand Cayman KY1-9008
Cayman Islands

HONG KONG SHARE REGISTRAR

Computershare Hong Kong Investor Services Limited
Shops 1712-1716, 17th Floor
Hopewell Centre
183 Queen's Road East
Wanchai
Hong Kong

AUDITOR

PricewaterhouseCoopers
Certified Public Accountants and Registered PIE Auditor
22/F, Prince's Building
Central, Hong Kong

LEGAL ADVISERS

Zhong Lun Law Firm LLP
4th Floor, Jardine House,
1 Connaught Place, Hong Kong

PRINCIPAL BANKER

Bank of China, Beijing Finance Street Sub-branch
2/F, Investment Square
No. 27 Finance Street
Xicheng District
Beijing

STOCK CODE

01518

COMPANY WEBSITE

www.ncich.com.cn

Chairman's Statement

Dear Shareholders,

On behalf of the Board, I am pleased to present the annual report of the Group for the year ended December 31, 2021.

In 2021, the Group's annual revenue recorded a remarkable increase compared with the same period in 2020, especially in revenue from the pediatrics, which was mainly due to the development of pediatric multi-specialty clinical services and refined customer operation management. At the same time, the revenue from obstetrics and gynecology in Beijing also increased compared with 2019, which was mainly due to the advantages of our obstetrics and gynecology medical technology and the multi-specialty synergy advantages of obstetrics, pediatric and gynecology which have been recognized by the market and customers, thus promoting the increase in the unit price of obstetrics and gynecology customers in Beijing.

The population and health of children are of strategic importance to the long-term development of the country's national strength. With the implementation of the two-child policy in 2015, the issuance of the "Outline of the Healthy China 2030 Plan" in 2016 and the "three-child policy" in 2021, the state raises the promotion of population growth, the improvement of prenatal and postnatal care and the promotion of healthy growth of children to unprecedented heights, and has frequently issued policy guidance and support. In addition, with the rise of women's first childbearing age and the increase in the number of pregnant and parturient women with advanced maternal age giving birth to the second and third children, Chinese families have great demands for medical technology, medical safety, service quality and one-stop, continuous health management for women and children, which also provides us with broad development space.

As a multi-specialty medical group with the competitive advantage of providing a full range of pediatric services, we have high-quality and scarce medical team resources, leading clinical technology and service concept, and we can provide common and complex disease diagnosis and treatment and health management services for women's and children's families, and thus are trusted by women's and children's families. By the end of 2021, we have served nearly 360,000 women's and children's families and served 260,000 hospital attendance in 2021. Among them, our pediatric family doctor members and commercial insurance direct payment customers contribute to over 50% of revenue from pediatric medical services.

Chairman's Statement (Continued)

Combined with the advantages of medical technology, we are committed to continuously developing innovative medical service content and methods according to the needs of target customers, such as management of child growth and development package, sub-specialty service package (optometry, oral cavity, endocrinology, etc.), surgical package, specialist night clinic service, etc.. We received positive feedback from customers. In 2021, we recorded a rapid growth in the number of customers served and revenue in both pediatric surgery and pediatric specialty services, with a combined revenue increase of 40.7% and 25.1% compared to 2020 and 2019, respectively. In order to further enhance the customer visit experience, dig deep into customer needs and improve customer stickiness, we established a medical technology company in 2018 to develop and empower physical medical institutions around the four dimensions of medical information construction, intelligent data analysis, customer continuous management and intelligent marketing, and completed phased research and development in the second half of 2021. We are confident that the integrated digital management platform of the medical technology company can effectively empower physical medical institutions to reach, serve and manage customers, thereby enhancing our market competitiveness.

Last but not least, on behalf of the Board of the Company, I would like to express our gratitude towards all our customers, partners and shareholders for their long-term support and trust, as well as our frontline medical staff and colleagues who are sticking to their posts. Looking forward, we will continue to provide high-quality medical services for women's and children's families in the PRC, actively explore the market, seize the opportunities arising from government policies to further develop our business, contribute to the implementation of the national strategy of Healthy China, and create sustainable value return for the shareholders.

Jason ZHOU
Chairman

Beijing, March 28, 2022

Management Discussion and Analysis

BUSINESS OVERVIEW AND OUTLOOK

Business Overview for 2021

For the year ended December 31, 2021, the Group witnessed a significant increase in business revenue compared with the same period last year. The Group recorded a revenue of RMB632.6 million, representing a 23.4% YoY increase. The revenue from medical services recoded a 25.3% YoY increase to RMB621.3 million, among which, the revenue from pediatric services recorded a 37.0% YoY increase to RMB504.1 million, accounting for 81.1% of the total revenue from medical services. The revenue from pediatric outpatient services recorded a 49.5% YoY increase to RMB302.1 million. The number of pediatric services outpatient visits was 204,535, representing a 36.2% YoY increase. The revenue from pediatric inpatient services recorded a 34.0% YoY increase to RMB162.5 million. The number of pediatric inpatient visits was 5,834, representing a 24.7% YoY increase.

As a leading private medical service provider in Beijing and the PRC, we provide customers with integrated medical services of gynecology, obstetrics and pediatrics, and are characterized by providing comprehensive and in-depth pediatric medical services. The rapid recovery of pediatric business is mainly due to 1) the Group's strengthening of clinical deployment, product and service organization and service promotion of pediatric surgery and pediatric specialties (mainly including ophthalmology, otolaryngology, stomatology, dermatology, etc.); 2) strengthening the buildup of commercial insurance team and actively developing commercial insurance business; and 3) with the help of digital customer operation and management, improving customer reach and enhancing customer visit experience, so as to improve customer stickiness. For the year ended December 31, 2021, the revenue from pediatric surgery services and pediatric specialties services increased by 40.7% compared with the year of 2020, and increased by 25.1% compared with the year of 2019. The combined contribution to the revenue from pediatric outpatient and inpatient services increased from 31.5% to 42.0% compared to the year of 2019. In addition, the revenue from the direct payment of commercial insurance in the pediatric business recorded a 93.9% YoY increase, and the contribution to the revenue from the pediatrics increased from 19.7% to 25.8% compared with the year of 2019. The combined revenue of pediatric membership and commercial insurance direct payment accounts for over 50% of revenue from pediatric services, reflecting a customer base with consumption power. The revenue from obstetrics and gynecology business recorded a 8.2% YoY decrease to RMB117.2 million, which was mainly affected by the decline of obstetrics and gynecology business.

The net loss of the Group amounted to RMB85.3 million, while that was RMB377.5 million for the year ended December 31, 2020. The adjusted net loss[1] of the Group amounted to RMB67.9 million.

As the impact of the pandemic on some of the newly opened clinics prior to COVID-19 pandemic (the "COVID-19") is significant and persistent, we have made a number of operational adjustments to these continuing loss-marking clinics. For the year ended December 31, 2021, the revenue from the Operating Medical Institutions amounted to RMB626.8 million, representing an increase of 25.4% compared to the year of 2020. The adjusted EBITDA[1][2] of the Operating Medical Institutions was RMB147.6 million, representing an increase of approximately 21.3% compared with RMB121.7 million in the same period last year. The increase in revenue and adjusted EBITDA[1][2] was mainly due to the increase in profit in Beijing.

(1) Adjustment includes impairment losses on non-current assets, exchange gains and losses and RSA Scheme.

(2) EBITDA = profit before income tax + interest expense + depreciation and amortisation.

Industry Outlook and the Group's Strategies

According to the Seventh National Census in 2020, as of November 2020, there were 254 million children aged 0-14 in the PRC, accounting for 18.0% of the total population, representing an increase of 1.5 percentage points as compared with 2015. Among which, the population of children aged 0-4 and 5-14 both recorded an increase. The population and health of children are of strategic importance to the long-term development of the country's national strength. However, the supply of specialized medical care for children is still scarce. At present, there are around 140,000 pediatricians in the PRC, serving 254 million children. The average number of pediatricians per 1,000 children is 0.56, while the average number of doctors in the PRC per 1,000 people is 2.3. There is still a shortage of over 100,000 pediatricians. With the implementation of the two-child policy in 2015 and the three-child policy in 2021, the state attaches great importance to the training of pediatricians and the development of pediatric medical services. In 2016, the state included the training of pediatricians into the "13th Five-Year Plan" and strengthened the recruitment and training of pediatricians to address the lack of professionals in pediatrics. The first method was the standardized training of pediatric residents, bringing pediatrics into the professional catalogue of standardized training of residents. After the implementation of this policy, the number of pediatric personnel training has increased significantly. The second method was deepening the collaborative reform of medical education with the Ministry of Education, putting forward clear requirements for colleges and universities, and strengthening the training of pediatric professionals. The third method was strengthening the on-the-job training and continuing education of medical personnel. In the "14th five-year plan" issued in 2021, it is even clear to improve the training quality and scale of medical staff and expand the number of doctors in shortage in pediatrics and general practice.

In addition, the state also attaches great importance to children's health. In 2016, the "Outline of the Healthy China 2030 Plan" was issued, which included the requirements for children's and adolescents' myopia prevention and control, mental health, oral health and health management for children aged 0-6. Policy guidance at the national level has greatly contributed to raising public awareness of children's health management, and has also triggered a significant increase in demand for children preventive care, growth and development management, and pediatric specialties. Pediatric medical services have transformed from demand for pediatric disease treatment in the past to that for diversified, niche, and personalized medical and health management. With the upgrading of children's families health consumption after the pandemic and the increasing interests of children's families in commercial insurance, new opportunities have been brought to the growth of children healthcare market.

Adhering to the previously formulated development strategies, the Group intends to grasp the industry opportunities by implementing the following measures in 2022:

- Building on the competitive advantages of cooperation from multiple disciplines in pediatrics, focus on the construction of pediatric subspecialties, and develop its product and service chain centering around the medical and health needs of customers.

- Strengthen marketing and cooperation with insurance institutions to expand the coverage of the target customer base.

- Empower offline physical medical institutions through technology companies and promote upgrading of operational structure and customer management system, and complete the in-depth integration of professional medical clinical pathway covering pre-treatment, treatment and post-treatment with customer operation to enhance customer experience and stickiness in all aspects.

- Optimize the organizational structure and talent management, strengthen cost control and implement employee incentive plans in due course in accordance with the Group's development strategy.

FINANCIAL REVIEW

Segment Revenue

We generate revenue primarily from providing (i) medical services, including pediatric services and obstetric and gynecologic services, and (ii) hospital consulting services. The following table sets forth a breakdown of the revenue for the periods indicated:

	Year ended December 31,			
	2021		2020	
	(in thousands of RMB, except percentages)			
Medical services	621,321	98.2%	495,769	96.7%
Hospital consulting services	4,620	0.7%	8,531	1.7%
Others[(1)]	6,624	1.1%	8,485	1.6%
Total	632,565	100%	512,785	100.0%

(1) Include revenue from cafeteria and gift shop sales at our medical institutions and online healthcare services after intersegment elimination.

Medical Services

Our revenue from the provision of medical services consists of healthcare services fees and revenue from pharmaceutical sales. The following table sets forth the revenue, cost of revenue, gross profit and gross profit margin of our medical services for the periods indicated:

	Year ended December 31,	
	2021	2020
	(in thousands of RMB, except percentages)	
Revenue	621,321	495,769
Cost of revenue	425,351	363,605
Gross profit	195,970	132,164
Gross profit margin	31.5%	26.7%

The following table sets forth the composition of our revenue from pediatric and obstetric and gynecologic services for the periods indicated:

	Year ended December 31,			
	2021		2020	
	(in thousands of RMB, except percentages)			
Pediatric services	504,081	79.7%	368,015	71.8%
Obstetric and gynecologic services	117,240	18.5%	127,754	24.9%
Total	621,321	98.2%	495,769	96.7%

Management Discussion and Analysis (Continued)

Our medical services can also be classified by service to inpatients and outpatients and membership card sales. The following table sets forth revenue and certain data relating to such classification for the periods indicated:

	Year ended December 31,	
	2021	2020
The Group		
Inpatient services		
Inpatient visits	8,158	7,581
Average inpatient spending per visit (RMB)	27,801	26,864
Outpatient services		
Outpatient visits	253,813	193,039
Average outpatient spending per visit (RMB)	1,399	1,281
Revenue from medical services attributable to inpatients *(RMB'000)*	226,801	203,656
Revenue from medical services attributable to outpatients *(RMB'000)*	354,979	247,322
Revenue recognized for membership card sales *(RMB'000)*	39,541	44,791
Pediatric Services		
Inpatient services		
Inpatient visits	5,834	4,677
Average inpatient spending per visit (RMB)	27,848	25,916
Outpatient services		
Outpatient visits	204,535	150,207
Average outpatient spending per visit (RMB)	1,477	1,345
Revenue from medical services attributable to inpatients *(RMB'000)*	162,467	121,207
Revenue from medical services attributable to outpatients *(RMB'000)*	302,073	202,017
Revenue recognized for membership card sales *(RMB'000)*	39,541	44,791
Obstetric and gynecologic services		
Inpatient services		
Inpatient visits	2,324	2,904
Average inpatient spending per visit (RMB)	27,682	28,391
Outpatient services		
Outpatient visits	49,278	42,832
Average outpatient spending per visit (RMB)	1,074	1,058
Revenue from medical services attributable to inpatients *(RMB'000)*	64,334	82,449
Revenue from medical services attributable to outpatients *(RMB'000)*	52,906	45,305

Revenue from provision of our medical services amounted to RMB621.3 million in 2021, representing a 25.3% YoY increase and accounting for 98.2% of the Group's total revenue. This increase was primarily due to (i) a 43.5% and 11.4% YoY increase in revenue from medical services attributable to the outpatients and inpatients respectively; and (ii) a 11.7% YoY decrease in revenue recognized for membership card sales.

In 2021, there were 5,834 pediatric services inpatient visits, representing a YoY increase of 24.7%. There were also 204,535 pediatric services outpatient visits, representing a YoY increase of 36.2%. For obstetric and gynecologic services, there were 2,324 inpatient visits, representing a YoY decrease of 20.0%, and 49,278 outpatient visits, representing a YoY increase of 15.0%.

The cost of revenue of our medical services consists primarily of employee benefits expenses, cost of inventories and consumables, consultation fees, outsourced examination and inspection fees and utilities, maintenance fees and office expenses. The cost of revenue of our medical services in 2021 reached RMB425.4 million, representing a YoY increase of 17.0%. This increase was primarily because (i) with the increased business, measures including optimizing personnel structure and working hours arrangement which were in place in 2020 in response to the COVID-19 Outbreak and the government relief on social security contribution were canceled in 2021, which led to an increase in personnel wages, and (ii) costs of medicines, consumables and specialists increased due to increase in business volume.

Hospital Consulting Services

We also generate a portion of our revenue from providing hospital consulting services. The following table sets forth the revenue, cost of revenue, gross profit and gross profit margin of our hospital consulting services for the periods indicated:

	Year ended December 31,	
	2021	2020
	(in thousands of RMB, except percentages)	
Revenue	4,620	8,531
Cost of revenue	885	5,065
Gross profit	3,735	3,466
Gross profit margin	80.8%	40.6%

The gross profit and the gross profit margin of our hospital consulting services for the year ended December 31, 2021 were RMB3.7 million and 80.8% respectively. Consulting services this period is mainly composed of the charge for use of brand, so the gross profit has been greatly improved.

Gross Profit and Gross Profit Margin

Our gross profit in 2021 amounted to RMB 198.7 million, representing a YoY increase of 46.4%. This was primarily because of the increase of pediatric services outpatient visits. Our gross profit margin increased from 26.5% in 2020 to 31.4% in 2021.

Selling Expenses

Our selling expenses in 2021 amounted to RMB60.8 million, representing a YoY increase of 38.0%. This was mainly due to the increase in the costs of staff remuneration.

Administrative Expenses

Our administrative expenses in 2021 amounted to RMB156.4 million, representing an increase from RMB123.3 million in 2020. Such increase was mainly a result of increase in personnel wages due to cancellation of measures including optimization of personnel structure and employees' working hours arrangement, which were in place in 2020 in response to the COVID-19 Outbreak and cancellation of government relief on social security contribution in 2021.

Research and Development Expenses

The expenses for research and development of the Group were RMB10.6 million, compared with RMB14.5 million in the same period last year. This decrease was mainly due to the reduction of research and development activities.

Impairment Loss of Non-current Assets

During the reporting period, the Group recorded an impairment loss of RMB15.0 million in property, plant and equipment. The impairment loss was mainly related to the impairment of assets and was caused by our decision to spin off BNC Qingnian Road Clinic, Chengdu Xinyi Health Management Co., Ltd., BNC Chaowai Clinic and New Century Healthcare (Hong Kong) Co. Limited.

Other Gains – Net

Our other net gains in 2021 amounted to RMB3.2 million as compared to other net gains of RMB4.0 million in 2020. Our other net gains in 2021 were a net result of gains from change in leases and retirement of fixed assets and intangible assets.

Finance Income and Expenses

Our finance income in 2021 decreased from RMB3.3 million in 2020 to RMB3.1 million, which was mainly a result of a decrease in deposit interest. Our finance expenses in 2021 decreased from RMB23.3 million in 2020 to RMB16.7 million, which was mainly a result of (i) a decrease of foreign exchange losses of RMB5.2 million, and (ii) a decrease in interest expenses and finance charges paid/payable for lease liabilities of RMB1.9 million.

Income Tax Expense

Our income tax expense in 2021 amounted to RMB26.1 million, representing a YoY decrease of 46.5%. This was mainly because there was no reversal of deferred tax assets related to accumulated tax losses during the year.

Due to the loss-making result for the years ended December 31, 2021 and 2020, the effective tax rate is not applicable.

Loss for the year ended December 31, 2021

Our loss attributable to the owners of the Company for the year ended December 31, 2021 amounted to RMB101.5 million, as compared to a net loss attributable to the owners of the Company of RMB371.4 for the year ended December 31, 2020.

FINANCIAL POSITION

Inventories

Our inventories increased by 7.7% from RMB19.6 million as of December 31, 2020 to RMB21.1 million as of December 31, 2021 primarily due to the increase of requisite medical inventories as a result of the growth of business of the Group's medical institutions.

Trade Receivables

Our trade receivables increased by 37.8% from RMB28.6 million as of December 31, 2020 to RMB39.4 million as of December 31, 2021 primarily driven by an increase in revenue from medical services.

Trade Payables

Our trade payables increased by 7.0% from RMB25.6 million as of December 31, 2020 to RMB27.4 million as of December 31, 2021 primarily due to an increase in business volume.

LIQUIDITY AND CAPITAL RESOURCES

Cash and Cash Equivalents

As of December 31, 2021, we had cash and cash equivalents of RMB223.8 million (December 31, 2020: RMB299.2 million). We did not have any interest-bearing borrowings as of December 31, 2021 (December 31, 2020: nil).

Significant Investments, Acquisitions and Disposals

We did not have any significant investments, material acquisitions or material disposals in the year ended December 31, 2021.

Capital Expenditures

Our capital expenditures primarily include expenditures on (i) property, plant and equipment, comprising buildings and construction, leasehold improvements, medical equipment, furniture and office equipment and motor vehicles; and (ii) intangible assets such as computer software relating to our operations. The amount of our capital expenditures in 2021 was RMB13.2 million (2020: RMB11.2 million), which was mainly attributable to the upgrade of existing medical institutions.

INDEBTEDNESS

Borrowings

As of December 31, 2021, we did not have any borrowings (2020: nil).

Exposure to Fluctuations in Exchange Rates

We mainly operate in the PRC with most of the transactions settled in RMB. Foreign exchange rate risk arises when recognised assets and liabilities are denominated in a currency that is not the entity's functional currency. On December 31, 2021, our assets and liabilities are primarily denominated in RMB, except for certain cash and cash equivalent denominated in USD or HKD and dividend payable denominated in HKD. We have not used any derivative financial instrument to hedge against our exposure to foreign exchange risk but will closely monitor such risk on an ongoing basis.

Contingent Liabilities

As of December 31, 2021, we did not have any contingent liabilities or guarantees that would have a material impact on our financial position or results of operations.

Pledge of Assets

As of December 31, 2021, none of our assets had been pledged.

Contractual Obligations

As of December 31, 2021, we did not have any contractual obligations that would have a material effect on our financial position or results of operations.

Financial Instruments

Our major financial instruments include trade receivables, other receivables excluding prepayments, amounts due from related parties, cash and cash equivalents, trade payables, other payables excluding non-financial liabilities and amounts due to related parties. Our management manages such exposure to ensure appropriate measures are implemented in a timely and effective manner.

Gearing Ratio

As of December 31, 2021, our gearing ratio, calculated as total borrowings divided by total equity, is not applicable (December 31, 2020: Not applicable).

USE OF IPO PROCEEDS

The net proceeds received by the Company from the global offering amounted to HK$857.2 million after deducting underwriting commissions and all related expenses, which have been and will be used in the manner consistent with that mentioned in the section headed "Future Plans and Use of Proceeds" of the prospectus of the Company dated December 30, 2016 and the announcements of the Company dated December 6, 2017 and March 25, 2019 regarding the change in use of proceeds.

The expected timeline of the intended use of the unutilized proceeds, subject to the then management assessment and market landscape, is set out as below:

Item	Net proceed as of March 31, 2021 *(HK$ million)*	Utilized between March 31, 2021 to March 31, 2022 *(HK$ million)*	Unutilized as of March 31, 2022 *(HK$ million)*	Expected timeline of the intended use of the unutilized proceeds, subject to the then management assessment and market landscape
Setting up, renovation and acquisition of new hospitals and clinics and the required working capital for such new hospitals and clinics	186.0	69.1	116.9	The remaining amount is expected to be fully utilized by the end of 2023.
Investment in surgery center and medical service technologies (including online diagnosis)	49.7	49.7	–	–
Total	235.7	118.8	116.9	

EMPLOYEE AND REMUNERATION POLICY

On December 31, 2021, the Group had 1,401 employees (December 31, 2020: 1,352 employees). Total staff remuneration expenses including Directors' remuneration in 2021 amounted to RMB322.5 million (FY2020: RMB263.8 million). Remuneration is determined with reference to performance, skills, qualifications and experience of the staff concerned and in accordance with the prevailing industry practice. On top of salary payments, other staff benefits include social insurances and housing provident contributions made by the Group, performance-based compensation and discretionary bonus. The Group has adopted the RSA Scheme and the Employee Share Scheme to attract, retain and motivate our key employees.

The remuneration of the Directors is reviewed by the Remuneration Committee and approved by the Board. The relevant Director's experience, duties and responsibilities, time commitment, performance at the Company and the prevailing market conditions are taken into consideration in determining the emolument of the Directors.

FINAL DIVIDEND

The Board does not recommend the payment of a final dividend for the year ended December 31, 2021 (2020: nil).

Directors and Senior Managements

DIRECTORS

Executive Directors

Mr. Jason ZHOU, aged 57, is the founder of our Group, a Controlling Shareholder and has been an executive Director, the Chief Executive Officer and the Chairman of our Group since August 2015. He is also the chairman of the Nomination Committee. Since Mr. Zhou founded our Group in 2002, he has been leading our Group for over 19 years to serve in the private healthcare industry. Mr. Zhou has been the driving force behind our development, growth and expansion and is primarily responsible for the overall management of our Group and directing the strategic development and business plans of our Group. Mr. Zhou is currently a director of Jiahua Yihe.

Mr. Zhou obtained his bachelor's degree in Electrical Engineering in July 1987.

Ms. XIN Hong (辛紅), aged 52, has been an executive Director since February 2016. In April 2016, she was also appointed as Senior Vice President and Chief Operating Officer of the Group. She is primarily responsible for overseeing the management and operation of the Group's hospitals and overall business, including assisting in obtaining relevant regulatory approvals, as well as being involved in the design and construction of the Group's hospitals, the Group's decision making process and organizational structure, and the management of day to day operations. Ms. Xin is a director of Jiahua Yihe, BNC Children's Hospital, Chengdu New Century Women's and Children's Hospital and certain other subsidiaries of the Group.

Ms. Xin began working with Mr. Zhou in August 2002, undertaking preparatory work for the establishment of the Group. Ms. Xin has been the chief operating officer and project director of BNC Children's Hospital following its establishment in December 2002, being primarily responsible for the preparation of the hospital's projects, commercial negotiations on behalf of the hospital, market development and the implementation of international best practice standards in the Group's hospitals.

Ms. Xin has more than 19 years of experience in hospital operations management and took up a number of positions in our Group throughout her current tenure. Ms. Xin has represented the Group in international medical exchanges and its participation in international and regional health organizations.

Ms. Xin is a guest lecturer on hospital management at Peking University, and has on several occasions addressed the general assembly at the annual meeting of China's private hospitals.

In June 2015, Ms. Xin was elected as a member of the Standing Committee of the Private Hospital Management Branch of the Chinese Hospital Association. Ms. Xin obtained a college degree in English from Beijing Institute of Aeronautics, Beijing (presently known as Beihang University) in July 1990.

Directors and Senior Managements (Continued)

Mr. XU Han (徐瀚), aged 50, joined our Group in October 2005 and has been an executive Director since February 2016. In April 2016, he was appointed as Senior Vice President of the Group. Mr. Xu serves as the Group's Chief Financial Officer, with overall responsibility for the financial management of each member of the Group and the Group's investment and financing activities, as well as overseeing the Group's internal controls and information technology. Mr. Xu is a director of Jiahua Yihe, BNC Women's and Children's Hospital, BNC Harmony Clinic, Chengdu New Century Women's and Children's Hospital and certain other subsidiaries of the Group.

Prior to joining our Group, Mr. Xu served as the group chief financial officer of United Family Healthcare Group (和睦家醫院集團) between July 2003 and September 2005, with primary responsibility for financial management of the hospitals and clinics in its Beijing and Shanghai network. Mr. Xu held the position of senior financial analyst at Intel (China) Co., Ltd. from December 2000 to May 2001. Between July 2001 and June 2003, Mr. Xu held the role of senior finance manager of Beijing Powerise Technology Co., Ltd. (北京創智科技有限公司), a subsidiary of Shenzhen Stock Exchange – Listed Powerise Information Technology Co., Ltd. Mr. Xu was also a financial analyst at China Hewlett Packard Co., Ltd. from October 1997 to October 2000. Mr. Xu served as a senior financial analyst in the consulting arm of Deloitte in Beijing from August 1996 to October 1997. Between August 1994 and July 1996, Mr. Xu worked in the finance department of China International Telecommunication Construction Corporation (中國通信建設總公司) in Beijing.

Mr. Xu obtained his bachelor's degree in Economics from the Harbin Institute of Technology (哈爾濱工業大學) in July 1994.

Non-executive Directors

Mr. GUO Qizhi (郭其志), aged 49, has been a non-executive Director since January 2018. He is also a member of the Audit Committee. He is primarily responsible for providing strategic advice and guidance on the business development and expansion of our Group.

Mr. Guo is currently a senior partner of CDH Venture and Growth Capital (鼎暉創新與成長基金), an investment fund established in 2015 focusing on healthcare, technology, new consumption and other innovation-based growth opportunities in the PRC. Mr. Guo joined CDH Equity Investment Management (Tianjin) Co., Ltd. (鼎暉股權投資管理(天津)有限公司) in 2011 and successively served as its executive director and manager director of operations, mainly responsible for investments in the medical services and technology sector.

Before joining CDH Equity Investment Management (Tianjin) Co., Ltd. in 2011, Mr. Guo had served as a vice president of operations and the chief financial officer of China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (listed on the Shenzhen Stock Exchange with stock code 000999), the general manager of strategic investments of the strategic investment department of China Resources (Group) Co., Ltd., the chief financial officer of China Resources (Jilin) Bio-Chemical Co., Ltd. (listed on the Shanghai Stock Exchange with stock code 600893 and now known as AECC Aviation Power Co., Ltd.), the financial manager of Shanghai Dare (Group) Co., Ltd., and an industry researcher of the research division of Pingan Securities Co., Ltd.

Mr. Guo received a bachelor's degree in engineering from Northeastern University in Shenyang city, Liaoning province, the PRC in 1994 and a master's degree in accounting from Liaoning University in the same city in 1998.

Mr. WANG Siye (王思業), aged 40, has been a non-executive Director since February 2016. He is primarily responsible for providing strategic advice and guidance on the business development and expansion of our Group. Mr. Wang has over 10 years of experience in corporate finance and investments. From June 2013 to December 2016, Mr. Wang served as an executive director of Boyu Capital, an investment firm focused on investing in Greater China, and served as a managing director of Boyu Capital since January 2017. Prior to joining Boyu Capital, Mr. Wang served as an investment manager at CITIC Private Equity Funds Management Co., Ltd. (中信產業投資基金) from August 2010 to June 2012 and, prior to that, as an associate at the Investment Banking Department of China International Capital Corporation Co., Ltd. (中國國際金融有限公司) from February 2007 to July 2010.

Mr. Wang received his master's degree in economics from the Hong Kong University of Science and Technology in November 2006, and his bachelor's degree in computer science from Nanjing University in June 2003.

Dr. CHENG Chi-Kong, Adrian JP (鄭志剛), aged 42, has been a non-executive Director since June 1, 2018. He is primarily responsible for providing strategic advice and guidance on the business development and expansion of our Group.

Dr. Cheng is an executive vice-chairman, executive director and chief executive officer of New World Development Company Limited (stock code: 17) ("New World Development"), an executive director of NWS Holdings Limited (stock code: 659), Chow Tai Fook Jewellery Group Limited (stock code: 1929), and a non-executive director of New World Department Store China Limited (stock code: 825), Giordano International Limited (stock code: 709), Arta Techfin Corporation Limited (stock code: 279), all of which are listed public companies in Hong Kong. He was a non-executive director of i-CABLE Communications Limited (stock code: 1097), which is a public listed company in Hong Kong, until his resignation with effect from July 2, 2019.

Dr. Cheng is the director and executive chairman of New World China Land Limited, chairman of New World Group Charity Foundation Limited, a member of the Tianjin Municipal Committee of The Chinese People's Political Consultative Conference, chairman of the China Young Leaders Foundation, and the honorary chairman of K11 Art Foundation.

Dr. Cheng holds a Bachelor of Arts degree (cum laude) from Harvard University and was conferred the Honorary Doctorate of Humanities by the Savannah College of Art and Design. Dr Cheng worked for a major international bank and had extensive corporate finance experience prior to joining New World Development in September 2006.

Directors and Senior Managements (Continued)

Mr. YANG Yuelin (楊躍林), aged 58, has been a non-executive Director since June 1, 2018. He is also a member of the Remuneration Committee. He is primarily responsible for providing strategic advice and guidance on the business development and expansion of our Group. Mr. Yang has been a tax senior manager at Ernst & Young (China) Corporate Consulting Co., Ltd. Beijing Branch since June 2008. Mr. Yang joined the tax department of Ernst & Young Hua Ming LLP in 1993.

Mr. Yang graduated from the Beijing College of Finance and Commerce with a diploma in finance and accounting in June 1988.

Mr. XIE Qiang (解 強), aged 43, has been a non-executive Director since January 1, 2021. He is currently the General Manager of CDB Capital FoF Management Co., Ltd. Mr. Xie worked at Beijing Guantao Law Firm as a legal assistant from July 2003 to July 2006, served as a Project Assistant at the Legal Affairs Department Contract Supervision Office of Beijing 29th Olympic Games Organizing Committee from July 2006 to January 2008, and a Supervisor at the Legal Affairs Department Contract Supervision Office of Beijing 29th Olympic Games Organizing Committee from January 2008 to November 2008. He served successively as an Officer of Market and Investment Division of China Development Bank Shenzhen Branch from November 2008 to December 2009, Senior Manager of Funds Division II of China Development Bank Capital Corporation Ltd. from January 2010 to September 2013, the Departmental Secretary at the Secretariat Division I of the General Office of China Development Bank from September 2013 to May 2018, and the Vice President of China Development Bank International Holdings Limited from May 2018 to December 2019.

Mr. Xie is currently serving as a non-independent director of Guangzhou Kingmed Diagnostics Group Co Ltd, a company listed on the Shanghai Stock Exchange. He has been serving in this role since November 2020.

Mr. Xie obtained a bachelor's degree in economic law from Tongji University in July 2000 and a master's degree in law from the University of Pittsburgh in July 2003. Mr. Xie has extensive experience in general corporate management, international banking, finance and investment management.

Independent Non-executive Directors

Mr. WU Guanxiong (吳冠雄), aged 50, was appointed as an independent non-executive Director in December 2016. He is also the chairman of the Remuneration Committee and a member of the Nomination Committee. He is primarily responsible for overseeing and providing independent judgment and analysis to the Board. Mr. Wu has substantial experience in capital markets and securities matters. He is a partner at Tian Yuan Law Firm (天元律師事務所). Prior to joining Tian Yuan Law Firm in March 1999, he served as a legal advisor at China North Industries Corporation (中國北方工業公司) from August 1994 to September 1997.

Mr. Wu obtained his bachelor of laws and master of laws in international law from Peking University Law School in July 1994 and January 2000, respectively.

Mr. SUN Hongbin (孫洪斌), aged 46, was appointed as an independent non-executive Director in December 2016. He is also the chairman of the Audit Committee. Mr. Sun has over 23 years of finance experience. He has been an independent non-executive director of CStone Pharmaceuticals (基石藥業) (stock code: 2616), a company listed on the Stock Exchange, since February 2019. He was appointed as an independent non-executive director of Mobvista Inc. (匯量科技有限公司) (stock code: 1860), a company listed on the Stock Exchange, since July 2020. He has been an independent non-executive director of Abbisko Cayman Limited (和譽開曼有限責任公司) (stock code: 2256), a company listed on the Stock Exchange, since September 2021. He has been the chief financial officer of MicroPort Scientific Corporation (微創醫療科學有限公司) (stock code: 0853), a company listed on the Stock Exchange, since September 2010 and served as its executive director from July 2010 to September 2012. Mr. Sun has served as a director of Shanghai MicroPort MedBot (Group) Co., Ltd. (上海微創醫療機器人(集團)股份有限公司)(stock code: 2252, "MedBot"), a company listed on the Stock Exchange, since April 2020, and as a non-executive director from June 2021. He has also served as chairman of the board of MedBot. He was the deputy financial director of Otsuka (China) Investment Co., Ltd. (大冢(中國)投資有限公司) from January 2004 to December 2005 and then worked as its general manager from January 2006 to August 2010. From August 1998 to January 2004, he was an assistant manager in the audit department of KPMG Huazhen (畢馬威華振會計師事務所) in Shanghai.

Mr. Sun has been a member of the Chinese Institute of Certified Public Accountants since December 2009 and is also a Chartered Financial Analyst since September 2009, Mr. Sun received his bachelor's degree in accounting from Shanghai Jiao Tong University in the PRC in July 1998.

Mr. JIANG Yanfu (姜彥福), aged 78, was appointed as an independent non-executive Director in December 2016. He is also a member of each of the Audit Committee and the Nomination Committee. He is primarily responsible for overseeing and providing independent judgment and analysis to the Board. Mr. Jiang has approximately 19 years of experience in corporate governance and compliance of listed companies. He served as an independent non-executive director of Jiangxi Bestoo Energy Co., Ltd. (江西百通能源股份有限公司), a company listed on the National Equities Exchange and Quotations (stock code: 835359), and Synthesis Electronic Technology Co., Ltd. (神思電子技術股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 300479), and resigned in September 2018 and August 2017, respectively.

Mr. Jiang had been working at Tsinghua University since March 1970 before retiring in April 2009 as a professor and doctoral supervisor at Tsinghua University School of Economics and Management. Between 2000 and 2010, he was also a director of Tsinghua University National Entrepreneurship Research Center (清華大學中國創業研究中心). He enjoys special government allowance from the State Council.

Mr. Jiang received a bachelor's degree in automation from Tsinghua University in March 1970.

Directors and Senior Managements (Continued)

Dr. MA Jing (馬晶), aged 61, was appointed as an independent non-executive Director in December 2016. She is also a member of the Remuneration Committee. She is primarily responsible for overseeing and providing independent judgment and analysis to the Board. Dr. Ma has over 30 years of experience in medical and public health studies. She has been an associate professor at Harvard School of Public Health since 2012 and an associate professor of medicine at Harvard Medical School since 2005. Prior to that, she had held various teaching and research positions at Harvard Medical School, Brigham and Women's Hospital in Boston, Massachusetts, the U.S. and the University of Minnesota. She is also a member of the American Association for Cancer Research.

Dr. Ma received her doctor of philosophy degree in epidemiology from the University of Minnesota in December 1993, her master of public health degree in preventive medicine from Tongji Medical University in July 1986 and her bachelor of medicine degree and bachelor of surgery degree in preventive medicine from Wuhan Medical College (武漢醫學院) in Wuhan, Hubei Province, the PRC in August 1983.

SENIOR MANAGEMENT

For the biographical details of Mr. Jason ZHOU, Ms. XIN Hong (辛紅) and Mr. XU Han (徐瀚), please see "– Directors – Executive Directors" of this section.

Ms. ZHOU Hong (周紅), aged 63, a chief physician, is the Vice President and the Chief Medical Officer of our Group with overall responsibility for the medical department of the Group's hospitals, including overseeing the overall management of our healthcare services and our professional team and the professional training, and assisting with the development of the Group's business, annual plans and strategic business plans. She is also involved in cultivating relationships between our Group and the medical community as well as the marketing and public relations activities of our Group. Ms. Zhou joined our Group in March 2005, initially as a medical director of BNC Children's Hospital.

Prior to joining our Group, Ms. Zhou had been involved in the field of child surgery clinical work for 27 years. Between September 1983 and September 2001, Ms. Zhou served at BCH, holding a number of roles including director of the surgery department. Ms. Zhou has also taught at the Capital University of Medical Sciences in Beijing as an associate professor from September 2000 to November 2003, and as a professor from November 2003 to February 2014.

Ms. Zhou is (i) a member of the Pediatric Nutrition Support Group of the Fourth Committee of the Parenteral and Enteral Nutrition Society, the Chinese Medical Association, and (ii) a vice director of the Pediatric Committee of the Beijing Medical Women's Association. Ms. Zhou is also on the editorial board of the Chinese Journal for Clinicians.

Ms. Zhou obtained her bachelor's degree in pediatrics from the Capital University of Medical Sciences in Beijing in August 1983.

Ms. TENG Lan (滕嵐), aged 46, joined our Group in February 2006 as the director of Human Resources of BNC Children's Hospital and since then has assumed various managerial positions, including clinic manager, director of operations, and the Human Resources Director of the Group. Since July 2021, she has served as the Chief Executive Officer of BNC Women's and Children's Hospital.

Ms. Teng has over 20 years of experience in the medical industry. Prior to joining our Group, Ms. Teng had served as the manager of government relations at Hua Mei Kang Medical Consultancy Management (Beijing) Limited (華美康醫療諮詢管理(北京)有限公司) between March 2005 and January 2006.

Ms. Teng obtained her bachelor's degree in economics from the Beijing University of Technology in July 1997. Ms. Teng also obtained her certificate in senior human resources management from Tsinghua University's School of Economics and Management in November 2015, and her certificate of completion in Applied Psychology from Peking University's Department of Psychology in December 2003.

Mr. JIA Xiaofeng (賈曉鋒), aged 43, has been the Vice President and the secretary of the Board of our Group. He is primarily responsible for the Group's corporate governance, overall company secretarial and management matters of the hospitals under the Company's brand.

Mr. Jia first joined BNC Children's Hospital in March 2009 as an investment manager before working at PricewaterhouseCoopers from April 2010 to November 2011, as a general manager in the investment division of Jiahua Likang, our connected person, from March 2014 to March 2016 and as the Investment Director of our Group from April 2016 to February 2021.

Mr. Jia has 20 years of experience in the healthcare and medical industry involving corporate investment and financing, compliance and hospital operation and management. Prior to initially joining our Group in March 2009, Mr. Jia also worked at The China Care Group Hospital Management and Consulting Co., Ltd. (華美康醫院管理諮詢有限公司) as a partner in its consultancy division from January 2007 to March 2009, where he was primarily responsible for analyzing the group's business and financial operations, as well as facilitating and managing investments and development projects in new and existing markets.

Mr. Jia obtained an International Master of Business Administration degree from Tsinghua University in Beijing in July 2007 and a bachelor's degree in clinical medicine from the Capital University of Medical Sciences in Beijing in July 2002.

Ms. Zhang Jingxin (張菁欣), aged 36, has been the Vice President and Director of Strategic Investment of our Group since February 2021. She is primarily responsible for the investment and financing, acquisitions, business expansion and investor relations of our Group. She joined our Group in May 2017 and was the Vice President and Director of Capital Markets of our Group until February 2021.

Ms. Zhang has approximately 16 years of experience in corporate finance and global capital markets. Ms. Zhang served in the investment banking division of Bank of America Merrill Lynch from June 2007 to April 2017. From March 2010 to April 2017, Ms. Zhang worked as associate and vice president in the investment banking division at Bank of America Merrill Lynch in the Asia Pacific region and was responsible for corporate finance and mergers and acquisitions of PRC corporations.

Ms. Zhang received a bachelor's degree in Economics and Mathematics from Yale University in May 2007.

Directors' Report

The Directors are pleased to present this annual report and the audited consolidated financial statements of the Group for the year ended December 31, 2021.

PRINCIPAL ACTIVITIES

The Company, together with its subsidiaries, is mainly engaged in provision of high-quality healthcare services to women and children. The Company is an investment holding company and its subsidiaries are principally engaged in the healthcare industry specializing in pediatric, obstetric and gynecologic services and certain hospital consulting services.

A list of the Company's subsidiaries, together with their places of incorporation, principal activities and particulars of their issued shares/paid up capital, is set out in note 9 to the consolidated financial statements.

BUSINESS REVIEW

A review of the business of the Group during the year and a discussion on the Group's future business development are set out in "Chairman's Statement" on pages 4 to 5 of this annual report and in "Management Discussion and Analysis – Business Overview and Outlook" on pages 6 to 8 of this annual report. The financial risk management objectives and policies of the Group are set out in note 3 to the consolidated financial statements. Significant events that have an effect on the Group subsequent to the end of the financial year ended December 31, 2021 are set out in note 36 to the consolidated financial statements. Besides, the potential risks and uncertainties faced by the Group, key relationships between the Group and its employees, customers and suppliers, the environmental policies of the Group and compliance with the relevant laws and regulations which have a significant impact are set out below. The environmental performance of the Group will be set out in the Environmental, Social and Governance Report to be issued by the Company separately pursuant to the Listing Rules.

Key Risks and Uncertainties

The Group's results and operations are subject to various factors with the key risks summarized below:

Reputation risk

Our business depends significantly on the soundness of our reputation. Failure to develop, maintain and enhance our reputation, or any negative publicity or allegations in the media against us, may adversely affect the level of market recognition of, and trust in, our services, and failure to properly manage our physicians' or other medical professionals' clinical activities may expose us to medical disputes, which could result in a material adverse impact on our business, financial condition and results of operations. Our reputation and business may be harmed accordingly.

Customer risk

As we provide mid- to high-end healthcare services, our business, financial condition and results of operations are subject to changes in patient preference, consumption capacity, consumer confidence index and general economic conditions in our market.

Talent risk

If we are unable to attract, train and retain a sufficient number of qualified physicians, management staff and other hospital personnel, our hospital operations could be materially and adversely affected.

Key Relationship

The Group fully understands that employees, customers and partners are the key to our sustainable and stable development. We are committed to establishing a close relationship with our employees, enhancing cooperation with our partners and providing high-quality services to our customers so as to ensure the Group's sustainable development.

Staff

Our staff is regarded as the most important resource of the Group. The Group has been endeavoring to provide our staff with a competitive compensation packages, attractive promotion opportunities, comprehensive training courses and a respectful and professional working environment. In order to assist us in attracting, retaining and motivating our key employees, the Group has adopted the RSA Scheme and the Employee Share Scheme, pursuant to which restricted shares will be granted to eligible employees. The Group has in place a Group-wide internal training systems and provide ongoing training to our employees. In addition, our new employees are required to participate in a three-day orientation program, followed by a rotational training scheme.

Customers

We uphold the principle of providing high-quality customer-centered healthcare services throughout our operation, which we believe is vital to achieving customer satisfaction and maintaining our reputation. Our customer-centered philosophy is reinforced by our high-quality customer service that goes beyond medical diagnosis and treatment. Our customers can make appointments in person or by phone to avoid long waiting time which is a common issue in public hospitals. We have dedicated dietitians working with our medical staff to provide appropriate nutrition care to our customers for their recovery and our food service staff help our customers select their daily menus and deliver the meals to their bedside. To adapt to the needs of our young customers and female customers, we designed our medical institutions to be a comfortable, intimate and relaxing environment to make them feel more at ease. A dedicated call center for each of our medical institutions was set up to provide various customer services, including providing general information about our medical institutions and our services, answering general enquiries, offering customers directions services, scheduling appointments and collecting post-consultation feedback.

Directors' Report (Continued)

Suppliers

We firmly believe that our suppliers are equally important in providing high-quality medical services. When selecting suppliers, we consider, among other things, their product offerings, pricing, reputation, service or product quality and delivery schedule. We generally require our suppliers to maintain requisite licenses and permits to operate their business, such as business licenses and GMP certificates and/or GSP certificates. We conduct regular review of our suppliers and will remove any suppliers who do not meet our supply standards or requirements from our list of approved suppliers. We usually have more than one supplier for each kind of our supply need to ensure we maintain sufficient inventory levels and bargaining power to deal with price fluctuations. We do not rely on any single supplier for any of our major pharmaceuticals, medical consumables or medical devices. We had stable business relationships with our suppliers in 2021.

We have established certain long-term cooperation relationships with third parties, such as other hospitals, medical associations and scientific research institutions, which enable us to access more medical resources, enhance the quality of our healthcare services, strengthen our reputation, and promote and grow our business.

Environmental Policies

We are subject to various PRC laws, rules and regulations with regard to environmental matters, including hospital sanitation, disease control, disposal of medical waste, and discharge of wastewater, pollutants and radioactive substances. We have established systems and procedures in place concerning environmental protection, such as requiring all our hospitals to engage qualified service providers to dispose of medical waste and radioactive substances. In 2021, our businesses were in compliance with all the relevant laws and regulations with regard to environmental protection in all material aspects.

Compliance with Laws and Regulations

The Group's operations are mainly carried out by the Company's subsidiaries in Mainland China while the Company is a holding company incorporated in the Cayman Islands with its shares listed on the Main Board of the Stock Exchange. Our establishments and operations accordingly shall comply with relevant laws and regulations in Mainland China, the Cayman Islands and Hong Kong. In 2021, our businesses were in compliance with all the relevant laws and regulations in Mainland China, the Cayman Islands and Hong Kong in all material aspects.

The Group was involved in certain legal proceedings with Serenium Inc., a Delaware corporation. For details, please refer to the announcement of the Company dated June 4, 2020. The legal proceedings were finally settled in December 2021.

RESULTS AND DIVIDEND

The results of the Group for the year ended December 31, 2021 are set out in the section headed "Consolidated Statement of Comprehensive Income" of this annual report.

The Board did not recommend the payment of a final dividend for the year ended December 31, 2021 (2020: nil).

SHARE CAPITAL

Details of the movements in the share capital of the Company for the year ended December 31, 2021 are set out in note 17 to the consolidated financial statements in this annual report.

RESERVES

Details of the movements in the reserves of the Group for the year ended December 31, 2021 are set out in the section headed "Consolidated Statement of Changes in Equity" of this annual report.

As of December 31, 2021, the Company had a share premium balance of RMB2,606.5 million, which shall be available for distribution to the Shareholders.

PROPERTY, PLANT AND EQUIPMENT

Details of the movements during the year in the Group's property, plant and equipment are set out in note 6 to the consolidated financial statements in this annual report.

FINANCIAL SUMMARY

A summary of the results and of the assets and liabilities of the Group for the past five financial years are set out in the section headed "Financial Summary" of this annual report.

BORROWINGS

As of December 31, 2021, the Group did not have any borrowings (2020: nil).

PLEDGE OF ASSETS

As of December 31, 2021, no assets of the Group were pledged.

MAJOR CUSTOMERS AND SUPPLIERS

During the year ended December 31, 2021, our five largest individual patients contributed to less than 5% of our total revenue. During the year ended December 31, 2021, our largest customer was a corporate customer and a connected person of us from which we derived hospital consulting service fee revenue, which in aggregate contributed to 0.71% of our revenue in 2021.

Purchases from the Group's five largest suppliers in aggregate accounted for approximately 45.9% (2020: 55.0%) of the total purchases for the year ended December 31, 2021 and purchases from the largest supplier accounted for approximately 18.8% (2020: 32.9%) of our total purchases.

Save for Mr. Zhou's equity interest (together with his spouse) in Jiahua Likang, our largest corporate customer, to the best knowledge of the Directors, none of the Directors or any of their close associates (as defined in the Listing Rules) or Shareholders that owned more than 5% of the issued Shares had any direct or indirect interest in the five largest customers or the five largest suppliers of the Group during the year ended December 31, 2021.

DIRECTORS

The Directors as of the Latest Practicable Date are as follows:

Executive Directors

Mr. Jason ZHOU *(Chairman and Chief Executive Officer)*
Ms. XIN Hong *(Senior Vice President and Chief Operating Officer)*
Mr. XU Han *(Senior Vice President and Chief Financial Officer)*

Non-executive Directors

Mr. GUO Qizhi
Mr. WANG Siye
Dr. CHENG Chi-Kong, Adrian *JP*
Mr. YANG Yuelin
Mr. XIE Qiang

Independent Non-executive Directors

Mr. WU Guanxiong
Mr. SUN Hongbin
Mr. JIANG Yanfu
Dr. MA Jing

THE BIOGRAPHY OF THE DIRECTORS AND SENIOR MANAGEMENT

The biographical details of the Directors and the senior management of the Company are set out in the section headed "Directors and Senior Managements" of this annual report.

SERVICE CONTRACTS OF THE DIRECTORS

Each of the Directors has entered into a service contract with the Company for a term of three years commencing from the date of service contract and automatically renewed for three years from the expiry date and shall be terminable by either party giving not less than three months' notice in writing to the other.

Pursuant to article 108(a) of the Articles of Association, Mr. WU Guanxiong, Mr. SUN Hongbin, Mr. JIANG Yanfu and Dr. MA Jing shall retire by rotation, and being eligible, have offered themselves for re-election as the Directors at the forthcoming AGM.

None of the Directors proposed for re-election at the forthcoming AGM has a service contract with any member of the Group which is not determinable by the employer within one year without payment of compensation (other than statutory compensation).

DISCLOSURE OF CHANGES IN DIRECTORS' INFORMATION

Pursuant to Rule 13.51B(1) of the Listing Rules, the changes of information on Directors for the year ended December 31, 2021 and up to the Latest Practicable Date are as follows:

- Dr. CHENG Chi-Kong, Adrian has been re-designated as a non-executive director and appointed as the chairman of the board of directors of New World Department Store China Limited (stock code: 825), a company listed on the Main Board of the Stock Exchange, from May 2021. He has been appointed as a non-executive director and chairman of Arta Techfin Corporation Limited (stock code: 279), a company listed on the Main Board of the Stock Exchange, from October 2021.

- Mr. Sun Hongbin has been appointed as an independent non-executive director of Abbisko Cayman Limited (stock code: 2256), a company listed on the Main Board of the Stock Exchange, from September 2021. He has been re-designated as a non-executive director of Shanghai MicroPort MedBot (Group) Co., Ltd. (stock code: 2252), a company listed on the Main Board of the Stock Exchange, from June 2021.

Save as disclosed above, there is no other information required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules regarding changes in Directors' biographical details from the publication of the Company's 2021 interim report up to the Latest Practicable Date.

REMUNERATION OF THE DIRECTORS AND FIVE HIGHEST PAID INDIVIDUALS

Details of the Directors' remuneration and the five highest paid individuals in the Group are set out in notes 38 and 26 to the consolidated financial statements in this annual report.

The annual remuneration of the members of the senior management (excluding Directors) by band for the year ended December 31, 2021 is as follow:

Remuneration Bands (HK$)	Number of Individuals
0-1,000,000	–
1,000,001-2,000,000	4
2,000,001-3,000,000	–
3,000,001 and above	–

REMUNERATION POLICY

As of December 31, 2021, the Group had 1,401 employees (December 31, 2020: 1,352 employees). Total staff remuneration expenses including Directors' remuneration in 2021 amounted to RMB322.5 million (2020: RMB263.8 million). Remuneration is determined with reference to performance, skills, qualifications and experience of the staff concerned and in accordance with the prevailing industry practice. On top of salary payments, other staff benefits include social insurance and housing provident contributions made by the Group, performance-based compensation and discretionary bonus.

The Group has adopted the RSA Scheme and the Employee Share Scheme to attract, retain and motivate our key employees. Under the RSA Scheme, 9,000,000 restricted shares have been granted to 2 Directors and 265 employees of the Group up to the Latest Practicable Date and all had either vested or lapsed. Details of the grant of restricted shares and the adoption of the Employee Share Scheme are set out in the announcement of the Company dated July 25, 2017 and August 31, 2020 respectively.

The remuneration of the Directors is reviewed by the Remuneration Committee and approved by the Board. The relevant Director's experience, duties and responsibilities, time commitment, performance at the Company and the prevailing market conditions are taken into consideration in determining the emolument of the Directors.

INDEPENDENCE OF THE INDEPENDENT NON-EXECUTIVE DIRECTORS

The Company has received from each of the independent non-executive Directors an annual confirmation of his/her independence pursuant to Rule 3.13 of the Listing Rules. The Company believes that all of the independent non-executive Directors are independent in accordance with the guidelines set out in the Listing Rules.

NON-COMPETITION UNDERTAKINGS

As disclosed in the Prospectus, our Controlling Shareholders, Jiahua Likang and Jiahua Kangming, have undertaken to the Company in a deed of non-competition that, subject to and except as mentioned in the Prospectus, they would not, and would procure that none of their close associates will directly or indirectly engage in any business which, directly or indirectly, competes or may compete with the Group's business in any Tier 1 Cities.

Each of them has confirmed in writing to the Company of their compliance with the deed of non-competition for disclosure in this annual report during the year ended December 31, 2021. No new business opportunity was informed by them as of December 31, 2021.

The independent non-executive Directors have reviewed the implementation of the deed of non-competition and are of the view that the non-competition undertakings have been complied with by our Controlling Shareholders, Jiahua Likang and Jiahua Kangming for the year ended December 31, 2021.

DIRECTORS' INTERESTS IN COMPETING BUSINESSES

As of December 31, 2021, the following Director had interests in the following businesses which were considered to compete or were likely to compete, either directly or indirectly, with the businesses of the Group:

	Businesses which were considered to compete or likely to compete with the business of the Group		
Name of Director	Name of entity	Description of business	Nature of interest of the Director in the entity
Dr. CHENG Chi-Kong, Adrian *JP*	New World Development Company Limited and all its subsidiaries and associated enterprises	Property development and investments in the areas of property, infrastructure, hotel operation, department store operation, commercial aircraft leasing, apparel, technology and medical (including rehabilitation, healthcare, nursing and elderly care)	Director
	Chow Tai Fook Enterprises Limited and all its subsidiaries and associated enterprises	Property investments and development, hotel operation, commercial aircraft leasing, aircraft sale and purchase and medical investments	Director

Save as disclosed above and in the section headed "Relationship with Our Controlling Shareholders" of the Prospectus, as of December 31, 2021, none of the Directors nor their respective associates had engaged in or had any interest in any business which competes or may compete with the business of the Group.

DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY OR ITS ASSOCIATED CORPORATIONS

As of December 31, 2021, the interests and short positions of the Directors and chief executive of the Company in the Shares, underlying Shares and debentures of the Company or its associated corporations (within the meaning of Part XV of the SFO) which were required (a) to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have under such provisions of the SFO); or (b) to be recorded in the register required to be kept pursuant to Section 352 of the SFO; or (c) as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code were as follows:

(a) Interests/short positions in the Shares

Name of Director or Chief Executive	Nature of interest	Number of Shares[1]	Approximate percentage of interest in the Company
Mr. Zhou[2]	Interests in a controlled corporation; interest held jointly with another person	217,556,394	44.40%
Ms. XIN Hong[3]	Beneficial owner	180,000	0.04%
Mr. XU Han[4]	Beneficial owner	180,000	0.04%

Notes:

1. All interests stated are long positions.

2. The entire issued share capital of each of JoeCare and Century Star is directly held by Mr. Zhou. Accordingly, Mr. Zhou is deemed to be interested in the 150,817,051 Shares held by JoeCare and the 8,999,162 Shares held by Century Star. Pursuant to the Voting Agreement, Ms. Liang irrevocably agreed to follow Mr. Zhou's voting directions when exercising the voting rights attached to the Shares beneficially owned by her during the term of such agreement. Hence, Mr. Zhou is deemed to be interested in all the Shares held by Ms. Liang in aggregate by virtue of the SFO.

3. 450,000 restricted Shares were granted to Ms. XIN Hong under the RSA Scheme, 180,000 of which have vested in her subject to certain conditions and 270,000 of which have lapsed. Hence, Ms. XIN Hong is interested in 180,000 restricted Shares vested in her under the RSA Scheme.

4. 450,000 restricted Shares were granted to Mr. XU Han under the RSA Scheme, 180,000 of which have vested in him subject to certain conditions and 270,000 of which have lapsed. Hence, Mr. XU Han is interested in 180,000 restricted Shares vested in him under the RSA Scheme.

Save as disclosed above, as of December 31, 2021, so far as is known to the Directors or chief executive of the Company, none of the Directors or chief executive of the Company had interests or short positions in the Shares, underlying Shares and debentures of the Company or its associated corporations which (a) were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have under such provisions of the SFO); or (b) were required, pursuant to Section 352 of the SFO, to be recorded in the register referred to therein; or (c) were required, pursuant to the Model Code, to be notified to the Company and the Stock Exchange.

SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

As of December 31, 2021, so far as was known to any Director or chief executive of the Company, the following persons (other than the Directors and chief executive of the Company) had interests and/or short positions in the Shares or underlying Shares which would fall to be disclosed to the Company pursuant to Divisions 2 and 3 of Part XV of the SFO or as recorded in the register required to be kept by the Company under Section 336 of the SFO:

Name of Shareholders	Capacity and nature of interest	Number of Shares	Approximate percentage of interest in the Company
JoeCare[(1)]	Beneficial owner	150,817,051	30.8%
Victor Gains[(2)]	Beneficial owner	57,740,181	11.8%
Ms. Liang[(2)]	Interests in a controlled corporation	57,740,181	11.8%
CDH Equity Investment Management (Tianjin) Co., Ltd. (鼎暉股權投資管理(天津)有限公司)[(3)]	Interests in a controlled corporation	31,728,156	6.5%
Tianjin Taiding Investment Company Limited (天津泰鼎投資有限公司)[(3)]	Interests in a controlled corporation	31,728,156	6.5%
Tianjin Haoyong Investment Management Co., Ltd. (天津浩永投資管理有限公司)[(3)]	Interests in a controlled corporation	31,728,156	6.5%
Tianjin Weiyuan Investment Management Co., Ltd. (天津維遠投資管理有限公司)[(3)]	Interests in a controlled corporation	31,728,156	6.5%

Name of Shareholders	Capacity and nature of interest	Number of Shares	Approximate percentage of interest in the Company
Mr. WU Shangzhi[3]	Interests in a controlled corporation	31,728,156	6.5%
Mr. JIAO Shuge[3]	Interests in a controlled Corporation	31,728,156	6.5%
Anyi Hekang (Tianjin) Investment Partnership L.P. (安怡和康(天津)投資合夥企業(有限合夥))[4]	Beneficial owner	31,562,713	6.4%
Boyu Guangqu (Shanghai) Investment Management Co., Ltd. (博裕廣渠(上海)投資管理有限公司)[4]	Interests in a controlled corporation	31,562,713	6.4%
Boyu (Shanghai) Equity Investment Management Co., Ltd. (博裕(上海)股權投資管理有限責任公司)[4]	Interests in a controlled corporation	31,562,713	6.4%
XIA Meiying[4]	Interests in a controlled corporation	31,562,713	6.4%
HUANG Ailian[4]	Interests in a controlled corporation	31,562,713	6.4%
China Life Reinsurance Company Ltd.[5]	Beneficial owner	31,444,000	6.4%
China Reinsurance (Group) Corporation [5]	Interests in a controlled corporation	31,444,000	6.4%
Central Huijin Investment Ltd.[5]	Interests in a controlled corporation	31,444,000	6.4%

Notes:

1. The entire issued share capital of JoeCare is directly held by Mr. Jason ZHOU. Accordingly, such 150,817,051 Shares held by JoeCare have been included and reflected in the number of shares interested by Mr. Jason ZHOU above.

2. The entire issued share capital of Victor Gains is directly held by Ms. Liang. Accordingly, Ms. Liang is deemed to be interested in the 57,740,181 Shares held by Victor Gains. Pursuant to the Voting Agreement, Ms. Liang irrevocably agreed to follow Mr. Zhou's voting directions when exercising the voting rights attached to the Shares beneficially owned by her during the term of such agreement.

3. Shanghai Fuyi Investment Partnership L.P. (Limited Partnership) is a limited liability partnership organized and existing under the laws of the PRC. The general partner of Shanghai Fuyi Investment Partnership L.P. (Limited Partnership) is CDH Huatai Investment Management (Beijing) Co., Ltd. (鼎暉華泰投資管理(北京)有限公司), which is owned directly as to 63.0% by CDH Equity Investment Management (Tianjin) Co., Ltd. (鼎暉股權投資管理(天津)有限公司). Shanghai Fuji Investment Partnership L.P. (Limited Partnership) is a limited liability partnership organized and existing under the laws of the PRC. The general partner of Shanghai Fuji Investment Partnership L.P. (Limited Partnership) is CDH Equity Investment Management (Tianjin) Co., Ltd. (鼎暉股權投資管理(天津)有限公司), which is owned directly as to 85.4% by Tianjin Taiding Investment Company Limited (天津泰鼎投資有限公司). Tianjin Taiding Investment Company Limited is owned directly as to 55.0% by Tianjin Haoyong Investment Management Co., Ltd. (天津浩永投資管理有限公司) (whose entire issued share capital is held by Mr. WU Shangzhi) and as to 45.0% by Tianjin Weiyuan Investment Management Co., Ltd. (天津維遠投資管理有限公司) (whose entire issued share capital is held by Mr. JIAO Shuge). Accordingly, each of CDH Equity Investment Management (Tianjin) Co., Ltd., Tianjin Taiding Investment Company Limited, Tianjin Haoyong Investment Management Co., Ltd., Tianjin Weiyuan Investment Management Co., Ltd., Mr. WU Shangzhi and Mr. JIAO Shuge is deemed to be interested in such number of Shares held by Shanghai Fuyi Investment Partnership L.P. (Limited Partnership) and Shanghai Fuji Investment Partnership L.P. (Limited Partnership).

4. Anyi Hekang (Tianjin) Investment Partnership L.P. (安怡和康(天津)投資合夥企業(有限合夥)) is a limited liability partnership organized and existing under the laws of the PRC. The general partner of Anyi Hekang (Tianjin) Investment Partnership L.P. is Boyu Guangqu (Shanghai) Investment Management Co., Ltd. (博裕廣渠(上海)投資管理有限公司) whose sole shareholder is Boyu (Shanghai) Equity Investment Management Co., Ltd. (博裕(上海)股權投資管理有限責任公司) which is owned as to 50% by Xia Meiying and 50% by Huang Ailian. Accordingly, each of Boyu Guangqu (Shanghai) Investment Management Co., Ltd. (博裕廣渠(上海)投資管理有限公司), Boyu (Shanghai) Equity Investment Management Co., Ltd. (博裕(上海)股權投資管理有限責任公司), XIA Meiying and HUANG Ailian is deemed to be interested in such number of Shares held by Anyi Hekang (Tianjin) Investment Partnership L.P..

5. China Life Reinsurance Company Ltd. is a company incorporated in the PRC with limited liability, whose sole shareholder is China Reinsurance (Group) Corporation, which is owned as to 71.6% by Central Huijin Investment Ltd.. China Reinsurance (Group) Corporation and Central Huijin Investment Ltd. are deemed to be interested in such number of Shares held by China Life Reinsurance Company Ltd..

Save as disclosed above, as of December 31, 2021, the Directors have not been notified by any person (other than the Directors or chief executive of the Company) who had interests or short positions in the Shares or underlying Shares which shall be disclosed to the Company pursuant to Divisions 2 and 3 of Part XV of the SFO or as recorded in the register required to be kept pursuant to Section 336 of the SFO.

RSA SCHEME AND EMPLOYEE SHARE SCHEME

(a) RSA Scheme

The RSA Scheme was adopted pursuant to the written resolutions of the Shareholders passed on August 29, 2016 (the "**RSA Scheme Adoption Date**"). The purpose of the RSA Scheme is to give incentives thereto in order to retain key employees for the continual operation and development of the Group and to attract suitable personnel for further development of the Group. The RSA Scheme shall be valid and effective for a period of ten years commencing on the RSA Scheme Adoption Date, under the administration of the administration committee and the trustee.

As of January 1, 2021, all restricted Shares previously granted under the RSA Scheme had either vested or lapsed and there were no restricted Shares outstanding. No restricted Shares were granted under the RSA Scheme during the year ended December 31, 2021.

(b) Employee Share Scheme

On August 28, 2020, the Board adopted the Employee Share Scheme in order to recognize the contributions by the selected participants, to provide them with incentives to achieve performance goals, and to attract suitable personnel for further development of the Group. The Employee Share Scheme shall be valid and effective for a period of ten years commencing on its adoption date, under the administration of the administration committee and the trustee.

No Shares shall be purchased pursuant to the Employee Share Scheme if as a result of such purchase, the number of Shares administered under the Employee Share Scheme reaches 5% or more of the issued share capital of the Company at the date of the Board's approval of the Employee Share Scheme, or such other limit as determined by the administration committee in its sole and absolute discretion provided always that it is in compliance with the Listing Rules. The maximum number of award shares which may be granted to a selected participant at any one time or in aggregate may not exceed 1% of the issued share capital of the Company at the same date.

In determining the selected participants, the number of award shares to be granted, the vesting conditions, the exercise price (if any) to be paid by the selected participants for each award share, the manner of payment of the exercise price and the other terms and conditions of the grants of award shares, the administration committee shall take into consideration any matter which it considers relevant. Any award share granted to a selected participant pursuant to the rules governing the Employee Share Scheme (the "**Employee Share Scheme Rules**") shall vest in such selected participant in accordance with the vesting conditions as set out in the grant letter.

As of December 31, 2021, for the purpose of the Employee Share Scheme, 1,923,500 shares have been purchased from the market by the trustee appointed by the Company for the administration of the Employee Share Scheme to hold on trust for the benefit of the selected participants pursuant to the Employee Share Scheme Rules and the provisions of the trust deed in relation to the Employee Share Scheme.

As at the Latest Practicable Date, no Shares were granted under the Employee Share Scheme. For further details of the Employee Share Scheme, please refer to the Company's announcement dated August 31, 2020.

DIRECTORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

Save as disclosed in the section headed "RSA Scheme and Employee Share Scheme" above, at no time during the year ended December 31, 2021, were there rights to acquire benefits by means of the acquisition of shares in or debentures of the Company granted to any Directors or their respective spouse or minor children, or were any such rights exercised by the Directors; or was the Company, or any of its holding companies, fellow subsidiaries and subsidiaries a party to any arrangement to enable the Directors to acquire such rights in any other body corporate.

DIRECTORS' INTERESTS IN TRANSACTION, ARRANGEMENT OR CONTRACT OF SIGNIFICANCE

Save as disclosed in this annual report and the Prospectus, no transaction, arrangement or contract of significance subsisted in which a Director or an entity connected with a Director was materially interested, whether directly or indirectly, during or at the end of 2021.

RELATED PARTY TRANSACTIONS

Related party transactions during the year ended December 31, 2021 are disclosed in note 34 to the consolidated financial statements in this annual report.

Save as disclosed in the section headed "Continuing Connected Transactions" below and item (d) of note 34 ("**Note 34**") to the consolidated financial statements in this annual report, the Directors consider that the other related party transactions disclosed in the Note 34 do not fall under the definition of "connected transaction" or "continuing connected transaction" in Chapter 14A of the Listing Rules. The Directors confirm that the five categories of transactions under "hospital consulting services provided to Tianjin Heping New Century Women's and Children's Hospital Co., Ltd.", "medical services to Chengdu Yunxi Ge Health Management Co., Ltd.", "examination, and laboratory test services received from Beijing Children's Hospital, Capital Medical University and Chengdu Women's and Children's Central Hospital", "purchase of goods from Beijing Children's Hospital, Capital Medical University", and "confinement services received from Chengdu Yunxi Ge Health Management Co., Ltd." set forth in item (d) of Note 34 are fully exempt under Rule 14A.76(1) of the Listing Rules. The Directors further confirm that the continuing connected transactions carried out by the Group as disclosed in the section headed "Continuing Connected Transactions" below and item (d) of Note 34 have complied with the requirements under Chapter 14A of the Listing Rules.

CONTINUING CONNECTED TRANSACTIONS

All the independent non-executive Directors of the Company have reviewed the below continuing connected transactions entered into by the Group and confirmed that they were entered into (i) in the ordinary and usual course of business of the Group; (ii) on normal commercial terms or better; and (iii) according to the relevant agreements governing them on terms that are fair and reasonable and in the interests of the Shareholders as a whole.

The Company's auditor was engaged to report on the group's continuing connected transactions in accordance with Hong Kong Standard on Assurance Engagements 3000 "Assurance Engagements Other Than Audits or Reviews of Historical Financial Information" and with reference to Practice Note 740 "Auditor's Letter on Continuing Connected Transactions under the Hong Kong Listing Rules" issued by the Hong Kong Institute of Certified Public Accountants.

The auditor has issued his unqualified letter containing his findings and conclusions in respect of the continuing connected transactions disclosed by the Group as below in accordance with paragraph 14A.56 of the Listing Rules. A copy of the auditor's letter has been provided by the Company to the Stock Exchange.

1. Framework Property Management and Cleaning Services Agreement

Reference is made to (i) the section headed "Connected Transactions" in the Prospectus which provides that Muhe Jiaye entered into the Property Management and Cleaning Services Agreements with each of BNC Children's Hospital and BNC Women's and Children's Hospital on August 22, 2016 for a period with effect from August 22, 2016 to August 21, 2019; and (ii) the announcements of the Company dated May 3, 2018, December 3, 2018 and December 6, 2018 in relation to the various property management services transactions between Muhe Jiaye and various members of the Group.

On April 12, 2019, Jiahua Yihe and Muhe Jiaye agreed the terms of the Framework Property Management and Cleaning Services Agreement for a term from April 12, 2019 to December 31, 2021 in relation to the provision of property management, facilities and equipment maintenance and cleaning services by Muhe Jiaye to Jiahua Yihe Hospitals. Details of the transaction have been disclosed in the circular of the Company dated May 15, 2019.

The aggregate annual caps for the property management and cleaning services for the year ended December 31, 2021 under the Framework Property Management and Cleaning Services Agreement was RMB35.0 million and the actual aggregate amount paid for the year ended December 31, 2021 was RMB8.9 million.

Muhe Jiaye is a company in which Ms. Zhao holds a 35.0% equity interest and thus is a connected person of the Group by virtue of it being an associate of Mr. Zhou pursuant to Rule 14A.12(1)(c) of the Listing Rules.

On December 31, 2021, Jiahua Yihe and Muhe Jiaye renewed the Framework Property Management and Cleaning Services Agreement for a term of 3 years with effect from January 1, 2022. Since the highest applicable percentage ratio calculated with reference to the maximum aggregate annual services fees payable to Muhe Jiaye under the renewed Framework Property Management and Cleaning Services Agreement for each of the three years ending December 31, 2024 exceeds 0.1% but is less than 5%, the renewed Framework Property Management and Cleaning Services Agreement and the transaction contemplated thereunder are subject to the reporting, annual review and announcement requirements but are exempt from circular (including independent financial advice) and independent shareholders' approval requirements under Chapter 14A of the Listing Rules. For further details, please refer to the announcements of the Company dated December 31, 2021 and January 5, 2022.

2. Framework Management Consulting Services Agreement

Reference is made to (i) the section headed "Connected Transactions" in the Prospectus which provides that Jiahua Likang entered into a management consulting services agreement with Jiahua Yihe on June 1, 2016 for a period with effect from December 1, 2015 to November 30, 2018; and (ii) the announcement of the Company dated December 6, 2018 which provides that Jiahua Likang entered into a management consulting services agreement with Jiahua Yihe on December 6, 2018 for a period with effect from December 6, 2018 to June 30, 2019.

On April 12, 2019, Jiahua Yihe and Jiahua Likang entered into the Framework Management Consulting Services Agreement, pursuant to which Jiahua Yihe will provide hospital consulting services to Jiahua Likang for the Likang Hospitals for a period from July 1, 2019 to December 31, 2021. Details of the transaction have been disclosed in the circular of the Company dated May 15, 2019.

For the year ended December 31, 2021, the annual cap of the maximum aggregate annual amount payable to Jiahua Yihe under the Framework Management Consulting Services Agreement is RMB44.0 million and the actual aggregate amount paid for the year ended December 31, 2021 was RMB3.6 million.

Jiahua Likang is held as to 37.67% by Beijing Jiahua Kangyong Investment and Management Co., Ltd. (北京嘉華康永投資管理有限公司), which is held as to 90.0% by Mr. Zhou and 10.0% by Ms. Zhao, and thus is a connected person of the Group by virtue of it being an associate of Mr. Zhou pursuant to Rule 14A.12(1) of the Listing Rules. Accordingly, the transactions contemplated thereunder constituted a continuing connected transaction of the Company pursuant to Chapter 14A of the Listing Rules.

Jiahua Yihe has been providing hospital consulting services to Jiahua Likang for the Likang Hospitals since December 2015 and the relationship was formalized by the 2016 Management Consulting Services Agreement.

On December 31, 2021, Jiahua Yihe and Jiahua Likang renewed the Framework Management Consulting Services Agreement for a term of 3 years with effect from January 1, 2022. Since the highest applicable percentage ratio calculated with reference to the maximum aggregate annual services fees payable to Jiahua Yihe under the renewed Framework Management Consulting Services Agreement for each of the three years ending December 31, 2024 is less than 5% and the total consideration for each of the three years ending December 31, 2024 is less than HK$3,000,000, the renewed Framework Management Consulting Services Agreement and the transaction contemplated thereunder are exempt from the reporting, annual review, announcement and circular (including independent financial advice) and independent shareholders' approval requirements under Chapter 14A of the Listing Rules.

3. Chengdu New Century Hospital Premises Lease Agreement

Pursuant to a lease agreement (the "**Chengdu New Century Hospital Premises Lease Agreement**") entered into between Chengdu New Century Women's and Children's Hospital and Chengdu Women's and Children's Central Hospital dated August 25, 2010, Chengdu New Century Women's and Children's Hospital agreed to lease the hospital premises of Chengdu Women's and Children's Central Hospital for a period of 20 years from November 1, 2010 to October 31, 2030 at an annual rent as follows:

Period	Annual Rent
November 1, 2010 to October 31, 2011	Nil
November 1, 2011 to October 31, 2014	RMB4,500,000
November 1, 2014 to October 31, 2015	RMB5,000,000
November 1, 2015 to October 31, 2016	RMB6,500,000
November 1, 2016 to October 31, 2019	RMB8,500,000
November 1, 2019 to October 31, 2020	RMB10,000,000
November 1, 2020 to October 31, 2025	RMB10,500,000
November 1, 2025 to October 31, 2030	RMB11,025,000

For the year ended December 31, 2021, the annual cap of the maximum aggregate annual amount payable to Chengdu Women's and Children's Central Hospital is RMB10.5 million and the actual aggregate amount is RMB10.0 million.

Since the acquisition of 85.0% equity interest of Chengdu New Century by the Group on August 10, 2018, Chengdu Women's and Children's Central Hospital is a connected person of the Group by virtue of it being a substantial shareholder of Chengdu New Century Women's and Children's Hospital, a subsidiary of the Company. Accordingly, the transactions contemplated thereunder constituted a continuing connected transaction of the Company pursuant to Chapter 14A of the Listing Rules.

The Directors considered that by entering into the Chengdu New Century Hospital Premises Lease Agreement, Chengdu New Century Women's and Children's Hospital would be able to secure a long term lease of hospital premises for its operations on normal commercial terms or better which is very important to the business development of the Group.

Details of the transaction have been disclosed in the announcement of the Company dated March 25, 2019.

Fully-Exempt Continuing Connected Transaction – VIE Acquisition Agreement and VIE Contracts

Pursuant to the VIE acquisition agreement (the "**VIE Acquisition Agreement**") dated September 26, 2017, Ms. Zhao, Ms. ZHOU Jie and Jiahua Kangming had conditionally agreed to enter into a series of VIE contracts (the "**VIE Contracts**") with, among others, Jiahua Yihe on or before November 3, 2017 and to cause Jiahua Yihe to perpetually and factually enjoy all the economic rights and benefits and other similar rights attaching or accruing to (i) the 100% equity interest in Jiahua Kangming held by Ms. Zhao and Ms. ZHOU Jie, and (ii) the 30% equity interest in each of BNC Women's and Children's Hospital and BNC Harmony Clinic held by Jiahua Kangming (the "**Economic Benefits**") from the date of completion, for a cash consideration of RMB30 million. Details of the transactions have been disclosed in the announcement and circular of the Company dated September 26, 2017 and November 3, 2017 respectively.

Ms. Zhao is the spouse of Mr. Zhou, the controlling Shareholder of the Company. Ms. ZHOU Jie is Mr. Zhou's sister. Jiahua Kangming is held as to 99% by Ms. Zhao and as to 1% by Ms. ZHOU Jie. Therefore, each of Ms. Zhao, Ms. ZHOU Jie and Jiahua Kangming is a connected person of the Company by virtue of her/it being an associate of Mr. Zhou pursuant to the Listing Rules. Accordingly, the transactions contemplated under the VIE Contracts constituted continuing connected transactions of the Company pursuant to Chapter 14A of the Listing Rules. The aggregate transaction amount under the VIE Contracts for the year ended December 31, 2021 is RMB0 and the Company does not expect to record any transaction amount under VIE Contracts for the year ending December 31, 2022. As all applicable percentage ratios are less than 0.1%, the transactions contemplated under the VIE Contracts for the three years ending December 31, 2022 are fully exempt from shareholders' approval, annual review and all disclosure requirements.

In respect of the VIE Acquisition Agreement, the Directors considered that it was necessary for the Company, through Jiahua Yihe, to enter into such agreement with Ms. Zhao, Ms. ZHOU Jie and Jiahua Kangming in order to execute the VIE Contracts for the benefits stated below.

In respect of the VIE Contracts, the Directors considered that by entering into the VIE Contracts, the Company, through Jiahua Yihe, controlled and consolidated Jiahua Kangming to prevent leakages of equity and values to the minority shareholder of BNC Women's and Children's Hospital and BNC Harmony Clinic, and to obtain the 30% economic benefits of these two medical institutions attributable to Jiahua Kangming.

MANAGEMENT CONTRACTS

The Company did not enter into any contract with any individual, firm or body corporate to manage or administer the whole or any substantial part of any business of the Group during the year ended December 31, 2021.

CONTROLLING SHAREHOLDERS' INTERESTS IN CONTRACTS OF SIGNIFICANCE

Save as disclosed in this annual report, neither contract of significance made between the Company or any of its subsidiaries and a controlling shareholder or any of its subsidiaries, nor contract of significance made for the provision of services to the Company or any of its subsidiaries by a controlling shareholder or any of its subsidiaries was entered into during the year ended December 31, 2021.

FUTURE PLANS FOR MATERIAL INVESTMENTS OR CAPITAL ASSETS

Save as disclosed in this annual report, the Company had no future plans for material investments or capital assets during the year ended December 31, 2021.

DIRECTORS' PERMITTED INDEMNITY PROVISION

Under the Articles of Association, every Director or officer of the Company acting in relation to any of the affairs of the Company shall be indemnified and secured harmless out of the assets of the Company from and against all actions, costs, charges, losses, damages and expenses which he may incur or sustain in or about the execution of the duties of his office or otherwise in relation thereto. The Company has arranged appropriate directors' and officers' liability insurance coverage for the Directors and officers of the Group.

EQUITY-LINKED AGREEMENTS

Save as disclosed in the section headed "RSA Scheme and Employee Share Scheme" above, no equity-linked agreements were entered into by the Company, or existed during the year ended December 31, 2021.

CHARITABLE DONATIONS

During the year ended December 31, 2021, the Company did not make any charitable donations.

SUBSEQUENT EVENTS

Reference is made to the Company's announcements dated January 30, 2022 and March 29, 2022 in relation to the acquisition of 12.47% equity interest of Beijing Jiahua Yongsheng Medical Investment Management Co., Ltd. for a cash consideration of RMB18.7 million. Save as disclosed above and in this annual report, there is no subsequent event after the reporting period up to the Latest Practicable Date which has a material impact on the consolidated financial statements of the Group.

PRE-EMPTIVE RIGHTS

There are no provisions for pre-emptive rights under the Articles of Association or the relevant laws of the Cayman Islands where the Company is incorporated which would oblige the Company to offer new Shares on a pro-rata basis to existing Shareholders.

DIVIDEND

The Directors did not recommend the payment of a final dividend for the year ended December 31, 2021 (2020: nil).

AGM AND CLOSURES OF REGISTER OF MEMBERS

The AGM of the Company will be held on Friday, May 20, 2022. A notice convening the AGM will be published on the Company's website and the Stock Exchange's website and dispatched to the Shareholders in accordance with the requirements of the Listing Rules in due course.

For determining the entitlement to attend and vote at the AGM, the register of members of the Company will be closed from Tuesday, May 17, 2022 to Friday, May 20, 2022, both dates inclusive, during which period no transfer of Shares will be registered. In order to be eligible to attend and vote at the AGM, non-registered holders of Shares shall ensure that all transfer documents accompanied by the relevant share certificates must be lodged with the Company's Hong Kong share registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong for registration not later than 4:30 p.m. on Monday, May 16, 2022.

CORPORATE GOVERNANCE

The Corporate Governance Report is set out on pages 46 to 58 of this annual report.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

As of December 31, 2021, for the purpose of the Employee Share Scheme, 1,923,500 shares have been purchased from the market by the trustee appointed by the Company for the administration of the Employee Share Scheme to hold on trust for the benefit of the selected participants pursuant to the rules governing the Employee Share Scheme and the provisions of the trust deed in relation to the Employee Share Scheme.

Save as disclosed in this report, during the year ended December 31, 2021, neither the Company nor any of its subsidiaries had purchased, sold or redeemed any of the Company's listed securities.

SUFFICIENCY OF PUBLIC FLOAT

Based on the information publicly available to the Company and to the best of the Directors' knowledge, information and belief, the Company has always maintained sufficient public float as required under the Listing Rules during the year ended December 31, 2021 and up to the Latest Practicable Date prior to the issue of this annual report.

AUDITOR

The Company has appointed PricewaterhouseCoopers as the auditor of the Company for the year ended December 31, 2021. A resolution will be proposed for approval by Shareholders at the forthcoming AGM to re-appoint PricewaterhouseCoopers as the auditor of the Company.

On behalf of the Board
Jason ZHOU
Chairman, Chief Executive Officer and Executive Director

Beijing, March 28, 2022

Corporate Governance Report

CORPORATE GOVERNANCE PRACTICE

The Board of Directors is committed to maintaining high corporate governance standards. The Board believes that good corporate governance standards are essential in providing a framework for the Group to formulate its business strategies and policies, and to enhance its transparency and accountability.

During the year ended December 31, 2021, the Company has applied the principles as set out in the Corporate Governance Code (the "**CG Code**") set out in Appendix 14 of the Listing Rules, which are applicable to the Company.

In the opinion of the Directors, during the year ended December 31, 2021, the Company has complied with all applicable code provisions as set out in the CG Code, save and except for code provision C.2.1 which states that the roles of chairman and chief executive officer should be separate and should not be performed by the same individual, details of which are set out in the "Chairman and Chief Executive Officer" of this annual report.

MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code as its code of conduct regarding securities transactions by the Directors. The Company has also set guidelines, at least as strict as the Model Code, on transactions of the Company's securities for relevant employees (as defined in the Listing Rules).

The Company has made specific inquiries to all Directors about their compliance with the Model Code, and they all confirmed that they complied with the standards specified in the Model Code during the year ended December 31, 2021. The Company has made specific inquiries of relevant employees about their compliance with the guidelines on transactions of the Company's securities, without noticing any violation of the guidelines.

BOARD OF DIRECTORS

The Board of the Company currently comprises twelve members as follows:

Executive Directors:

Mr. Jason ZHOU *(Chairman, Chief Executive Officer and Chairman of the Nomination Committee)*
Ms. XIN Hong *(Senior Vice President and Chief Operating Officer)*
Mr. XU Han *(Senior Vice President and Chief Financial Officer)*

Non-executive Directors:

Mr. GUO Qizhi *(Member of the Audit Committee)*
Mr. WANG Siye
Dr. CHENG Chi-Kong, Adrian *JP*
Mr. YANG Yuelin *(Member of the Remuneration Committee)*
Mr. XIE Qiang

Independent Non-executive Directors:

Mr. WU Guanxiong *(Chairman of the Remuneration Committee and member of the Nomination Committee)*
Mr. SUN Hongbin *(Chairman of the Audit Committee)*
Mr. JIANG Yanfu *(Member of the Audit Committee and member of the Nomination Committee)*
Dr. MA Jing *(Member of the Remuneration Committee)*

The biographical information of the Directors are set out in the section headed "Directors and Senior Managements" on pages 17 to 22 of this annual report. The relationships between the members of the Board are also disclosed under the same section.

The Board possesses the skills, experience and expertise either in the same industry or relevant to the management of the business of the Group which brings a good balance of relevant skills and experience to the Company. The independent non-executive Directors also provide their independent professional judgements on the assessment of the development, performance and risk management of the Group.

Chairman and Chief Executive Officer

Code provision C.2.1 of the CG Code stipulates that the roles of chairman and chief executive should be separate and should not be performed by the same individual. Mr. Zhou is both Chairman and Chief Executive Officer of the Company, and is responsible for the overall management of our Group and directing the strategic development and business plans of our Group. We believe Mr. Zhou is instrumental to our growth and business expansion since our establishment in 2002. Our Board considers that the roles of chairman and chief executive officer being vested in the same person is beneficial to the business prospects, management and overall strategic direction of our Group by ensuring consistent leadership within our Group and facilitating more effective and efficient overall strategic planning and decision-making for our Group. After considering all the corporate governance measures that have been taken, the Board considers that the balance of power and authority will not be impaired by the present arrangement and the current structure will enable the Company to make and implement decisions more promptly and effectively. Thus, the Company does not segregate the roles of Chairman and Chief Executive Officer. The Board will continue to review the situation and consider splitting the roles of Chairman and Chief Executive Officer of the Company in due course after taking into account of the then overall circumstances of the Group.

Independent Non-executive Directors

During the year ended December 31, 2021, the Board at all times complied with Rules 3.10(1) and (2), and Rule 3.10A of the Listing Rules relating to the appointment of at least three independent non-executive Directors representing one-third of the Board with one of whom possessing appropriate professional qualifications or accounting or related financial management expertise.

The Company has received written annual confirmation from each of the independent non-executive Directors in respect of his/her independence in accordance with the independence guidelines set out in Rule 3.13 of the Listing Rules. The Company is of the view that all independent non-executive Directors are independent.

Relationship

Save as disclosed in this annual report, none of the members of the Board has any relationship between each other.

DIRECTORS' RE-ELECTION

Code provision B.2.2 states that every director, including those appointed for a specific term, shall be subject to retirement by rotation at least once every three years.

Each of the Directors is appointed under a service contract for a term of three years commencing from the date of the service contract which is terminable by either party by giving three months' written notice to the other party.

In accordance with the Articles of Association, all Directors are subject to retirement by rotation and re-election at AGM at least once every three years. Any Director appointed by the Board to fill a casual vacancy shall hold office until the first general meeting and any Director appointed by the Board as an addition to the Board shall hold office until the next following AGM after his/her appointment and they will be subject to re-election at such meeting.

RESPONSIBILITIES, ACCOUNTABILITIES AND CONTRIBUTIONS OF THE BOARD AND MANAGEMENT

The Board is responsible for leadership and control of the Company and oversees the Group's businesses, strategic decisions and performance and is collectively responsible for promoting the success of the Company by directing and supervising its affairs. The Board takes decisions objectively in the interests of the Company.

All Directors, including non-executive Directors and independent non-executive Directors, have brought a wide spectrum of valuable business experience, knowledge and professionalism to the Board for its efficient and effective functioning.

All Directors have full and timely access to all the information of the Company as well as the services and advice from the senior management. The Directors may, upon request, seek independent professional advice in appropriate circumstances, at the Company's expenses for discharging their duties to the Company.

The Directors shall disclose to the Company details of other offices held by them and the Board regularly reviews the contribution required from each Director to perform his responsibilities to the Company.

The Board reserves its decision for all major matters relating to policy matters, strategies and budgets, internal control and risk management, material transactions (in particular those that may involve conflict of interests), financial information, appointment of Directors and other significant operational matters of the Company. Responsibilities relating to implementing decisions of the Board, directing and co-ordinating the daily operation and management of the Company are delegated to the management.

CONTINUOUS PROFESSIONAL DEVELOPMENT OF DIRECTORS

Directors keep abreast of responsibilities as a director of the Company and of the conduct, business activities and development of the Company.

Every newly appointed Director will receive formal and comprehensive induction on the first occasion of his/her appointment to ensure appropriate understanding of the business and operations of the Company and full awareness of director's responsibilities and obligations under the Listing Rules and relevant statutory requirements.

Directors should participate in appropriate continuous professional development to develop and refresh their knowledge and skills to ensure that their contribution to the Board remains informed and relevant. All Directors are encouraged to attend relevant training courses at the Company's expenses.

The Directors confirmed that they have complied with the code provision C.1.4 of the CG Code on Director's training. For the year ended December 31, 2021, all Directors read materials regarding corporate governance, directors' duties, the Listing Rules and other relevant laws. The Directors and senior management have also reviewed the performance of the Company and the sales strategy of the industry and have also discussed the market condition of the industry.

BOARD COMMITTEES

The Board has established three committees, namely, the Audit Committee, the Remuneration Committee and the Nomination Committee for overseeing particular aspects of the Company's affairs. All Board committees of the Company are established with defined written terms of reference. The terms of reference of the Board committees are posted on the Company's website (www.ncich.com.cn) and the HKEx's website (www.hkexnews.hk) and are available to Shareholders upon request.

The majority of the members of each Board committee are independent non-executive Directors and the list of the chairman and members of each Board committee is set out under "Board of Directors" in this Corporate Governance Report.

Audit Committee

The primary duties of the Audit Committee are to review, supervise, and assist our Board in providing an independent view of our financial reporting processes, and internal control and risk management systems, as well as to oversee the audit process, review our annual and interim financial statements, provide advice and comments to the Board on matters related to corporate governance, and perform other duties and responsibilities as assigned by our Board from time to time.

In 2021, the Audit Committee held 3 meetings to review the interim and annual financial results and reports and significant issues on the financial reporting, operational and compliance controls, the effectiveness of the risk management and internal control systems and internal audit function, appointment of external auditors and relevant scope of work and discuss the annual audit plan with auditors.

In 2021, the Audit Committee had 3 meetings with the external auditors of the Company.

Remuneration Committee

The primary duties of the Remuneration Committee are to (i) review the policies and the structure of the remuneration for our Directors and senior management; (ii) evaluate the performance of, and make recommendations on the remuneration packages and long-term incentive compensation or equity plans for, our Directors and senior management; and (iii) evaluate and make recommendations on employee benefit arrangements.

In 2021, the Remuneration Committee held 1 meeting to review and make recommendations to the Board on the remuneration policy and structure of the Company, and the remuneration packages of the Directors and senior management and other related matters.

Nomination Committee

The primary functions of the Nomination Committee are to make recommendations to our Board in relation to the appointment and removal of Directors and senior management, and on matters of succession planning.

In assessing the Board composition, the Nomination Committee would take into account various aspects set out in the board diversity policy of the Company (the "**Board Diversity Policy**"), including but not limited to professional qualifications, regional and industry experience, educational and cultural background, skills, industry knowledge, reputation and gender. The Nomination Committee would discuss and agree on measurable objectives for achieving diversity on the Board, where necessary, and recommend them to the Board for adoption.

In identifying and selecting suitable candidates for directorships, the Nomination Committee would consider the candidate's character, qualifications, experience, independence and other relevant criteria necessary to complement the corporate strategy and achieve Board diversity, where appropriate, before making recommendations to the Board.

In 2021, the Nomination Committee held 1 meeting to review the structure, size and composition of the Board and the independence of the independent non-executive Directors.

Director Nomination Policy

The Company has adopted a director nomination policy (the "**Director Nomination Policy**"), pursuant to which in evaluating and selecting any candidate for directorship, the following criteria should be considered:

- Character and integrity.
- Qualifications including professional qualifications, skills, knowledge and experience and diversity aspects under the Board Diversity Policy that are relevant to the Company's business and corporate strategy.
- Any measurable objectives adopted for achieving diversity on the Board.
- Requirement for the Board to have independent non-executive directors in accordance with the Listing Rules and whether the candidate would be considered independent with reference to the independence guidelines set out in the Listing Rules.
- Any potential contributions the candidate can bring to the Company and/or the Board in terms of qualifications, skills, experience, independence, gender and race diversity.
- Willingness and ability to devote adequate time to discharge duties as a member of the Board and/or Board committee(s) of the Company.
- Such other perspectives that are appropriate to the Company's business and succession plan and where applicable, may be adopted and/or amended by the Board and/or the Nomination Committee from time to time for the nomination of the Directors and succession planning.

As regards selection and appointment of a new Director:

- The Nomination Committee and/or the Board should, upon receipt of a proposal on the appointment of a new director and the biographical information (or relevant details) of the candidate, evaluate such candidate based on the criteria as set out above to determine whether such candidate is qualified for directorship.

- If the process yields more than one desirable candidate, the Nomination Committee and/or the Board should rank them by order of preference based on the needs of the Company and the reference check of each candidate (where applicable).

- The Nomination Committee should then recommend that the Board appoint the most appropriate candidate for directorship, as applicable.

- For any person that is nominated by a shareholder for election as a director at a general meeting of the Company, the Nomination Committee and/or the Board should evaluate such candidate based on the criteria as set out above to determine whether such candidate is qualified for directorship.

Where appropriate, the Nomination Committee and/or the Board should make recommendations to shareholders with respect to the proposed election of directors at a general meeting.

As regards re-election of Directors at general meeting:

- The Nomination Committee and/or the Board should review the overall contribution and service to the Company of each Director and his/her level of participation and performance on the Board.

- The Nomination Committee and/or the Board should also review and determine whether the Director continues to meet the criteria as set out above.

- The Nomination Committee and/or the Board should then make recommendations to shareholders in respect of the proposed re-election or replacement of the Directors at a general meeting.

Where the Board proposes a resolution to elect or re-elect a candidate as Director at a general meeting, the relevant information of the candidate will be disclosed in the circular to Shareholders and/or the explanatory statement that accompanies the notice of the relevant general meeting in accordance with the Listing Rules and/or applicable laws and regulations.

Board Diversity Policy

The Company believes that the Board diversity will have a substantial benefit in improving its performance. Therefore, the Company has adopted the Board Diversity Policy to ensure that the diversity of Board members be considered from a number of perspectives. All Board appointments will be based on meritocracy, and candidates will be considered against objective criteria, having due regard for the benefits of diversity on the Board. A summary of the Board Diversity Policy is set out below:

The Board continuously seeks to enhance its effectiveness and to maintain the highest standards of corporate governance and recognizes diversity at the Board level as an essential element in helping the Company to attract, retain and motivate employees from widest possible pool of available talent so as to better understand and meet customer needs and maintain competitive advantages and sustainable development.

In designing the Board's composition, the Board diversity is considered from a number of perspectives, including but not limited to gender, age, ethnicity, nationality, language skills, cultural and educational background, regional and industry experience and reputation, technical and professional skills and/or qualifications, knowledge, length of services and time to be devoted as a Director. The Company will also take into account factors relating to its own business model and specific needs from time to time. The ultimate decision will be based on merit and contribution that the selected candidates will bring to the Board.

The Nomination Committee will monitor the implementation of the Board Diversity Policy by conducting review of the Board's composition at least once annually taking into account the benefits of all relevant diversity aspects, and adhering to the Board Diversity Policy when making recommendation on any Board appointments.

The Board strives to ensure that it has the appropriate balance of skills, experience and diversity of perspectives that are required to support the execution of its business strategies in order for the Board to be effective.

Corporate Governance Functions

The Board is responsible for performing the functions set out in the code provision A.2.1 of the CG Code.

The Board reviewed the Company's corporate governance policies and practices, training and continuous professional development of Directors and senior management, the Company's policies and practices on compliance with legal and regulatory requirements, the compliance of the Model Code and the guidelines, and the Company's compliance with the CG Code and disclosure in this Corporate Governance Report.

ATTENDANCE RECORD OF DIRECTORS AND COMMITTEE MEMBERS

The attendance record of each Director at the Board and Board Committee meetings and AGM of the Company held during the year ended December 31, 2021 is set out in the table below:

	Attendance/Number of Meetings				
Name of Directors	Board	Nomination Committee	Remuneration Committee	Audit Committee	AGM
Executive Directors					
Mr. Jason ZHOU	4/4	1/1	N/A	N/A	1/1
Ms. XIN Hong	4/4	N/A	N/A	N/A	1/1
Mr. XU Han	4/4	N/A	N/A	N/A	1/1
Non-executive Directors					
Mr. GUO Qizhi	4/4	N/A	N/A	3/3	1/1
Mr. WANG Siye	3/4	N/A	N/A	N/A	1/1
Dr. CHENG Chi-Kong, Adrian *JP*	4/4	N/A	N/A	N/A	1/1
Mr. YANG Yuelin	4/4	N/A	1/1	N/A	1/1
Mr. XIE Qiang	4/4	N/A	N/A	N/A	1/1
Independent Non-executive Directors					
Mr. WU Guanxiong	4/4	1/1	1/1	N/A	1/1
Mr. SUN Hongbin	2/4	N/A	N/A	3/3	1/1
Mr. JIANG Yanfu	3/4	1/1	N/A	3/3	1/1
Dr. MA Jing	3/4	N/A	1/1	N/A	1/1

DIRECTORS' RESPONSIBILITY IN RESPECT OF THE FINANCIAL STATEMENTS

The Directors acknowledge their responsibility for preparing the financial statements of the Company for the year ended December 31, 2021.

The Directors are not aware of any material uncertainties relating to events or conditions that may cast significant doubt upon the Company's ability to continue as a going concern.

The statement of the independent auditor of the Company about their reporting responsibilities on the financial statements is set out in the Independent Auditor's Report on pages 59 to 65 of this annual report.

AUDITOR'S REMUNERATION

An analysis of the remuneration that should be paid to the external auditor of the Company, PricewaterhouseCoopers, for the audit of the year ended December 31, 2021 and non-audit services is set out below:

Service Category	Fees Paid/Payable *RMB'000*
Audit Service of Annual Report	3,200

RISK MANAGEMENT AND INTERNAL CONTROLS

The Board is responsible for maintaining an effective risk management and internal control systems to safeguard the Company's assets and the interests of Shareholders. The Board, through the Audit Committee, conducted a review of the effectiveness of the internal control system of the Company on August 27, 2021, including the adequacy of resources, staff qualifications and experience, training programs and budget of the Company's accounting, internal audit and financial reporting function.

Our risk management and internal control focus primarily on (i) customers and staff safety; (ii) quality control; and (iii) other general risk management. The executive management committee at our Group level is generally responsible for approving all the risk management procedures and internal control systems and our safety and risk management committee oversees the implementation of such procedures and systems by our various operational departments. Meanwhile, our quality assurance committee and various other special committees work together to monitor the implementation of and to conduct regular review and evaluation of such procedures and internal control systems. However, the mechanism under the risk management and internal control systems reasonably but not absolutely ensures the non-occurrence of significant error, loss or fraud and it is designed to manage, rather than eliminate the risk of failure to achieve business objectives.

COMPANY SECRETARY

Mr. JIA Xiaofeng, our company secretary, is responsible for advising the Board on corporate governance matters and ensuring that Board policy and procedures and applicable laws, rules and regulations are followed.

In compliance with Rule 3.29 of the Listing Rules, Mr. JIA Xiaofeng have undertaken no less than 15 hours of relevant professional training during the year ended December 31, 2021.

Dividend Policy

The Company has adopted a dividend policy (the "**Dividend Policy**"). According to the Dividend Policy, in considering the declaration and payment of dividends, the Board shall take into account the following factors of the Group:

- financial results;
- cash flow situation;
- business conditions and strategies;
- future operations and earnings;
- capital requirements and expenditure plans;
- interests of the Shareholders;
- any restrictions on payment of dividends; and
- any other factors that the Board may consider relevant.

The payment of dividend is also subject to compliance with applicable laws and regulations including the laws of the Cayman Islands and the Articles of Association. The Board will continually review the Dividend Policy from time to time and there can be no assurance that dividends will be paid in any particular amount for any given period.

SHAREHOLDERS' RIGHTS

To safeguard shareholder interests and rights, separate resolution will be proposed for each substantially separate issue at general meetings, including the election of individual Directors. All resolutions put forward at general meetings will be voted on by poll pursuant to the Listing Rules and poll results will be posted on the websites of the Company and of the Stock Exchange after each general meeting.

Convening an Extraordinary General Meeting

Pursuant to article 64 of the Articles of Association, any one or more Shareholders holding at the date of deposit of the requisition not less than one-tenth of the paid up capital of the Company carrying the right of voting at general meetings of the Company shall at all times have the right, by written requisition to the Board or the secretary of the Company, to require an extraordinary general meeting to be called by the Board for the transaction of any business specified in such requisition, and such meeting shall be held within two months after the deposit of such requisition. If within twenty-one days of such deposit the Board fails to proceed to convene such meeting, the requisitionist(s) himself (themselves) may do so in the same manner, and all reasonable expenses incurred by the requisitionist(s) as a result of the failure of the Board shall be reimbursed to the requisitionist(s) by the Company.

Putting Forward Proposals at General Meetings

There are no provisions in the Articles of Association or the Companies Law of the Cayman Islands for putting forward proposals of new resolutions by Shareholders at general meetings. Shareholders who wish to move a resolution may request the Company to convene a general meeting in accordance with the procedures set out in the preceding paragraph to consider the business specified in the requisition. For proposing a person for election as a Director, please refer to the "Procedures for Shareholders to Propose a Person for Election as a Director" posted on the Company's website.

Putting Forward Enquiries to the Board

For putting forward any enquiries to the Board of the Company, Shareholders may send written enquiries to the Company. The Company will not normally deal with verbal or anonymous enquiries.

Contact Details

Shareholders may send their enquiries or requests as mentioned above to the following:

Address:	Unit 1-4, 21st Floor, West Tower, Genesis Beijing, 8 Xinyuan South Road Chaoyang District, Beijing, PRC For the attention of the Company Secretary
Fax:	(86) (10) 8524 9988
Email:	xiaofeng.jia@ncich.com.cn

For the avoidance of doubt, Shareholder(s) must deposit and send the original duly signed written requisition, notice or statement, or enquiry (as the case may be) to the above address and provide their full name, contact details and identification in order to give effect thereto. Shareholders' information may be disclosed as required by law.

COMMUNICATION WITH SHAREHOLDERS AND INVESTORS/INVESTOR RELATIONS

The Company considers that effective communication with Shareholders is essential for enhancing investor relations and investor understanding of the Group's business performance and strategies. The Company endeavours to maintain an on-going dialogue with Shareholders and in particular, through AGMs and other extraordinary general meetings. At the AGM, Directors (or their delegates as appropriate) are available to meet Shareholders and answer their enquiries.

During the year ended December 31, 2021, the Company did not make any changes to its Memorandum and Articles of Association. An up-to-date version of the Company's Memorandum and Articles of Association is available on the websites of the Company and the HKEx.

To the Shareholders of New Century Healthcare Holding Co. Limited
(incorporated in the Cayman Islands with limited liability)

OPINION

What we have audited

The consolidated financial statements of New Century Healthcare Holding Co. Limited (the "Company") and its subsidiaries (the "Group"), which are set out on pages 66 to 173, comprise:

- the consolidated balance sheet as at 31 December 2021;
- the consolidated statement of comprehensive income for the year then ended;
- the consolidated statement of changes in equity for the year then ended;
- the consolidated statement of cash flows for the year then ended; and
- the notes to the consolidated financial statements, which include significant accounting policies and other explanatory information.

Our opinion

In our opinion, the consolidated financial statements give a true and fair view of the consolidated financial position of the Group as at 31 December 2021, and of its consolidated financial performance and its consolidated cash flows for the year then ended in accordance with Hong Kong Financial Reporting Standards ("HKFRSs") issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA") and have been properly prepared in compliance with the disclosure requirements of the Hong Kong Companies Ordinance.

Independent Auditor's Report (Continued)

BASIS FOR OPINION

We conducted our audit in accordance with Hong Kong Standards on Auditing ("HKSAs") issued by the HKICPA. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We are independent of the Group in accordance with the HKICPA's Code of Ethics for Professional Accountants ("the Code"), and we have fulfilled our other ethical responsibilities in accordance with the Code.

KEY AUDIT MATTERS

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key audit matter identified in our audit is related to impairment assessment of goodwill:

Key Audit Matter	How our audit addressed the Key Audit Matter
Impairment assessment of goodwill	
Refer to notes 2.8.1, 4(a) and 8 to the consolidated financial statements. As at 31 December 2021, the goodwill amounting to RMB157.84 million arose from historical acquisitions of Beijing New Century Women's and Children's Hospital Co., Ltd., Beijing New Century Ao-dong Clinic Outpatient Service Co., Ltd., Beijing New Century Yide Consultancy Co., Ltd. and Chengdu New Century Women's and Children's Hospital Co., Ltd. Each goodwill was allocated to a cash-generating unit ("CGU") or a group of CGUs to which it related by considering the synergies gained from the acquisitions as described in note 8. The Group performed an impairment assessment as at 31 December 2021 to assess whether goodwill suffered any impairment. The recoverable amount of each CGU or a group of CGUs was determined based on the higher of its respective fair value less costs of disposal and value-in-use calculations. The determination of recoverable amount involved a variety of assumptions, such as compound growth rate of revenue within forecast period, compound growth rate of costs and operating expenses, long-term growth rate and discount rate. Changes in the conditions for these assumptions could significantly affect the recoverable amounts.	We obtained an understanding of the management's internal control and assessment process of impairment assessment of goodwill and assessed the inherent risk of material misstatement by considering the degree of estimation uncertainty and level of other inherent risk factors. We evaluated and tested the key controls over the impairment assessment of goodwill. We evaluated the competence, capability and objectivity of the external valuation expert engaged by management. With the support of our internal valuation experts, we assessed the appropriateness of valuation model applied and parameters selected by management under the support of the external valuation expert. We assessed the significant estimates and judgements used in determining the recoverable amounts of each CGU or a group of CGUs as follows: • compound growth rate of revenue within forecast period by reference to management's research and analysis based on industry information and data; • compound growth rate of costs and operating expenses by reference to the historical financial performance of each CGU or a group of CGUs; • long-term growth rate by reference to the long-term inflation rate of China; • discount rate by reference to the cost of equity of comparable companies. We also checked the mathematical accuracy of the calculations of methods used by management when performed the impairment assessment.

Key Audit Matter	How our audit addressed the Key Audit Matter
Impairment assessment of goodwill	
We focused on auditing the impairment assessment of goodwill because the estimation of recoverable amounts is subject to high degree of estimation uncertainty. The inherent risk in relation to the impairment assessment of goodwill is considered significant due to subjectivity of significant assumptions used and significant judgements involved in selecting parameters.	We assessed the sensitivity analysis performed by management with potential impacts on the above key assumptions to further understand the extent to which adverse changes, either individually or in aggregate, would result in the goodwill being impaired. We also considered whether the judgements made in selecting the significant assumptions and data would give rise to indicators of possible management bias. We assessed the adequacy of the disclosures related to impairment assessment of goodwill in the context of the applicable financial reporting framework. Based on the above, we considered that management's judgements and assumptions applied in the impairment assessment of goodwill were supportable by the evidence obtained and procedures performed.

OTHER INFORMATION

The directors of the Company are responsible for the other information. The other information comprises all of the information included in New Century Healthcare Holding Co. Limited Annual Report 2021 (the "annual report") other than the consolidated financial statements and our auditor's report thereon. We have obtained some of the other information including the Chairman's Statement, Management Discussion and Analysis and Directors' Report prior to the date of this auditor's report. The remaining other information, including the Directors and Senior Managements, Corporate Governance Report and the other sections to be included in the annual report, is expected to be made available to us after that date.

Our opinion on the consolidated financial statements does not cover the other information and we do not and will not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed on the other information that we obtained prior to the date of this auditor's report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

When we read the remaining other information to be included in the annual report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to the Audit Committee and take appropriate action considering our legal rights and obligations.

RESPONSIBILITIES OF DIRECTORS AND THE AUDIT COMMITTEE FOR THE CONSOLIDATED FINANCIAL STATEMENTS

The directors of the Company are responsible for the preparation of the consolidated financial statements that give a true and fair view in accordance with HKFRSs issued by the HKICPA and the disclosure requirements of the Hong Kong Companies Ordinance, and for such internal control as the directors determine is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, the directors are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

The Audit Committee is responsible for overseeing the Group's financial reporting process.

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. We report our opinion solely to you, as a body, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with HKSAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with HKSAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.

- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with the Audit Committee regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the Audit Committee with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or safeguards applied.

From the matters communicated with the Audit Committee, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partner on the audit resulting in this independent auditor's report is Tsun Ng.

PricewaterhouseCoopers
Certified Public Accountants

Hong Kong, 28 March 2022

Consolidated balance sheet

	Notes	As at 31 December 2021 RMB'000	2020 RMB'000
ASSETS			
Non-current assets			
Property, plant and equipment	6	161,967	198,898
Right-of-use assets	7(a)	223,969	308,785
Intangible assets	8	412,989	424,330
Investments accounted for using the equity method	10	1,809	2,575
Deferred tax assets	24	598	499
Long-term deposits and prepayments	14	8,133	10,709
Total non-current assets		809,465	945,796
Current assets			
Inventories	12	21,142	19,584
Trade receivables	13	39,351	28,577
Other receivables, deposits and prepayments	14	18,170	16,874
Amounts due from related parties	15	158,925	161,003
Cash and cash equivalents	16	223,843	299,211
Total current assets		461,431	525,249
Total assets		1,270,896	1,471,045
EQUITY			
Share capital	17	335	335
Shares held for employee share scheme	18	(2,829)	(2,826)
Share premium	19	2,606,495	2,606,495
Reserves	19	(1,494,950)	(1,499,996)
Accumulated losses		(371,592)	(265,375)
Equity attributable to owners of the Company		737,459	838,633
Non-controlling interests		(53,221)	(26,781)
Total equity		684,238	811,852

		As at 31 December	
	Notes	2021 RMB'000	2020 RMB'000
LIABILITIES			
Non-current liabilities			
Lease liabilities	7(a)	243,498	321,256
Deferred tax liabilities	24	51,983	55,790
Deferred income		–	2,641
Total non-current liabilities		295,481	379,687
Current liabilities			
Trade payables	22	27,448	25,618
Accruals, other payables and provisions	23	185,421	171,183
Contract liabilities	5(g)	30,399	30,539
Current tax liabilities		5,852	8,113
Lease liabilities	7(a)	36,743	39,839
Amounts due to related parties	15	5,314	4,214
Total current liabilities		291,177	279,506
Total liabilities		586,658	659,193
Total equity and liabilities		1,270,896	1,471,045

The above consolidated balance sheet should be read in conjunction with the accompanying notes.

The financial statements on pages 66 to 173 were approved by the Board of Directors on 28 March 2022 and were signed on its behalf:

Jason ZHOU

XU Han

Consolidated statement of comprehensive income

	Notes	Year ended 31 December 2021 RMB'000	2020 RMB'000
Revenue	5(f)	632,565	512,785
Cost of revenue	25	(433,830)	(377,021)
Gross profit		198,735	135,764
Selling expenses	25	(60,811)	(44,068)
Administrative expenses	25	(156,429)	(123,269)
Research and development expenses	25	(10,574)	(14,467)
Net impairment losses on financial assets	3.1.2	(7,582)	(6,211)
Impairment losses on non-current assets	27	(15,010)	(264,271)
Other income		3,661	3,782
Other gains – net	28	3,160	3,979
Operating loss		(44,850)	(308,761)
Finance income	29	3,059	3,287
Finance costs	29	(16,653)	(23,327)
Share of net (loss)/profit of investments accounted for using the equity method	10	(703)	54
Loss before income tax		(59,147)	(328,747)
Income tax expense	30	(26,115)	(48,787)
Loss for the year		(85,262)	(377,534)
(Loss)/profit for the year is attributable to:			
Owners of the Company		(101,461)	(371,383)
Non-controlling interests		16,199	(6,151)
Other comprehensive income			
Items that may be reclassified to profit or loss			
– Exchange differences on translation of foreign operations		290	406
Total comprehensive loss		(84,972)	(377,128)
Total comprehensive (loss)/income for the year is attributable to:			
Owners of the Company		(101,171)	(370,977)
Non-controlling interests		16,199	(6,151)
Loss per share for loss attributable to the ordinary equity holders of the Company (expressed in RMB per share)			
Basic and diluted loss per share	31	(0.21)	(0.77)

The above consolidated statement of comprehensive income should be read in conjunction with the accompanying notes.

Consolidated statement of changes in equity

		Attributable to owners of the Company							
	Notes	Share capital *RMB'000*	Share held for employee share scheme *RMB'000*	Share premium *RMB'000*	Reserves *RMB'000*	Retained earnings/ (accumulated losses) *RMB'000*	Total *RMB'000*	Non-controlling interests *RMB'000*	Total equity *RMB'000*
Balance at 1 January 2020		335	–	2,606,262	(1,507,673)	111,881	1,210,805	22,723	1,233,528
Total comprehensive (loss)/income									
– Loss for the year		–	–	–	–	(371,383)	(371,383)	(6,151)	(377,534)
– Translation differences		–	–	–	406	–	406	–	406
		–	–	–	406	(371,383)	(370,977)	(6,151)	(377,128)
Transactions with owners									
– Dividends	21	–	–	–	–	–	–	(43,353)	(43,353)
– Appropriation to statutory surplus reserves		–	–	–	5,873	(5,873)	–	–	–
– Shares exercised under restricted share award scheme		–	–	233	(168)	–	65	–	65
– Share-based payments	20	–	–	–	1,566	–	1,566	–	1,566
– Acquisition of shares for employee share scheme	18	–	(2,826)	–	–	–	(2,826)	–	(2,826)
		–	(2,826)	233	7,271	(5,873)	(1,195)	(43,353)	(44,548)
Balance at 31 December 2020		335	(2,826)	2,606,495	(1,499,996)	(265,375)	838,633	(26,781)	811,852

Consolidated statement of changes in equity (Continued)

		Attributable to owners of the Company							
	Notes	Share capital *RMB'000*	Share held for employee share scheme *RMB'000*	Share premium *RMB'000*	Reserves *RMB'000*	Retained earnings/ (accumulated losses) *RMB'000*	Total *RMB'000*	Non-controlling interests *RMB'000*	Total equity *RMB'000*
Balance at 1 January 2021		335	(2,826)	2,606,495	(1,499,996)	(265,375)	838,633	(26,781)	811,852
Total comprehensive (loss)/income									
– (Loss)/profit for the year		–	–	–	–	(101,461)	(101,461)	16,199	(85,262)
– Translation differences		–	–	–	290	–	290	–	290
		–	–	–	290	(101,461)	(101,171)	16,199	(84,972)
Transactions with owners									
– Dividends	21	–	–	–	–	–	–	(42,639)	(42,639)
– Appropriation to statutory surplus reserves		–	–	–	4,756	(4,756)	–	–	–
– Acquisition of shares for employee share scheme	18	–	(3)	–	–	–	(3)	–	(3)
		–	(3)	–	4,756	(4,756)	(3)	(42,639)	(42,642)
Balance at 31 December 2021		335	(2,829)	2,606,495	(1,494,950)	(371,592)	737,459	(53,221)	684,238

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

Consolidated statement of cash flows

		Year ended 31 December	
		2021	2020
	Notes	*RMB'000*	*RMB'000*
Cash flows from operating activities			
Cash generated from operations	32(a)	62,700	26,055
Interest paid		(10,220)	(9,663)
Interest received		2,057	2,162
Income taxes paid		(32,282)	(22,776)
Net cash generated from/(used in) operating activities		22,255	(4,222)
Cash flows from investing activities			
Proceeds from acquisition of subsidiaries, net of cash acquired		–	3,342
Payments for property, plant and equipment		(11,232)	(11,389)
Payments for intangible assets		(1,923)	(3,120)
Proceeds from disposals of property, plant and equipment		262	134
Payments for financial assets		–	(294,200)
Proceeds from redemption of financial assets		–	355,100
Interest received on financial assets		–	1,354
Loans to related parties		(2,850)	(3,400)
Net cash (used in)/generated from investing activities		(15,743)	47,821

Consolidated statement of cash flows (Continued)

	Notes	Year ended 31 December 2021 RMB'000	2020 RMB'000
Cash flows from financing activities			
Dividends paid to the non-controlling interests	21	(42,639)	(43,353)
Principal elements of lease payments		(37,201)	(40,359)
Proceeds from shares exercised under share award scheme		–	65
Shares repurchase for employee share scheme		(3)	(2,826)
Net cash used in financing activities		(79,843)	(86,473)
Net decrease in cash and cash equivalents		(73,331)	(42,874)
Cash and cash equivalents at the beginning of the year		299,211	349,125
Effects of exchange rate changes on cash and cash equivalents		(2,037)	(7,040)
Cash and cash equivalents at the end of the year		223,843	299,211

The above consolidated statement of cash flows should be read in conjunction with the accompanying notes.

1 GENERAL INFORMATION AND BASIS OF PRESENTATION

1.1 General information

New Century Healthcare Holding Co. Limited (the "Company") and its subsidiaries (together, the "Group") are principally engaged in provision of pediatrics and obstetrics and gynecology specialty services in the People's Republic of China (the "PRC"). The Group also provides hospital consulting services to a related party of the Group and online healthcare services.

The Company is a limited liability company incorporated in the Cayman Islands on 31 July 2015. The address of its registered office is c/o Walkers Corporate Limited, 190 Elgin Avenue, George Town, Grand Cayman KY1-9008, Cayman Islands.

The ordinary shares of the Company were listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "Listing") on 18 January 2017.

The consolidated financial statements are presented in Renminbi ("RMB") and rounded to nearest thousand yuan, unless otherwise stated.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

This note provides a list of the significant accounting policies adopted in the preparation of these consolidated financial statements. These policies have been consistently applied to all the years presented, unless otherwise stated. The consolidated financial statements are for the Group consisting of the Company and its subsidiaries.

2.1 Basis of preparation

2.1.1 Compliance with HKFRS and HKCO

The consolidated financial statements of the Group have been prepared in accordance with Hong Kong Financial Reporting Standards ("HKFRS") and requirements of the Hong Kong Companies Ordinance ("HKCO") Cap. 622.

2.1.2 Historical cost convention

The consolidated financial statements have been prepared under the historical cost basis.

2.1.3 New and amended standards and interpretations adopted by the Group

The Group has applied the following for the first time for their annual reporting period commencing 1 January 2021:

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.1 Basis of preparation (Continued)

2.1.3 New and amended standards and interpretations adopted by the Group (Continued)

- Interest Rate Benchmark Reform – Phase 2 – Amendments to HKFRS 9, HKAS 39, HKFRS 7, HKFRS 4 and HKFRS 16

The amendments listed above do not have any material impact on the amounts recognised in prior periods and are not expected to significantly affect the current or future periods.

2.1.4 New and amended standards and interpretations not yet adopted

		Effective for annual periods beginning on or after
• Amendments to HKAS 16	Property, Plant and Equipment: Proceeds before intended use	1 January 2022
• Amendments to HKAS 37	Onerous Contracts – Cost of Fulfilling a Contract	1 January 2022
• Amendments to HKFRS 3	Reference to the Conceptual Framework	1 January 2022
• Annual Improvements 2018-2020 cycle	Annual Improvements 2018-2020 cycle	1 January 2022
• HKFRS 17	Insurance Contracts	1 January 2023
• Amendments to HKAS 1	Classification of Liabilities as Current or Non-current	1 January 2023
• Amendments to HKAS 1 and HKFRS Practice Statement 2	Disclosure of Accounting Policies	1 January 2023
• Amendments to HKAS 8	Definition of Accounting Estimates	1 January 2023
• Amendments to HKAS 12	Deferred Tax related to Assets and Liabilities arising from a Single Transaction	1 January 2023

There are no new standards, amendments to existing standards or interpretations that are not yet effective and would be expected to have a material impact to the Group.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.2 Principles of consolidation and equity accounting

2.2.1 Subsidiaries

Subsidiaries are all entities (including structured entities) over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date that control ceases.

The acquisition method of accounting is used to account for business combinations by the Group (refer to note 2.3).

Intercompany transactions, balances and unrealised gains on transactions between group companies are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group.

Non-controlling interests in the results and equity of subsidiaries are shown separately in the consolidated statement of comprehensive income, statement of changes in equity and balance sheet respectively.

2.2.2 Associates

Associates are entities over which the Group has significant influence but not control or joint control. Investments in associates are accounted for using the equity method of accounting (see 2.2.3 below), after initially being recognised at cost.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.2 Principles of consolidation and equity accounting(Continued)

2.2.3 Equity method

Under the equity method of accounting, the investments are initially recognised at cost and adjusted thereafter to recognise the Group's share of the post-acquisition profits or losses of the investee in profit or loss, and the Group's share of movements in other comprehensive income of the investee in other comprehensive income. Dividends received or receivable from associates are recognised as a reduction in the carrying amount of the investment.

When the Group's share of losses in an equity-accounted investment equals or exceeds its interest in the entity, including any other unsecured long-term receivables, the Group does not recognise further losses, unless it has incurred obligations or made payments on behalf of the other entity.

Unrealised gains on transactions between the Group and its associates are eliminated to the extent of the Group's interest in these entities. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Accounting policies of equity accounted investees have been changed where necessary to ensure consistency with the policies adopted by the Group.

The carrying amount of equity-accounted investments is tested for impairment in accordance with the policy described in note 2.9.

2.2.4 Changes in ownership interests

The Group treats transactions with non-controlling interests that do not result in a loss of control as transactions with equity owners of the Group. A change in ownership interest results in an adjustment between the carrying amounts of the controlling and non-controlling interests to reflect their relative interests in the subsidiary. Any difference between the amount of the adjustment to non-controlling interests and any consideration paid or received is recognised in a separate reserve within equity attributable to owners of the Group.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.3 Business combinations

The acquisition method of accounting is used to account for all business combinations, regardless of whether equity instruments or other assets are acquired. The consideration transferred for the acquisition of a subsidiary comprises the:

- Fair values of the assets transferred
- Liabilities incurred to the former owners of the acquired business
- Equity interests issued by the Group
- Fair value of any asset or liability resulting from a contingent consideration arrangement, and
- Fair value of any pre-existing equity interest in the subsidiary.

Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are, with limited exceptions, measured initially at their fair values at the acquisition date. The Group recognises any non-controlling interest in the acquired entity on an acquisition-by-acquisition basis either at fair value or at the non-controlling interest's proportionate share of the acquired entity's net identifiable assets.

Acquisition-related costs are expensed as incurred.

The excess of the:

- Consideration transferred,
- Amount of any non-controlling interest in the acquired entity, and
- Acquisition-date fair value of any previous equity interest in the acquired entity

over the fair value of the net identifiable assets acquired is recorded as goodwill. If those amounts are less than the fair value of the net identifiable assets of the business acquired, the difference is recognised directly in profit or loss as a bargain purchase.

Where settlement of any part of cash consideration is deferred, the amounts payable in the future are discounted to their present value as at the date of exchange. The discount rate used is the entity's incremental borrowing rate, being the rate at which a similar borrowing could be obtained from an independent financier under comparable terms and conditions. Contingent consideration is classified either as equity or a financial liability. Amounts classified as a financial liability are subsequently remeasured to fair value with changes in fair value recognised in profit or loss.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.3 Business combinations (Continued)

If the business combination is achieved in stages, the acquisition date carrying value of the acquirer's previously held equity interest in the acquire is remeasured to fair value at the acquisition date. Any gains or losses arising from such remeasurement are recognised in profit or loss.

2.4 Separate financial statements

Investments in subsidiaries are accounted for at cost less impairment. Cost includes direct attributable costs of investment. The results of subsidiaries are accounted for by the Company on the basis of dividend received and receivable.

Impairment testing of the investments in subsidiaries is required upon receiving a dividend from these investments if the dividend exceeds the total comprehensive income of the subsidiary in the period the dividend is declared or if the carrying amount of the investment in the separate financial statements exceeds the carrying amount in the consolidated financial statements of the investee's net assets including goodwill.

2.5 Segment reporting

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segment and making strategic decisions. The chief operating decision-maker has been identified as the executive directors.

2.6 Foreign currency translation

2.6.1 Functional and presentation currency

Items included in the financial statements of each of the Group's entities are measured using the currency of the primary economic environment in which the entity operates ("the functional currency"). Since the majority of the assets and operations of the Group are located in the PRC, the consolidated financial statements are presented in RMB, which is the Group's functional and presentation currency.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.6 Foreign currency translation (Continued)

2.6.2 Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the consolidated statement of comprehensive income.

Foreign exchange gains and losses that relate to cash and cash equivalents are presented in the consolidated statement of comprehensive income within finance income or expenses. All other foreign exchange gains and losses are presented in the consolidated statement of comprehensive income within "other gains — net".

Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. Translation differences on assets and liabilities carried at fair value are reported as part of the fair value gain or loss. For example, translation differences on non-monetary assets and liabilities such as equities held at fair value through profit or loss are recognised in profit or loss as part of the fair value gain or loss and translation differences on non-monetary assets such as equities classified as fair value through other comprehensive income are recognised in other comprehensive income.

2.7 Property, plant and equipment

Property, plant and equipment is stated at historical cost less accumulated depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognised when replaced. All other repairs and maintenance are charged to the income statement during the reporting period in which they are incurred.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.7 Property, plant and equipment (Continued)

Depreciation on property, plant and equipment is calculated using the straight-line method to allocate their cost, net of their residual values, over their estimated useful lives or, in the case of leasehold improvements and certain leased plant and equipment, as follows:

–	Medical equipment	5-10 years
–	Office equipment and furniture	3-5 years
–	Motor vehicles	4-10 years
–	Leasehold improvements	Shorter of remaining lease term or estimated useful life

The assets' residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.

An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount (note 2.9).

Gains and losses on disposals are determined by comparing proceeds with carrying amount and are recognised within "other gains — net" in the consolidated statement of comprehensive income.

Construction-in-progress (the "CIP") represents leasehold improvements under construction and is stated at cost less accumulated impairment losses, if any. Cost includes the costs of construction and acquisition and capitalized borrowing costs. No provision for depreciation is made on CIP until such time as the relevant assets are completed and ready for intended use. When the assets concerned are available for use, the cost are transferred to leasehold improvement and amortised in accordance with the policy as stated above.

2.8 Intangible assets

2.8.1 Goodwill

Goodwill is measured as described in note 2.3. Goodwill on acquisitions of subsidiaries is included in intangible assets. Goodwill is not amortised but it is tested for impairment annually, or more frequently if events or changes in circumstances indicate that it might be impaired, and is carried at cost less accumulated impairment losses.

Goodwill is allocated to each of the cash-generating unit ("CGU"), or groups of CGUs, that are expected to benefit from the synergies of the business combination in which the goodwill arose. Each unit or group of units are identified at the lowest level at which the goodwill is monitored for internal management purposes, being the operating segments.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.8 Intangible assets (Continued)

2.8.2 Medical licenses

Medical licenses acquired in a business combination are recognised at fair value at the acquisition date. These medical licenses have a finite useful life and are subsequently carried at cost less accumulated amortisation and impairment losses. Amortisation is calculated using the straight-line method to allocate the cost of licenses over their estimated useful lives.

2.8.3 Software

Acquired computer software and mobile software are capitalised on the basis of the costs incurred to acquire and bring the specific software into usage.

Costs associated with maintaining computer and mobile software programs are recognised as an expense as incurred. Development costs that are directly attributable to the design and testing of identifiable and unique software products controlled by the Group are recognised as intangible assets when the following criteria are met:

- It is technically feasible to complete the software product so that it will be available for use;
- Management intends to complete the software product and use or sell it;
- There is an ability to use or sell the software product;
- It can be demonstrated how the software product will generate probable future economic benefits;
- Adequate technical, financial and other resources to complete the development and to use or sell the software product are available; and
- The expenditure attributable to the software product during its development can be reliably measured.

Development expenditures that do not meet these criteria are recognised as an expense as incurred.

Software are amortised using the straight-line method over their estimated useful lives.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.9 Impairment of non-financial assets

Goodwill is tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. Other assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or group of assets (cash-generating units, CGUs). Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting period.

2.10 Financial assets

2.10.1 Classification

The Group classifies its financial assets in the following measurement categories:

- Those to be measured subsequently at fair value (either through other comprehensive income ("OCI"), or through profit or loss); and
- Those to be measured at amortised cost.

The classification depends on the entity's business model for managing the financial assets and the contractual terms of the cash flows.

For assets measured at fair value, gains and losses will either be recorded in profit or loss or OCI. For investments in equity instruments that are not held for trading, this will depend on whether the Group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through other comprehensive income ("FVOCI").

The Group reclassifies debt investments when and only when its business model for managing those assets changes.

2.10.2 Recognition and derecognition

Regular way purchases and sales of financial assets are recognised on the trade-date, the date on which the Group commits to purchase or sell the asset. Financial assets are derecognised when the rights to receive cash flows from the financial assets have expired or have been transferred and the Group has transferred substantially all the risks and rewards of ownership.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.10 Financial assets (Continued)

2.10.3 Measurement

At initial recognition, the Group measures a financial asset at its fair value plus, in the case of a financial asset not at FVPL, transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVPL are expensed in the consolidated statement of comprehensive income.

Financial assets with embedded derivatives are considered in their entirety when determining whether their cash flows are solely payment of principal and interest.

Debt Instruments

Subsequent measurement of debt instruments depend on the Group's business model for managing the asset and the cash flow characteristics of the asset. There are three measurement categories into which the Group classifies its debt instruments:

- Amortised cost: Assets that are held for collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortised cost. Interest income from these financial assets is included in "finance income" using the effective interest rate method. Any gain or loss arising on derecognition is recognised directly in the consolidated statement of comprehensive income and presented in "other gains – net", together with foreign exchange gains and losses. Impairment losses are presented as separate line item in the consolidated statement of comprehensive income.

- FVOCI: Assets that are held for collection of contractual cash flows and for selling the financial assets, where the assets' cash flows represent solely payments of principal and interest, are measured at FVOCI. Movements in the carrying amount are taken through OCI, except for the recognition of impairment gains or losses, interest income and foreign exchange gains and losses which are recognised in the consolidated statement of comprehensive income. When the financial asset is derecognised, the cumulative gain or loss previously recognised in OCI is reclassified from equity to the consolidated statement of comprehensive income and recognised in "other gains – net". Interest income from these financial assets is included in "finance income" using the effective interest rate method. Foreign exchange gains and losses are presented in "other gains – net" and impairment expenses are presented as separate line item in the consolidated statement of comprehensive income.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.10 Financial assets (Continued)

2.10.3 Measurement (Continued)

Debt Instruments (Continued)

- FVPL: Assets that do not meet the criteria for amortised cost or FVOCI are measured at FVPL. A gain or loss on a debt investment that is subsequently measured at FVPL is recognised in the consolidated statement of comprehensive income and presented net within "other gains – net" in the period in which it arises.

Equity instruments

The Group subsequently measures all equity investments at fair value. Where the Group's management has elected to present fair value gains and losses on equity investments in OCI, there is no subsequent reclassification of fair value gains and losses to profit or loss following the derecognition of the investment. Dividends from such investments continue to be recognised in profit or loss as other income when the Group's right to receive payments is established.

Changes in the fair value of financial assets at FVPL are recognised in "other gains – net" in the statement of comprehensive income as applicable. Impairment losses (and reversal of impairment losses) on equity investments measured at FVOCI are not reported separately from other changes in fair value.

2.10.4 Impairment

The Group assesses on a forward looking basis the expected credit losses associated with its debt instruments carried at amortised cost and FVOCI. The impairment methodology applied depends on whether there has been a significant increase in credit risk.

For trade receivables, the Group applies the simplified approach permitted by HKFRS 9, which requires expected lifetime losses to be recognised from initial recognition of the receivables, see note 13 for further details.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.11 Offsetting financial instruments

Financial assets and liabilities are offset and the net amount reported in the balance sheet when there is a legally enforceable right to offset the recognised amounts, and there is an intention to settle on a net basis or realise the asset and settle the liability simultaneously. The legally enforceable right must not be contingent on future events and must be enforceable in the normal course of business and in the event of default, insolvency or bankruptcy of the company or the counterparty.

2.12 Inventories

Inventories are stated at the lower of cost and net realisable value. Cost is determined using the first-in, first-out (FIFO) method. Net realisable value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses.

2.13 Trade and other receivables

Trade receivables are amounts due from customers, government's social insurance schemes, and commercial insurance companies for services rendered and goods sold in the ordinary course of business. If collection of trade and other receivables is expected in one year or less (or in the normal operating cycle of the business if longer), they are classified as current assets. If not, they are presented as non-current assets.

Trade and other receivables are recognised initially at the amount of consideration that is unconditional unless they contain significant financing components, when they are recognised at fair value. The Group holds the trade and other receivables with the objective to collect the contractual cash flows and therefore measures them subsequently at amortised cost using the effective interest method. See note 13 for further information about the Group's accounting for trade receivables and note 3.1.2 for the description of the Group's impairment policies.

2.14 Cash and cash equivalents

For the purpose of presentation in the consolidated statement of cash flows, cash and cash equivalents includes cash on hand, deposits held at call with banks, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.15 Share capital

Ordinary shares are classified as equity.

Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.

Where any group company purchases the Company's equity share capital (treasury share), the considerations paid, including any directly attributable incremental costs, is deducted from equity attributable to the owners of the Company until the shares are cancelled or reissued. Where such shares are subsequently reissued, any consideration received (net of any directly attributable incremental transaction costs) is included in equity attributable to the owners of the Company.

2.16 Shares held for restricted share award scheme ("RSA Scheme") and employee share scheme

2.16.1 The consideration paid by the Talent Wise Investments Limited (note 20) for purchasing the Company's shares for the RSA Scheme from the market, including any directly attributable incremental cost, is presented as "Shares held for restricted share award scheme" and the amount is deducted from total equity.

When the Talent Wise Investments Limited transfers the Company's shares to the awardees upon vesting, the related costs of the awarded shares vested are credited to "Shares held for restricted share award scheme", with a corresponding adjustment made to "Share premium".

2.16.2 Where the Company purchases the Company's equity instruments, for example as the result of a share buy-back or a share-based payment plan, the consideration paid, including any directly attributable incremental costs (net of income taxes) is deducted from equity attributable to the owners of the Group as treasury shares until the shares are cancelled or reissued. Where such ordinary shares are subsequently reissued, any consideration received, net of any directly attributable incremental transaction costs and the related income tax effects, is included in equity attributable to the owners of the Group.

Shares held for employee share scheme (note 18) are disclosed as treasury shares and deducted from equity attributable to the owners of the Group.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.17 Trade and other payables

Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Trade and other payables are classified as current liabilities if payment is due within one year or less (or in the normal operating cycle of the business if longer). If not, they are presented as non-current liabilities.

Trade and other payables are recognised initially at fair value and subsequently measured at amortised cost using the effective interest method.

2.18 Current and deferred income tax

The income tax expense or credit for the period is the tax payable on the current period's taxable income based on the applicable income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses.

2.18.1 Current income tax

The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the Company and its subsidiaries and associates operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

2.18.2 Deferred income tax

Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, deferred tax liabilities are not recognised if they arise from the initial recognition of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit nor loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantively enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realised or the deferred tax liability is settled.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.18 Current and deferred income tax (Continued)

2.18.2 Deferred income tax (Continued)

Deferred tax assets are recognised only to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized.

Deferred tax liabilities and assets are not recognised for temporary differences between the carrying amount and tax bases of investments in foreign operations where the Group is able to control the timing of the reversal of the temporary differences and it is probable that the differences will not reverse in the foreseeable future.

Deferred tax assets and liabilities are offset where there is a legally enforceable right to offset current tax assets against current tax liabilities and where the deferred tax balances relate to the same taxation authority. Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Current and deferred tax is recognised in the statement of comprehensive income.

2.18.3 Investment allowances and similar tax incentives

Companies within the Group may be entitled to claim special tax deductions for investments in qualifying assets or in relation to qualifying expenditure (eg. the Research and Development Tax Incentive regime in technology development). The Group accounts for such allowances as tax credits, which means that the allowance reduces income tax payable and current tax expense. A deferred tax asset is recognised for unclaimed tax credits that are carried forward as deferred tax assets.

2.19 Employee benefits

2.19.1 Short-term obligations

Liabilities for wages and salaries, including non-monetary benefits and accumulating sick leave that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognised in respect of employees' services up to the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. The liabilities are presented as current employee benefit obligations in the balance sheet.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.19 Employee benefits (Continued)

2.19.2 Pension obligations

The subsidiaries of the Group which are incorporated in the PRC contribute based on certain percentage of the salaries of the employees to a defined contribution retirement plan organised by relevant government authorities in the PRC on a monthly basis. The government authorities undertake to assume the retirement benefit obligations payable to all existing and future retired employees under these plans and the Group has no further obligation for post-retirement benefits beyond the contributions made. Contributions to these plans are expensed as incurred. Assets of the plans are held and managed by government authorities and are separate from those of the Group.

There were no forfeited contributions (by employers on behalf of employees who leave the scheme prior to vesting fully in such contributions) to offset existing contributions under the defined contribution schemes.

No other defined benefit plan was operated by the Group.

2.20 Share-based payments

Under the RSA Scheme, equity-settled share-based payments to directors and employees are measured at the fair value of restricted shares at the grant date. Details regarding the determination of the fair value of the shares relating to the RSA Scheme is set out in note 20.

The difference between the fair value determined at the grant date of the equity-settled share-based payments and the exercise price is expensed on a straight-line basis over the vesting period with a corresponding increase in equity.

At the end of each reporting period, management will assess the number of the shares which would be vested based on the Group's estimation with consideration of the non-market performance and service conditions of the employees under the RSA Scheme. It recognises the impact of the revision to original estimates, if any, in profit or loss, with a corresponding adjustment to reserves for share-based payments.

Where any modifications to the terms and conditions of RSA Scheme increases the fair value or the number of the shares granted, or are otherwise beneficial to the employee, the Group should recognise the incremental fair value of the equity-settled share-based payments at the date of the modification. If the Group modifies the terms or conditions of the equity instruments granted in a manner that reduces the total fair value of the share-based payments arrangement, or is not otherwise beneficial to the employee, the entity shall nevertheless continue to account for the services received as consideration for the equity instruments granted as if that modification had not occurred.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.21 Provisions

Provisions are recognised when the Group has a present legal or constructive obligation as a result of past events, it is probable that an outflow of resources will be required to settle the obligation, and the amount can be reliably estimated. Provisions are not recognised for future operating losses.

Where there are a number of similar obligations, the likelihood that an outflow will be required in settlement is determined by considering the class of obligations as a whole. A provision is recognised even if the likelihood of an outflow with respect to any one item included in the same class of obligations may be small.

Provisions are measured at the present value of management's best estimate of the expenditures required to settle the present obligation at the end of the reporting period. The discount rate used to determine the present value is a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the obligation. The increase in the provision due to passage of time is recognised as interest expense.

2.22 Revenue recognition

The Group's revenue is primarily derived from providing medical services to customers, especially in pediatric, obstetric and gynecologic and other related medical services, sales of pharmaceuticals and related goods and the hospital consulting services to the related party.

Revenues are recognised when, or as, the control of the goods or services is transferred to the customer. Depending on the terms of the contract and the laws applicable, control of the goods and services may be transferred over time or at a point in time. Control of the goods and services is transferred over time if the Group's performance:

- Provides all of the benefits received and consumed simultaneously by the customer;
- Creates and enhances an asset that the customer controls as the Group performs; or
- Does not create an asset with an alternative use to the Group and the Group has an enforceable right to payment for performance completed to date.

If control of the goods and services transfers over time, revenue is recognised over the period of the contract by reference to the progress towards complete satisfaction of that performance obligation. Otherwise, revenue is recognised at a point in time when the customer obtains control of the goods and services.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.22 Revenue recognition (Continued)

The progress towards complete satisfaction of performance obligation, depending on the nature of the good and service to be transferred, is measured based on one of the following methods that best depicts the Group's performance in satisfying the performance obligation:

- Direct measurements of the value of individual services transferred by the Group to the customer; or

- The Group's efforts or inputs to the satisfaction of the performance obligation.

The following is a description of the accounting policy for the principal revenue streams of the Group.

2.22.1 Provision of medical services

Revenue from providing medical services including pediatrics, obstetrics and gynecology services is recognised at the point when the related services are rendered. Transactions are settled by payment from commercial insurance, government's insurance scheme, or directly paid by bank cards or cash from customers.

The Group sells membership cards to customers which entitles them to purchase medical services at different discount rates depending on the type of membership cards. The Group initially recognised the total membership fees received from customers as "contract liabilities". After initial recognition, the Group recognises relevant membership fees as revenue at the time when provides services to the membership card holder during the membership period. The contract liabilities is recognised as revenue based on the portion of the enjoyed discount amount to the total expected discount amount during the whole membership period.

The Group provides hospital services in package which is accounted as multiple element transactions. The total consideration of the package will be allocated by using the fair value of the consideration of each element under the package. The Group also sells stored-value cards to customers which entitles them to offset the payment amount when they purchase pharmaceuticals or accept hospital services from the Group. Such consideration will be prepaid by customers and is recognised as refund liabilities when the customer has a right to refund the prepayment for the unused service package or unused value amount in the stored-value card within a given period. See note 23 for details. Therefore, the consideration is not recognised as revenue at the time of the initial sale transaction but is deferred and recognised as revenue when the Group's obligations have been fulfilled.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.22 Revenue recognition (Continued)

2.22.2 Pharmaceutical sales

Revenue from pharmaceutical sales are recognised when control of the inventory has transferred, being when the inventory are delivered to the customers, the customers has full discretion to use the inventory, and there is no unfulfilled obligation that could affect the customers' acceptance of the inventory.

2.22.3 Revenue from hospital consulting service

The hospital consulting service is the consulting services rendered to the subsidiaries of Beijing Jiahua Likang Medical Investment and Management Co., Ltd. ("Jiahua Likang"), a related party of the Group (note 34 (d)(i)). The service includes the fixed service fees portion related with the brand authorisation to the subsidiaries of Jiahua Likang and variable service fees portion based on the time-based services rendered by the Group. Revenue from providing hospital consulting service is recognised in the accounting period in which the services are rendered. Revenue related with the fixed brand authorization fee is recognised over time in the contract effective period. Revenue from services provided as request by the subsidiaries of Jiahua Likang is recognised as the point when the actual service provided.

2.22.4 Others

The Group also operates canteens, sells gift and groceries shops in its own hospitals. Revenue is recognised when control of the goods has been transferred, being when the goods are delivered to the customers.

The Group through its subsidiary New Century Healthcare Technology (Beijing) Co., Ltd. ("New Century Healthcare Technology") (previously named as Jiarun Yunzhong Health Technology Co., Ltd.) provides hospital appointment, online consultation services and online products sales to customers. Revenue from hospital appointment services are recognised on a net basis for the commission earned by the Group. Revenue from online products sales are recognised on a net basis when the control of the goods transferred out to the customers and the commission earned by the Group. Revenue from online consultation services are recognised on a gross basis when the Group is regarded as the primary obligor, otherwise net basis when the Group is regarded as an agent.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.23 Earnings per share

2.23.1 Basic earnings per share

Basic earnings per share is calculated by dividing:

- The profit attributable to owners of the Company, excluding any costs of servicing equity other than ordinary shares
- By the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the year and excluding treasury shares.

2.23.2 Diluted earnings per share

Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account:

- The after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares, and
- The weighted average number of additional ordinary shares that would have been outstanding assuming the conversion of all dilutive potential ordinary shares.

2.24 Leases

Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments:

- fixed payments (including in-substance fixed payments), less any lease incentives receivable
- variable lease payment that are based on an index or a rate, initially measured using the index or rate as at the commencement date
- amounts expected to be payable by the Group under residual value guarantees
- the exercise price of a purchase option if the Group is reasonably certain to exercise that option, and
- payments of penalties for terminating the lease, if the lease term reflects the Group exercising that option.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.24 Leases (Continued)

Lease payments to be made under reasonably certain extension options are also included in the measurement of the liability.

The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily determined, which is generally the case for leases in the Group, the lessee's incremental borrowing rate is used, being the rate that the individual lessee would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms, security and conditions.

To determine the incremental borrowing rate, the Group:

- where possible, uses recent third-party financing received by the individual lessee as a starting point, adjusted to reflect changes in financing conditions since third party financing was received
- uses a build-up approach that starts with a risk-free interest rate adjusted for credit risk for leases held by the Company, which does not have recent third party financing, and
- makes adjustments specific to the lease, e.g. term, country, currency and security.

Lease payments are allocated between principal and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period.

Right-of-use assets are measured at cost comprising the following:

- the amount of the initial measurement of lease liability
- any lease payments made at or before the commencement date less any lease incentives received
- any initial direct costs, and
- restoration costs.

Right-of-use assets are generally depreciated over the shorter of the asset's useful life and the lease term on a straight-line basis. If the Group is reasonably certain to exercise a purchase option, the right-of-use asset is depreciated over the underlying asset's useful life.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.24 Leases (Continued)

Payments associated with short-term leases of equipment and vehicles and all leases of low-value assets are recognised on a straight-line basis as an expense in the consolidated statement of comprehensive income. Short-term leases are leases with a lease term of 12 months or less without a purchase option. Low-value assets comprise IT equipment and small items of office furniture.

The scope of the lease decreases if the lease is modified to terminate the right of use of one or more underlying assets or to shorten the contractual lease term. For a modification that decreases the scope of the lease, the Group decreases the carrying amount of the right-of-use asset to reflect the partial or full termination of the lease and recognises gain or loss relating to the partial or full termination in the consolidated statement of comprehensive income within "other gains — net".

2.25 Dividend distribution

Provision is made for the amount of any dividend declared, being appropriately authorised and no longer at the discretion of the entity, on or before the end of the reporting period but not distributed at the end of the reporting period.

2.26 Interest income

Interest income from financial assets at FVPL is included in the "other gains – net" in the consolidated statement of comprehensive income, see note 28 below.

Interest income is presented as finance income where it is earned from financial assets that are held for cash management purposes, see note 29 below. Any other interest income is included in other income.

Interest income is calculated by applying the effective interest rate to the gross carrying amount of a financial asset except for financial assets that subsequently become credit-impaired. For credit-impaired financial assets the effective interest rate is applied to the net carrying amount of the financial asset (after deduction of the loss allowance).

3 FINANCIAL RISK MANAGEMENT

3.1 Financial risk factors

The Group's activities expose it to a variety of financial risks: market risk (including foreign exchange risk, cash flow and fair value interest rate risk), credit risk and liquidity risk. The Group's overall risk management program focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the Group's financial performance.

Risk management is carried out by the senior management of the Group and approved by the executive directors.

3.1.1 Market risk

(i) Foreign exchange risk

Foreign currency risk is the risk that the value of a financial instrument fluctuates because of the changes in foreign exchange rates.

The Group mainly operates in the PRC with most of the transactions settled in RMB. Foreign exchange rate risk arises when recognised assets and liabilities are denominated in a currency that is not the entity's functional currency.

As at 31 December 2021, the Group's assets and liabilities are primarily denominated in RMB, except for certain cash and cash equivalent denominated in USD or HKD (note 16) and dividend payable denominated in HKD (note 23).

The Group is primarily exposed to change in RMB/USD exchange rate. As at 31 December 2021, if RMB had weakened/strengthened by 5% against the US dollar with all other variables held constant, post-tax profit for the year would have been RMB3,338,000 (2020: RMB3,952,000) higher/lower, mainly as a result of foreign exchange gains/losses on translation of US dollar-denominated cash at banks and short term bank deposit.

The Group will constantly review the economic situation and its foreign exchange risk profile, and will consider appropriate hedging measures in the future, as may be necessary.

3 FINANCIAL RISK MANAGEMENT (CONTINUED)

3.1 Financial risk factors (Continued)

3.1.1 Market risk (Continued)

(ii) Cash flow and fair value interest rate risk

Other than interest-bearing cash and cash equivalents, the Group has no other significant variable interest-bearing assets or liabilities. The directors of the Company do not anticipate there is any significant impact to variable interest-bearing assets resulted from the changes in interest rates, because the interest rates of bank balances are not expected to change significantly.

3.1.2 Credit risk

Credit risk mainly arises from cash and cash equivalents and other financial assets at amortised cost, as well as credit exposures to receivables from customers, government's insurance schemes, commercial insurance companies and related parties. The maximum exposure to credit risk is represented by the carrying amount of each financial asset in the consolidated balance sheet.

The credit risk of cash and cash equivalents is limited because the counterparties are mainly state-owned or public listed commercial banks which are high-credit-quality financial institutions located in the PRC.

(i) Impairment of financial assets

The Group has three types of financial assets that are subject to the expected credit loss model:

- Trade receivable,
- Other receivables and deposits, and
- Amounts due from related parties.

While cash and cash equivalents are also subject to the impairment requirements of HKFRS 9, the identified impairment loss was immaterial.

3 FINANCIAL RISK MANAGEMENT (CONTINUED)

3.1 Financial risk factors (Continued)

3.1.2 Credit risk (Continued)

(i) Impairment of financial assets (Continued)

Trade receivables

The Group applies the HKFRS 9 simplified approach to measure expected credit losses which uses a lifetime expected loss allowance for all trade receivables.

To measure the expected credit losses, trade receivables have been grouped based on shared credit risk characteristics and the days past due.

The expected credit loss of trade receivables is determined based on historical loss rate of the customers over a period not less than 3 years before 31 December 2021, or by reference to credit rating of the customers. The Group has identified certain forward looking information (e.g. the Gross Domestic Product (GDP), Consumer Price Index (CPI) and Producer Price Index (PPI), etc. of China) and adjusts the historical loss rates.

Other receivables and deposits

The Group assesses the 12-month expected credit losses of other receivables and deposits upon initial recognition. Once there is a significant increase in credit risk, lifetime expected credit losses shall be assessed.

The expected credit loss of other receivables and deposits is determined by reference to industrial non-performing loan ratios of the customers and adjusted to reflect forward looking information (e.g. GDP, CPI, PPI, etc.).

Amounts due from related parties

The Group assesses the 12-month expected credit losses of amounts due from related parties (non-trade) and lifetime expected credit loss of amounts due from related parties (trade) upon initial recognition. Once there is a significant increase in credit risk from amounts due from related parties (non-trade), lifetime expected credit losses shall be assessed.

The expected credit loss of amounts due from related parties (trade and non-trade) is determined by applying discounted cash flow model based on future collections. The discount rate has been adjusted to reflect forward looking information (e.g. GDP, CPI, PPI, etc.).

3 FINANCIAL RISK MANAGEMENT (CONTINUED)

3.1 Financial risk factors (Continued)

3.1.2 Credit risk (Continued)

On that basis, the loss allowance as at 31 December 2021 and 31 December 2020 was determined as follows for trade receivables, amounts due from related parties and other receivables and deposits:

31 December 2021	Expected credit loss rate	Basis for recognition of expected credit loss	Gross carrying amount *RMB'000*	Expected credit loss *RMB'000*	Net carrying Amount *RMB'000*
Provision on trade receivables from insurance companies and government's insurance scheme	0.79%	Life time expected credit loss	38,105	(301)	37,804
Provision on trade receivables from individual customers	8.57%	Life time expected credit loss	1,692	(145)	1,547
Provision on amounts due from related parties	7.81%	Life time expected credit loss	172,389	(13,464)	158,925
Provision on other receivables and deposits	1.09%	12 months expected credit loss	20,032	(218)	19,814
			232,218	(14,128)	218,090

31 December 2020	Expected credit loss rate	Basis for recognition of expected credit loss	Gross carrying amount *RMB'000*	Expected credit loss *RMB'000*	Net carrying Amount *RMB'000*
Provision on trade receivables from insurance companies and government's insurance scheme	1.20%	Life time expected credit loss	27,247	(326)	26,921
Provision on trade receivables from individual customers	7.28%	Life time expected credit loss	1,786	(130)	1,656
Provision on amounts due from related parties (trade in nature)	4.30%	Life time expected credit loss	141,712	(6,090)	135,622
Provision on other receivables and deposits	0.00%	12 months expected credit loss	17,989	–	17,989
			188,734	(6,546)	182,188

3 FINANCIAL RISK MANAGEMENT (CONTINUED)

3.1 Financial risk factors (Continued)

3.1.2 Credit risk (Continued)

The loss allowances for trade receivables, amounts due from related parties and other receivables and deposits as at 31 December 2021 and 2020 reconcile to the opening loss allowances as follows:

	2021 *RMB'000*	2020 *RMB'000*
Opening loss allowance as at 1 January	(6,546)	(373)
Increase in loss allowance for trade receivables, amounts due from related parties and other receivables and deposits recognised in profit or loss during the year	(7,582)	(6,211)
Receivables written off during the year as uncollectible	–	38
Closing loss allowance as at 31 December	(14,128)	(6,546)

Trade receivables, amounts due from related parties and other receivables and deposits are written off when there is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery include, amongst others, the failure of a debtor to engage in a repayment plan with the Group and indicator(s) of severe financial difficulty.

Impairment losses on trade receivables, amounts due from related parties and other receivables and deposits are presented as net impairment losses within operating profit. Subsequent recoveries of amounts previously written off will be credited against the same line item.

3 FINANCIAL RISK MANAGEMENT (CONTINUED)

3.1 Financial risk factors (Continued)

3.1.3 Liquidity risk

The Group aims to maintain sufficient cash to meet operating capital requirements. The table below analyses the Group's financial liabilities into relevant maturity groupings based on the remaining period at the balance sheet date to the contractual maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows.

	Less than 1 year *RMB'000*	Between 1 and 2 years *RMB'000*	Between 2 and 5 years *RMB'000*	Over 5 years *RMB'000*	Total *RMB'000*
At 31 December 2021					
Trade payables	27,448	–	–	–	27,448
Accruals and other payables (excluding non-financial liabilities) *(note 23)*	152,940	–	–	–	152,940
Amounts due to related parties	5,314	–	–	–	5,314
Lease liabilities	44,256	42,449	97,074	146,366	330,145
	229,958	42,449	97,074	146,366	515,847
At 31 December 2020					
Trade payables	25,618	–	–	–	25,618
Accruals and other payables (excluding non-financial liabilities) *(note 23)*	145,704	–	–	–	145,704
Amounts due to related parties	4,214	–	–	–	4,214
Lease liabilities	51,603	49,747	128,871	177,779	408,000
	227,139	49,747	128,871	177,779	583,536

3 FINANCIAL RISK MANAGEMENT (CONTINUED)

3.2 Capital management

The Group's primary objectives when managing capital are to safeguard the Group's ability to continue as a going concern in order to provide returns to the shareholders and benefits for other stakeholders and to maintain an optimal capital structure to reduce the cost of capital.

The Group actively and regularly reviews and manages its capital structure to maintain a balance between the higher equity shareholders returns that might be possible with higher levels of borrowings and the advantages and security afforded by a sound capital position, and makes adjustments to the capital structure in light of changes in economic conditions.

In order to maintain or adjust the capital structure, the Group may adjust the amount of dividends paid to shareholders, return capital to the shareholders, issue new shares or sell assets to reduce debt.

The Group monitors its capital structure on the basis of liability-to-asset ratio, which is calculated as total liabilities divided by total assets. The liability-to-asset ratio of the Group as at 31 December 2021 and 2020 was as follows:

	As at 31 December	
	2021	2020
The liability-to-asset ratio	46.16%	44.81%

3.3 Fair value estimation

As at 31 December 2021 and 31 December 2020, the Group does not have any financial assets or liabilities measured at fair value.

4 CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS

The preparation of financial statements requires the use of accounting estimates which, by definition, will seldom equal the actual results. Management also needs to exercise judgement in applying the Group's accounting policies.

Estimates and judgements are continually evaluated. They are based on historical experience and other factors, including expectations of future events that may have a financial impact on the entity and that are believed to be reasonable under the circumstances.

(a) Estimated impairment of goodwill

The Group performed impairment assessment of goodwill at each balance sheet date to assess whether goodwill has suffered any impairment, in accordance with the accounting policy stated in note 2.8.1. The recoverable amounts of each CGU or a group of CGUs have been determined based on the higher of CGU's or a group of CGUs' fair value less costs of disposal or of value-in-use which require the use of estimates. The determination of recoverable amounts also involves variety of assumptions, such as compound growth rate of revenue, compound growth rate of costs and operating expense, long-term growth rate and discount rate. The estimation of recoverable amounts is subject to high degree of estimation uncertainty. Changes in the conditions for these estimates and assumptions can significantly affect the assessed result of goodwill impairment test.

Details of impairment charge, key assumptions and impact of possible changes in key assumptions are described in note 8.

(b) Current and deferred income taxes

There are many transactions and events for which the ultimate tax determination is uncertain during the ordinary course of business. Significant judgement is required in determining the provision for income taxes in each of these jurisdictions. Where the final tax outcome of these matters is different from the amounts that were initially recorded, such differences will impact the current and deferred income tax provision in the period in which such determination is made.

The Group recognises deferred tax assets based on estimates that it is probable to generate sufficient taxable profits in the foreseeable future against which the deductible losses will be utilised. The recognition of deferred tax assets mainly involved management's estimations about the timing and the amount of taxable profits of the companies who had tax losses.

5 SEGMENT INFORMATION

Mr. Jason ZHOU in his role as the executive director and chairman of the Company, serves as the chief operating decision-maker (the "CODM") of the Group. Management has determined the operating segments based on the information reviewed by the CODM for the purposes of allocating resources and assessing performance.

The CODM considers the business from both the service and product perspectives and reviews the Group's business performance by service line rather than by legal entity. The Group aggregates businesses that have similar economic characteristics, such as: (i) the nature of the products and services; (ii) the nature of the production processes; (iii) the type or class of customers for their products and services; (iv) the methods used to distribute their products or provide their services; and (v) if applicable, the nature of the regulatory environment.

In the view of the CODM, the Group is principally engaged in four distinct segments: (i) pediatric services, (ii) obstetrics and gynecology services, (iii) hospital consulting services, and (iv) others, which are subject to different business risks and economic characteristics.

The Group's reportable segments are as follows:

(a) Pediatrics

Revenue derived from specialized pediatric services is mainly contributed by Beijing New Century Children's Hospital Co., Ltd. ("BNC Children's Hospital"), Beijing New Century Harmony Clinic Co., Ltd. ("BNC Harmony Clinic"), Beijing New Century Women's and Children's Hospital Co., Ltd. ("BNC Women's and Children's Hospital"), Beijing New Century Ao-dong Clinic Outpatient Service Co., Ltd. ("BNC Ao-dong Clinic") and Chengdu New Century Women's and Children's Hospital Co., Ltd. ("Chengdu New Century").

(b) Obstetrics and gynecology

Revenue derived from specialised obstetric and gynecologic services is mainly contributed by BNC Women's and Children's Hospital, BNC Ao-dong Clinic and Chengdu New Century.

(c) Hospital consulting services

The Group provides hospital consulting services to Jiahua Likang and its hospital subsidiaries under hospital consulting service agreements. The Group receives hospital consulting fees from Jiahua Likang.

5 SEGMENT INFORMATION (CONTINUED)

(d) Others

The Group operates canteens, sell gift and groceries shops in its own hospitals. The Group also provided hospital appointment, online consultation services and online products sales to customers. Management group these revenue in others since each of them do not exceed 10% of the total revenue of the Group.

For the purposes of monitoring segment performances and allocating resources between segments, segment results represent the profit before tax earned by each segment, without allocation of finance income, finance costs, other income, and other gains – net that not directly related to the respective segments, which represent the internally generated financial information regularly reviewed by the CODM. This is the measure reported to the CODM for the purposes of resource allocation and assessment of segment performance.

Assets and liabilities dedicated to a particular segment's operation are included in that segment's total assets and liabilities. Segment assets include all tangible and intangible assets, except for cash and cash equivalents, deferred tax assets and liabilities and other assets that not directly related to the respective segment. Segment liabilities exclude tax payable and other liabilities that not directly related to the respective segment.

No geographical information is presented as most of the Group's revenue is derived from activities in the PRC, and the Group's operations and non-current assets are mainly located in the PRC.

5 SEGMENT INFORMATION (CONTINUED)

(e) Segment information

	Pediatrics RMB'000	Obstetrics and Gynecology RMB'000	Hospital consulting services RMB'000	Others RMB'000	Intersegment eliminations RMB'000	Unallocated RMB'000	Total RMB'000
For the year ended 31 December 2021							
Revenue from external customers	504,081	117,240	4,620	6,624	–	–	632,565
Inter-segment revenue	–	–	–	18,012	(18,012)	–	–
Total revenue	504,081	117,240	4,620	24,636	(18,012)	–	632,565
Cost of revenue	(313,571)	(111,780)	(885)	(22,553)	14,959	–	(433,830)
Segment results	57,490	(37,450)	(35,288)	(19,787)	–	–	(35,035)
Unallocated income						10,855	10,855
Unallocated cost						(34,967)	(34,967)
Profit/(loss) before income tax	57,490	(37,450)	(35,288)	(19,787)	–	(24,112)	(59,147)
Income tax expense						(26,115)	(26,115)
Loss for the year							(85,262)
As at 31 December 2021							
Assets							
Segment assets	433,410	279,842	139,784	5,719	–	–	858,755
Goodwill	123,826	34,014	–	–	–	–	157,840
Unallocated assets						254,301	254,301
Total assets	557,236	313,856	139,784	5,719	–	254,301	1,270,896
Total liabilities	302,864	199,794	4,209	7,577	–	72,214	586,658

5 SEGMENT INFORMATION (CONTINUED)

(e) Segment information (Continued)

	Pediatrics *RMB'000*	Obstetrics and Gynecology *RMB'000*	Hospital consulting services *RMB'000*	Others *RMB'000*	Intersegment eliminations *RMB'000*	Unallocated *RMB'000*	Total *RMB'000*
For the year ended 31 December 2020							
Revenue from external customers	368,015	127,754	8,531	8,485	–	–	512,785
Inter-segment revenue	–	–	–	3,651	(3,651)	–	–
Total revenue	368,015	127,754	8,531	12,136	(3,651)	–	512,785
Cost of revenue	(259,426)	(104,396)	(5,065)	(8,351)	217	–	(377,021)
Segment results	(74,944)	(165,395)	(27,800)	(57,073)	–	–	(325,212)
Unallocated income						11,340	11,340
Unallocated cost						(14,875)	(14,875)
Loss before income tax	(74,944)	(165,395)	(27,800)	(57,073)	–	(3,535)	(328,747)
Income tax expense						(48,787)	(48,787)
Loss for the year							(377,534)
As at 31 December 2020							
Assets							
Segment assets	482,033	313,299	159,651	7,679	–	–	962,662
Goodwill	123,826	34,014	–	–	–	–	157,840
Unallocated assets						350,543	350,543
Total assets	605,859	347,313	159,651	7,679	–	350,543	1,471,045
Total liabilities	303,868	227,131	12,979	9,877	–	105,338	659,193

5 SEGMENT INFORMATION (CONTINUED)

(f) Disaggregation of revenue from contracts with customers

The Group derives revenue from providing service and transfer of goods over time and at a point in time in the following segments.

For the year ended 31 December 2021	Pediatrics RMB'000	Obstetrics and Gynecology RMB'000	Hospital consulting services RMB'000	Others RMB'000	Total RMB'000
Revenue from external customers					
At a point in time*	504,081	117,240	997	6,624	628,942
Over time	–	–	3,623	–	3,623
	504,081	117,240	4,620	6,624	632,565

For the year ended 31 December 2020	Pediatrics RMB'000	Obstetrics and Gynecology RMB'000	Hospital consulting services RMB'000	Others RMB'000	Total RMB'000
Revenue from external customers					
At a point in time*	368,015	127,754	4,691	8,485	508,945
Over time	–	–	3,840	–	3,840
	368,015	127,754	8,531	8,485	512,785

* Majority medial services of the Group are provided in a very short period, therefore, the related revenue is categorized as revenue at a point in time. The revenue from others includes intersegment eliminations.

5 SEGMENT INFORMATION (CONTINUED)

(g) Liabilities related to contracts with customers

The Group has recognised the following liabilities related to contracts with customers.

	Year ended 31 December	
	2021 *RMB'000*	2020 *RMB'000*
Contract liabilities	30,399	30,539
Revenue recognised that was included in the contract liability balance at the beginning of the year	24,015	37,387

Contract liabilities mainly arise from the membership cards purchased by customers while the underlying services are yet to be provided. Major contracts of the Group are short-term contracts and the performance obligation would be provided depends on customer's solely discretion. The Company expects approximate 80% of these remaining obligations under such contracts will be fulfilled within one year and 20% will be fulfilled after one year based on the estimation from management.

6 PROPERTY, PLANT AND EQUIPMENT

	Buildings and leasehold improvements *RMB'000*	Medical equipment *RMB'000*	Motor vehicles *RMB'000*	Office equipment and furniture *RMB'000*	Construction in progress *RMB'000*	Total *RMB'000*
At 1 January 2020						
Cost	211,968	102,876	7,366	33,899	–	356,109
Accumulated depreciation	(70,648)	(45,784)	(3,530)	(18,595)	–	(138,557)
Net book amount	141,320	57,092	3,836	15,304	–	217,552
Year ended 31 December 2020						
Opening net book amount	141,320	57,092	3,836	15,304	–	217,552
Additions	–	4,248	224	2,116	8,609	15,197
Acquisition of subsidiaries	–	1,137	–	105	–	1,242
Disposals	–	(219)	(103)	(153)	–	(475)
Transfer upon completion	7,106	145	–	–	(7,251)	–
Depreciation charges	(18,862)	(11,095)	(650)	(4,011)	–	(34,618)
Closing net book amount	129,564	51,308	3,307	13,361	1,358	198,898
At 31 December 2020						
Cost	219,074	107,827	7,399	35,383	1,358	371,041
Accumulated depreciation	(89,510)	(56,519)	(4,092)	(22,022)	–	(172,143)
Net book amount	129,564	51,308	3,307	13,361	1,358	198,898
Year ended 31 December 2021						
Opening net book amount	129,564	51,308	3,307	13,361	1,358	198,898
Additions	–	4,874	–	2,764	1,460	9,098
Disposals	–	(711)	–	(135)	–	(846)
Transfer upon completion	2,818	–	–	–	(2,818)	–
Depreciation charges	(15,479)	(10,751)	(587)	(3,356)	–	(30,173)
Impairment charges (c)	(11,448)	(3,327)	–	(235)	–	(15,010)
Closing net book amount	105,455	41,393	2,720	12,399	–	161,967
At 31 December 2021						
Cost	196,931	105,967	7,399	34,025	–	344,322
Accumulated depreciation and impairment	(91,476)	(64,574)	(4,679)	(21,626)	–	(182,355)
Net book amount	105,455	41,393	2,720	12,399	–	161,967

6 PROPERTY, PLANT AND EQUIPMENT (CONTINUED)

(a) Premises provided by Beijing Children's Hospital, Capital Medical University ("BCH")

The Group has established BNC Children's Hospital based on a public-private-partnership arrangement with BCH, a public hospital in Beijing, the PRC. Pursuant to the cooperation agreement in 2002, BCH has agreed to provide certain premises on its allocated land for the business operation of BNC Children's Hospital without extra payments to each other. The term of the cooperation with BCH lasts until 12 December 2022. Accordingly, the Group further carried out a massive construction and decoration project for BNC Children's Hospital. As at 31 December 2021, relevant buildings and leasehold improvements which were located at BCH's allocated land with an aggregate carrying amount of approximately RMB449,000 (as at 31 December 2020: RMB898,000). The directors of the Company are of the opinion that the Group is entitled to lawful and valid occupancy or use of these premises.

(b) Depreciation charges

Depreciation charges were expensed in the following categories in the consolidated statements of comprehensive income:

	Year ended 31 December	
	2021	2020
	RMB'000	*RMB'000*
Cost of revenue	22,086	25,673
Administration expenses	7,190	8,031
Selling expenses	897	914
Total	30,173	34,618

No property, plant and equipment was pledged as collateral under borrowing agreements as at 31 December 2021 (2020: nil).

During the year of 2021, the Group has no capitalized borrowing costs on qualifying assets (2020: nil).

(c) Impairment charges

During the year ended 31 December 2021, the Group resolved to spin off certain clinics by closure of business. As at 31 December 2021, impairments for the property, plant and equipment of RMB15,010,000 were provided for these clinics. And the Group has reached agreements with landlords of certain clinics to terminate the property lease agreements, which resulted in net gains of RMB3,429,000 for de-recognition of relevant right-of-use assets and lease liabilities.

7 LEASES

This note provides information for leases where the Group is a lessee.

(a) Amounts recognised in the balance sheet

The balance sheet shows the following amounts relating to leases:

Right-of-use assets	Properties *RMB'000*	Equipment *RMB'000*	Total *RMB'000*
At 1 January 2020			
Cost	344,426	949	345,375
Accumulated depreciation	(33,496)	(295)	(33,791)
Net book amount	310,930	654	311,584
Year ended 31 December 2020			
Opening net book amount	310,930	654	311,584
Additions	64,956	5,575	70,531
Acquisition of subsidiaries	7,807	–	7,807
Disposal	(36,228)	–	(36,228)
Depreciation	(44,418)	(491)	(44,909)
Closing net book amount	303,047	5,738	308,785
At 31 December 2020			
Cost	360,945	6,524	367,469
Accumulated depreciation	(57,898)	(786)	(58,684)
Net book amount	303,047	5,738	308,785
Year ended 31 December 2021			
Opening net book amount	303,047	5,738	308,785
Additions	14,475	–	14,475
Disposal	(57,910)	–	(57,910)
Depreciation	(40,543)	(838)	(41,381)
Closing net book amount	219,069	4,900	223,969
At 31 December 2021			
Cost	297,058	6,524	303,582
Accumulated depreciation	(77,989)	(1,624)	(79,613)
Net book amount	219,069	4,900	223,969

7 LEASES (CONTINUED)

(a) Amounts recognised in the balance sheet (Continued)

Lease liabilities

	As at 31 December	
	2021 *RMB'000*	2020 *RMB'000*
Current	36,743	39,839
Non-current	243,498	321,256
	280,241	361,095

(b) Amounts recognised in the consolidated statement of comprehensive income

The statement of profit or loss shows the following amounts relating to leases:

	2021 *RMB'000*	2020 *RMB'000*
Depreciation charges of right-of-use assets		
Buildings	40,543	44,418
Equipment	838	491
	41,381	44,909
Interest expense (included in finance costs) *(note 29)*	13,902	15,787
Expense relating to short-term leases (included in cost of revenue, selling expenses and administrative expenses)	2,362	1,839
Expense relating to leases of low-value assets that are not shown above as short-term leases (included in administrative expenses)	733	582
	16,997	18,208

The total cash outflow for leases in 2021 was RMB50,516,000 (2020: RMB52,443,000).

7 LEASES (CONTINUED)

(c) The Group's leasing activities and how these are accounted for

The Group leases various properties and equipment. Rental contracts are typically made for fixed periods of 1 to 20 years, but may have extension options as described in (d) below.

Lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions. The lease agreements do not impose any covenants other than the security interests in the leased assets that are held by the lessor. Leased assets may not be used as security for borrowing purposes.

(d) Extension and termination options

Extension and termination options are included in a number of property and equipment leases across the Group. These are used to maximise operational flexibility in terms of managing the assets used in the Group's operations. The majority of extension and termination options held need to further negotiate with lessor. However, the Group will assess the impact on business and will prefer to extend if it's favorable.

8 INTANGIBLE ASSETS

	Medical licenses *RMB'000*	Goodwill *RMB'000*	Software *RMB'000*	Total *RMB'000*
At 1 January 2020				
Cost	311,684	392,326	29,258	733,268
Accumulated amortisation	(34,707)	–	(5,660)	(40,367)
Net book amount	276,977	392,326	23,598	692,901
Year ended 31 December 2020				
Opening net book amount	276,977	392,326	23,598	692,901
Additions	–	–	1,429	1,429
Acquisition of subsidiaries	285	–	–	285
Amortisation	(13,318)	–	(3,002)	(16,320)
Impairment charge (b) *(note 27)*	(2,504)	(234,486)	(16,975)	(253,965)
Closing net book amount	261,440	157,840	5,050	424,330
At 31 December 2020				
Cost	311,969	392,326	30,687	734,982
Accumulated amortisation	(48,025)	–	(8,662)	(56,687)
Impairment charge	(2,504)	(234,486)	(16,975)	(253,965)
Net book amount	261,440	157,840	5,050	424,330
Year ended 31 December 2021				
Opening net book amount	261,440	157,840	5,050	424,330
Additions	–	–	3,841	3,841
Disposals	–	–	(115)	(115)
Amortisation	(13,050)	–	(2,017)	(15,067)
Closing net book amount	248,390	157,840	6,759	412,989
At 31 December 2021				
Cost	311,969	392,326	33,776	738,071
Accumulated amortisation	(61,075)	–	(10,042)	(71,117)
Impairment charge	(2,504)	(234,486)	(16,975)	(253,965)
Net book amount	248,390	157,840	6,759	412,989

8 INTANGIBLE ASSETS (CONTINUED)

(a) Impairment tests for goodwill

Management reviews business performance of each CGU or each group of CGUs. Goodwill is monitored by the management at each CGU or each group of CGUs level.

A summary of the goodwill allocation is presented below.

	Beginning of year *RMB'000*	Addition *RMB'000*	Impairment *RMB'000*	End of year *RMB'000*
Year ended 31 December 2021				
The group of CGUs of Pediatric in Beijing area (i)	111,698	–	–	111,698
The group of CGUs of Obstetrics and Gynecology in Beijing area (i)	12,544	–	–	12,544
The CGU of Pediatric in Chengdu New Century (ii)	12,128	–	–	12,128
The CGU of Obstetrics and Gynecology in Chengdu New Century (ii)	21,470	–	–	21,470
	157,840	–	–	157,840
Year ended 31 December 2020				
The group of CGUs of Pediatric in Beijing area (i)	111,698	–	–	111,698
The group of CGUs of Obstetrics and Gynecology in Beijing area (i)	12,544	–	–	12,544
The CGU of Pediatric in Chengdu New Century (ii)	88,695	–	(76,567)	12,128
The CGU of Obstetrics and Gynecology in Chengdu New Century (ii)	165,002	–	(143,532)	21,470
The CGU of New Century Healthcare Technology (iii)	14,387	–	(14,387)	–
	392,326	–	(234,486)	157,840

8 INTANGIBLE ASSETS (CONTINUED)

(a) Impairment tests for goodwill (Continued)

(i) Goodwill arose from acquisition of BNC Women's and Children's Hospital, BNC Ao-dong Clinic and Beijing New Century Yide Consultancy Co., Ltd. ("BNC Yide Consultancy")

Goodwill of RMB97,682,000, RMB15,537,000 and RMB11,023,000 arose from the acquisitions of BNC Women's and Children's Hospital, BNC Ao-dong Clinic and BNC Yide Consultancy on 30 November 2015, 16 January 2018 and 9 February 2018, respectively. The goodwill arose from the acquisitions of BNC Women's and Children's Hospital, BNC Ao-dong Clinic and BNC Yide Consultancy was allocated to the group of CGUs of Pediatric in Beijing area and the group of CGUs of Obstetrics and Gynecology in Beijing area because the directors of the Company's has expected to benefit from the synergies of the combination.

(ii) Goodwill arose from acquisition of Chengdu New Century

Goodwill of RMB253,697,000 was resulted from the acquisition of Chengdu New Century on 2 August 2018. Chengdu New Century is principally engaged in the provision of medical services to women and children in Chengdu. The goodwill arose from acquisition of Chengdu New Century was allocated to its Pediatric CGU and Obstetrics and Gynecology CGU, respectively.

(iii) Goodwill arose from acquisition of New Century Healthcare Technology

Goodwill of RMB14,387,000 was resulted from the acquisition of New Century Healthcare Technology on 23 August 2019. New Century Healthcare Technology is principally engaged in the provision of hospital appointment services, online consultation services and online products sales to customers. Management consider New Century Healthcare Technology is a stand-alone CGU since management allocate resources and assess the performance obligations to New Century Healthcare Technology as a whole business unit. Therefore, management allocate the goodwill to the CGU of New Century Healthcare Technology. Goodwill amounting to RMB14,387,000 was fully impaired on 30 June 2020 according to the impairment assessment performed by management of the Group.

8 INTANGIBLE ASSETS (CONTINUED)

(a) Impairment tests for goodwill (Continued)

The recoverable amount of each CGU or a group of CGUs is determined based on the higher of value-in-use and fair value less costs of disposal calculations. These calculations use cash flow projections based on financial forecasts approved by management covering six to eight years forecast period. Cash flows beyond the forecast period are extrapolated using the estimated growth rates stated below. The growth rate does not exceed the long-term average growth rate for the business in which the each CGU or the group of CGUs operate. Management uses a forecast period of six to eight years considering that: 1) the investment cycle in the healthcare industry is longer than other industries; 2) management has searched industry information to help make more accurate prediction and better plan of the future operation; 3) based on the available industry information, the compound annual growth rate of healthcare industry is projected to maintain a high level in the forecast period. It is consistent with management's forecast.

The following table sets out the key assumptions and recoverable amounts of value-in-use for those CGUs or group of CGUs that have significant goodwill allocated to them as at 31 December 2021 and 2020:

	The group CGUs of Pediatric in Beijing area	
	31 December 2021	31 December 2020
Revenue *(% compound growth rate)*	6.86%	11.70%
Costs and operating expenses *(% compound growth rate)*	6.78%	9.18%
Long-term growth rate	3.00%	3.00%
Pre-tax discount rate	17.65%	17.38%
Recoverable amount *(RMB'000)*	1,112,709	1,196,901

8 INTANGIBLE ASSETS (CONTINUED)

(a) Impairment tests for goodwill (Continued)

	The group CGUs of Obstetrics and Gynecology in Beijing area	
	31 December 2021	31 December 2020
Revenue *(% compound growth rate)*	9.47%	6.36%
Costs and operating expenses *(% compound growth rate)*	5.77%	6.45%
Long-term growth rate	3.00%	3.00%
Pre-tax discount rate	16.44%	16.32%
Recoverable amount *(RMB'000)*	145,274	163,892

	The CGU of Pediatric in Chengdu New Century	
	31 December 2021	31 December 2020
Revenue *(% compound growth rate)*	13.93%	14.25%
Costs and operating expenses *(% compound growth rate)*	5.52%	3.21%
Long-term growth rate	3.00%	3.00%
Pre-tax discount rate	16.00%	14.33%
Recoverable amount *(RMB'000)*	114,916	108,045

	The CGU of Obstetrics and Gynecology in Chengdu New Century	
	31 December 2021	31 December 2020
Revenue *(% compound growth rate)*	17.96%	14.18%
Costs and operating expenses *(% compound growth rate)*	6.76%	2.59%
Long-term growth rate	3.00%	3.00%
Pre-tax discount rate	15.93%	14.49%
Recoverable amount *(RMB'000)*	174,989	200,532

8 INTANGIBLE ASSETS (CONTINUED)

(b) Impairment charge

Due to the prolonged impact of Coronavirus Disease 2019 in early 2020 ("COVID-19") and the uncertainty of the macroeconomic environment, the Group performed an impairment test on goodwill as at 30 June 2020. According to the results, impairment loss on goodwill was provided for the operating segments of Chengdu New Century amounting to RMB220,099,000 and New Century Healthcare Technology amounting to RMB14,387,000, respectively.

During the year ended 31 December 2020, an impairment loss on software amounting to RMB16,975,000 was recognised for New Century Healthcare Technology due to the low recoverable amount.

During the year ended 31 December 2020, an impairment loss on medical license amounting to RMB2,504,000 was recognised for Beijing New Century Yide Chaowai Clinic of BNC Yide Consultancy ("BNC Chaowai Clinic") due to closure of business.

(c) Impact of possible changes in key assumptions

The directors and management have considered and assessed the impact of reasonably possible changes in key assumptions for each of the reporting segment.

(i) The group CGUs of Pediatric, Obstertrics and Gynecology in Beijing area

The recoverable amount is estimated to exceed the carrying amount of the group CGUs of Pediatric in Beijing area at 31 December 2021 by RMB767,931,000 (2020: RMB798,781,000). The recoverable amount is estimated to exceed the carrying amount of the group CGUs of Obstertrics and Gynecology in Beijing area at 31 December 2021 by RMB60,359,000 (2020: RMB74,017,000).

Based on the results of the aforesaid impairment assessments, the directors of the Company concluded that no provision for impairment on the goodwill has to be recognized in the group CGUs of Pediatric, Obstertrics and Gynecology in Beijing area as at 31 December 2021.

8 INTANGIBLE ASSETS (CONTINUED)

(c) Impact of possible changes in key assumptions (continued)

(ii) The CGUs of Pediatric, Obstertrics and Gynecology in Chengdu New Century

The table below sets forth each key assumption for the eight-year forecast period as at the year end (estimates based on the operation for the period indicated) used in goodwill impairment testing and the breakeven point of such key assumptions:

	The CGU of Pediatric in Chengdu New Century			
	31 December 2021		31 December 2020	
	Key Assumption	Breakeven Point	Key Assumption	Breakeven Point
Revenue *(% compound growth rate)*	13.93%	13.66%	14.25%	12.44%
Costs and operating expenses *(% compound growth rate)*	5.52%	5.66%	3.21%	3.80%
Pre-tax discount rate	16.00%	16.31%	14.33%	15.75%

8 INTANGIBLE ASSETS (CONTINUED)

(c) Impact of possible changes in key assumptions (continued)

(ii) The CGUs of Pediatric, Obstertrics and Gynecology in Chengdu New Century (continued)

	The CGU of Obstetrics and Gynecology in Chengdu New Century			
	31 December 2021		31 December 2020	
	Key Assumption	Breakeven Point	Key Assumption	Breakeven Point
Revenue *(% compound growth rate)*	17.96%	17.75%	14.18%	11.63%
Costs and operating expenses *(% compound growth rate)*	6.76%	6.84%	2.59%	3.55%
Pre-tax discount rate	15.93%	16.10%	14.49%	16.05%

The recoverable amounts of each CGU (including goodwill and intangible acquired in the business combination) based on the estimated value-in-use calculations were higher than their carrying amounts at 31 December 2021.

(d) Amortisation charges

Amortisation charges were expensed in the following categories in the consolidated statements of comprehensive income:

	Year ended 31 December	
	2021	2020
	RMB'000	*RMB'000*
Cost of revenue	13,336	14,893
Administration expenses	1,596	1,199
Selling expenses	135	228
Total	15,067	16,320

9 SUBSIDIARIES

The Group's principal subsidiaries at 31 December 2021 are set out below. Unless otherwise stated, they have share capital consisting solely of ordinary shares that are held directly by the Group, and the proportion of ownership interests held equals the voting rights held by the Group. The country of incorporation or registration is also their principal place of business.

Name	Place of incorporation and kind of legal entity	Principal activities and place of operation	Particulars of issued share capital and debt securities	Ownership interest held by the Group (%)		Ownership interest held by non-controlling interests (%)	
				2021	2020	2021	2020
Directly owned:							
New Millennium Investment Co., Ltd.	The BVI, limited liability company	Investment holding in the BVI	50,000 ordinary shares, USD50,000	100%	100%	–	–
NCH Marvel Investment (BVI) Limited	The BVI, limited liability company	Investment holding in the BVI	50,000 ordinary shares, USD50,000	100%	100%	–	–
Indirectly owned:							
New Century Healthcare (International) Co., Ltd. (新世紀醫療(國際)有限公司)	Hong Kong, limited liability company	Investment holding in Hong Kong	1 ordinary shares, HKD1	100%	100%	–	–
Beijing Jiahua Yihe Management Consulting Co., Ltd. (北京嘉華怡和管理諮詢有限公司)	The PRC, limited liability company*	Investment holding and hospital consulting services in the PRC	RMB400,000,000	100%	100%	–	–
Beijing New Century Children's Hospital Co., Ltd. (北京新世紀兒童醫院有限公司)	The PRC, limited liability company**	Operating of hospital in the PRC	RMB20,000,000	65%	65%	35%	35%
Beijing New Century Women's and Children's Hospital Co., Ltd. (北京新世紀婦兒醫院有限公司)	The PRC, limited liability company**	Operating of hospital in the PRC	RMB45,000,000	100% (i)	100% (i)	–	–

9 SUBSIDIARIES (CONTINUED)

Name	Place of incorporation and kind of legal entity	Principal activities and place of operation	Particulars of issued share capital and debt securities	Ownership interest held by the Group (%)		Ownership interest held by non-controlling interests (%)	
				2021	2020	2021	2020
Indirectly owned: (continued)							
Beijing New Century Harmony Clinic Co., Ltd. (北京新世紀榮和門診部有限公司)	The PRC, limited liability company**	Operating of hospital in the PRC	RMB3,000,000	100% (i)	100% (i)	–	–
Beijing New Century Ao-dong Clinic Outpatient Service Co., Ltd. (北京新世紀奧東門診部有限公司)	The PRC, limited liability company**	Operating of hospital in the PRC	RMB5,000,000	100% (i)	100% (i)	–	–
New Century Healthcare (Hong Kong) Co. Limited (新世紀醫療(香港)有限公司) (iv)	Hong Kong, limited liability company	Investment holding in Hong Kong	1 ordinary shares, HKD1	100%	100%	–	–
Beijing New Century Yide Consultancy Co., Ltd. (北京新世紀怡德諮詢有限公司) (iii)	The PRC, limited liability company**	Investment holding and hospital consulting services in the PRC	RMB23,333,333	100% (i)	100% (i)	–	–
Beijing New Century Qingnian Road Pediatric Clinic Co., Ltd. (北京新世紀青年路兒科診所有限公司)	The PRC, limited liability company**	Operating of hospital in the PRC	RMB1,000,000	100% (i)	100% (i)	–	–
Zhuhai Jiahua Yihe Medical Investment Co., Ltd (珠海嘉華怡和醫療投資有限公司)	The PRC, limited liability company**	Investment holding and hospital consulting services in the PRC	RMB200,000,000	100%	100%	–	–

9 SUBSIDIARIES (CONTINUED)

Name	Place of incorporation and kind of legal entity	Principal activities and place of operation	Particulars of issued share capital and debt securities	Ownership interest held by the Group (%)		Ownership interest held by non-controlling interests (%)	
				2021	2020	2021	2020
Indirectly owned: (continued)							
Chengdu New Century Women's and Children's Hospital Co., Ltd (成都新世紀婦女兒童醫院有限公司)	The PRC, limited liability company**	Operating of hospital in the PRC	RMB30,000,000	85%	85%	15%	15%
Beijing New Century Wenyu Clinic Outpatient Services Co., Ltd. (北京新世紀溫榆門診部有限公司)	The PRC, limited liability company**	Operating of hospital in the PRC	RMB27,000,000	100% (i)	100% (i)	–	–
Chengdu Qingyang New Century Shangjin Xinyi Clinic Co., Ltd. (成都青羊新世紀尚錦信怡門診部有限公司)	The PRC, limited liability company**	Operating of hospital in the PRC	RMB6,000,000	100% (i)	100% (i)	–	–
Chengdu Xinyi Health Management Co., Ltd. (成都信怡健康管理有限公司)	The PRC, limited liability company**	Operating of hospital in the PRC	RMB1,000,000	100%	100%	–	–
Qinhuangdao New Century Binhai Outpatient Department Co. Ltd. (秦皇島新世紀濱海門診部有限公司)	The PRC, limited liability company**	Operating of hospital in the PRC	RMB1,000,000	100% (i)	100% (i)	–	–

* Registered as a wholly foreign owned enterprise under the PRC law.
** Registered as a domestic owned enterprise under the PRC law.

9 SUBSIDIARIES (CONTINUED)

Some of the Entity's English names are translated for identification purpose only. These companies incorporated in the PRC which do not have official English names.

In addition to the subsidiaries set forth above, the Company has also consolidated Beijing Jiahua Kangming Medical Investment and Management Co., Ltd. ("Jiahua Kangming"), and Beijing Jiahua Yunzhong Management Consulting Co., Ltd. ("Jiahua Yunzhong").

(i) Consolidation of Jiahua Kangming and the other 30% equity interests of BNC Women's and Children's Hospital and BNC Harmony Clinic.

Jiahua Kangming is a holding company incorporated in the PRC with limited liability, which is owned by Ms. ZHAO Juan as to 99.0% and by Ms. ZHOU Jie (Mr. Jason ZHOU's sister) as to 1.0% (the "Shareholders of Jiahua Kangming"), and hold 30% interest of BNC Women's and Children's Hospital and BNC Harmony Clinic. The Company's wholly-owned subsidiary, Beijing Jiahua Yihe Management Consulting Co., Ltd. ("Jiahua Yihe") has entered into a series of contractual arrangements (the "Jiahua Kangming Contractual Arrangements") with Jiahua Kangming, the Shareholders of Jiahua Kangming, BNC Women's and Children's Hospital, and BNC Harmony Clinic.

Through the Jiahua Kangming Contractual Arrangements, the Company consolidated Jiahua Kangming and the other 30% equity interests of BNC Women's and Children's Hospital and BNC Harmony Clinic.

9 SUBSIDIARIES (CONTINUED)

(i) Consolidation of Jiahua Kangming and the other 30% equity interests of BNC Women's and Children's Hospital and BNC Harmony Clinic. (continued)

The Jiahua Kangming Contractual Arrangements are irrevocable and enable Jiahua Yihe, and ultimately, the Group to:

- Provide to Jiahua Kangming and its affiliated medical institutions, including BNC Women's and Children's Hospital and BNC Harmony Clinic, on an exclusive basis, shareholder's rights and investment management related services and medical institution operation services based on their actual business demand. For return, the Group will receive an annual service fee in an amount equivalent to 30.0% of the annual distributable profits of BNC Women's and Children's Hospital and BNC Harmony Clinic after deducting any loss in prior year and the statutory surplus reserve (if applicable);

- Exercise all of its rights and powers as a shareholder of Jiahua Kangming, BNC Women's and Children's Hospital and BNC Harmony Clinic;

- Obtain an irrevocable and exclusive right to purchase all or any part of equity interest of Jiahua Kangming, all or any part of equity interest of BNC Women's and Children's Hospital and BNC Harmony Clinic attributable to Jiahua Kangming. Jiahua Yihe may exercise such options at any time until it has acquired all equity interests and/or all assets of the Jiahua Kangming, all equity interests and/or all assets of BNC Women's and Children's Hospital and BNC Harmony Clinic attributable to Jiahua Kangming. In addition, the transfer price of the relevant equity interests and assets shall be the minimum purchase price permitted under PRC law and each of Ms. ZHAO Juan, Ms. ZHOU Jie, Jiahua Kangming, BNC Women's and Children's Hospital and BNC Harmony Clinic will undertake that she/it will return in full the consideration received in relation to such transfer of equity interests or assets to Jiahua Yihe;

- Obtain a pledge over the entire equity interest in Jiahua Kangming, BNC Women's and Children's Hospital and BNC Harmony Clinic from their equity holders to secure performance of all their obligations and the obligations of BNC Women's and Children's Hospital and BNC Harmony Clinic under the Jiahua Kangming Contractual Arrangements, respectively.

9 SUBSIDIARIES (CONTINUED)

(i) Consolidation of Jiahua Kangming and the other 30% equity interests of BNC Women's and Children's Hospital and BNC Harmony Clinic. (continued)

Nevertheless, the Jiahua Kangming Contractual Arrangements may not be as effective as direct legal ownership in providing the Group with direct control over the Jiahua Kangming and the 30% equity interests of BNC Women's and Children's Hospital and BNC Harmony Clinic attributable to Jiahua Kangming and uncertainties presented by the PRC legal system could impede the Group's beneficiary rights to the results, assets and liabilities of Jiahua Kangming and the 30% equity interests of BNC Women's and Children's Hospital and BNC Harmony Clinic attributable to Jiahua Kangming. The Group believes that the Jiahua Kangming Contractual Arrangements are in compliance with the relevant PRC laws and regulations and are legally binding and enforceable.

In the view of the directors of the Group, the Group could obtain the control over Jiahua Kangming and obtain the 30.0% economic benefits of BNC Women's and Children's Hospital and BNC Harmony Clinic attributable to Jiahua Kangming based on the Group has the power over Jiahua Kangming and 30.0% equity interests of BNC Women's and Children's Hospital and BNC Harmony Clinic attributable to Jiahua Kangming, has rights to variable returns from its involvement with Jiahua Kangming and 30.0% equity interests of BNC Women's and Children's Hospital and BNC Harmony Clinic attributable to Jiahua Kangming, and has the ability to affect those returns through its power over Jiahua Kangming and 30.0% equity interests of BNC Women's and Children's Hospital and BNC Harmony Clinic attributable to Jiahua Kangming. Consequently, the Group has consolidated the financial information of Jiahua Kangming and the 30.0% equity interests of BNC Women's and Children's Hospital and BNC Harmony Clinic attributable to Jiahua Kangming in the consolidated financial statements.

Furthermore, in accordance with the Jiahua Kangming Contractual arrangements, the Group also consolidated 100% equity interest of BNC Ao-dong Clinic, Beijing New Century Qingnian Road Pediatric Clinic Co., Ltd. ("BNC Qingnian Road Clinic), Beijing New Century Wenyu Clinic Outpatient Service Co., Ltd. (BNC Wenyu Clinic), BNC Yide Consultancy and Qinhuangdao New Century Binhai Outpatient Department Co. Ltd. which were fully owned by BNC Women's and Children's Hospital directly and Chengdu Qingyang New Century Shangjin Xinyi Clinic Co., Ltd. was owned by Jiahua Yihe as to 65% and by BNC Women's and Children's Hospital as to 35%.

9 SUBSIDIARIES (CONTINUED)

(ii) Consolidation of Jiahua Yunzhong and the 57.5% equity interests of New Century Healthcare Technology.

Jiahua Yunzhong is a company incorporated in the PRC with limited liability, which is owned by Ms. Teng Lan as to 99.0% and by Mr. Jia Xiaofeng as to 1.0% (the "Shareholders of Jiahua Yunzhong"), and hold 57.5% interest of New Century Healthcare Technology. The Company's wholly-owned subsidiary, Jiahua Yihe has entered into a series of contractual arrangements (the "Jiahua Yunzhong Contractual Arrangements") with Jiahua Yunzhong, the Shareholders of Jiahua Yunzhong and New Century Healthcare Technology in 2019.

Through the Jiahua Yunzhong Contractual Arrangements, the Company consolidated Jiahua Yunzhong and the 57.5% equity interests of New Century Healthcare Technology.

The Jiahua Yunzhong Contractual Arrangements are irrevocable and enable Jiahua Yihe, and ultimately, the Group to:

- Provide to Jiahua Yunzhong and its affiliated institutions, including New Century Healthcare Technology, on an exclusive basis, management and operation related services based on their actual business demand. For return, the Group will receive an annual service fee in an amount equivalent to 100% of the annual distributable profits of Jiahua Yunzhong and 57.5% of the annual distributable profits of New Century Healthcare Technology after deducting any loss in prior year and the statutory surplus reserve (if applicable);

- Exercise all of its rights and powers as a shareholder of Jiahua Yunzhong and New Century Healthcare Technology;

- Obtain an irrevocable and exclusive right to purchase all equity interest of Jiahua Yunzhong, 57.5% equity interest of New Century Healthcare Technology attributable to Jiahua Yunzhong. Jiahua Yihe may exercise such options at any time until it has acquired all equity interests and/or all assets of the Jiahua Yunzhong, 57.5% equity interests and/or the related portion assets New Century Healthcare Technology attributable to Jiahua Yunzhong;

- Obtain a pledge over the entire equity interest in Jiahua Yunzhong and New Century Healthcare Technology from their equity holders to secure performance of all their obligations and the obligations of Jiahua Yunzhong and New Century Healthcare Technology under the Jiahua Yunzhong Contractual Arrangements, respectively.

9 SUBSIDIARIES (CONTINUED)

(ii) Consolidation of Jiahua Yunzhong and the 57.5% equity interests of New Century Healthcare Technology. (continued)

Nevertheless, the Jiahua Yunzhong Contractual Arrangements may not be as effective as direct legal ownership in providing the Group with direct control over the Jiahua Yunzhong and the 57.5% equity interests of New Century Healthcare Technology attributable to Jiahua Yunzhong and uncertainties presented by the PRC legal system could impede the Group's beneficiary rights to the results, assets and liabilities of Jiahua Yunzhong and the 57.5% equity interests of New Century Healthcare Technology attributable to Jiahua Yunzhong. The Group believes that the Jiahua Yunzhong Contractual Arrangements are in compliance with the relevant PRC laws and regulations and are legally binding and enforceable.

In the view of the directors of the Group, the Group could obtain the control over Jiahua Yunzhong and obtain the 57.5% economic benefits of New Century Healthcare Technology attributable to Jiahua Yunzhong based on the Group has the power over Jiahua Yunzhong and 57.5% equity interests of New Century Healthcare Technology attributable to Jiahua Yunzhong, has rights to variable returns from its involvement with Jiahua Yunzhong and 57.5% equity interests of New Century Healthcare Technology attributable to Jiahua Yunzhong, and has the ability to affect those returns through its power over Jiahua Yunzhong and 57.5% equity interests of New Century Healthcare Technology attributable to Jiahua Yunzhong. Consequently, the Group has consolidated the financial information of Jiahua Yunzhong and the 57.5% equity interests of New Century Healthcare Technology attributable to Jiahua Yunzhong in the consolidated financial statements.

(iii) BNC Yide Consultancy has a branch which is BNC Chaowai Clinic, a clinic providing pediatric services to customers.

(iv) New Century Healthcare (Hong Kong) Co. Limited has two branches which are New Century Child Development Center and New Century Healthcare Medical Center (HK), the clinics providing pediatric services to customers.

9 SUBSIDIARIES (CONTINUED)

(a) Significant restrictions

Cash and cash equivalents of RMB152,040,000 (2020: RMB206,579,000) are held in mainland China and are subject to local exchange control regulations. These local exchange control regulations provide for restrictions on exporting capital from the country, other than through normal dividends.

(b) Non-controlling interests

Set out below is summarised financial information for each subsidiary that has non-controlling interests that are material to the Group. The amounts disclosed for each subsidiary are before inter-company eliminations.

Summarised balance sheets

	BNC Children's Hospital As at 31 December		Chengdu New Century As at 31 December		New Century Healthcare Technology As at 31 December	
	2021 *RMB'000*	2020 *RMB'000*	2021 *RMB'000*	2020 *RMB'000*	2021 *RMB'000*	2020 *RMB'000*
Current						
Assets	151,697	167,796	24,346	20,260	29,430	10,781
Liabilities	(104,618)	(82,318)	(315,685)	(276,064)	(121,792)	(84,239)
Total net current assets/ (liabilities)	47,079	85,478	(291,339)	(255,804)	(92,362)	(73,458)
Non-current						
Assets	31,539	23,919	267,040	288,675	3,330	5,691
Liabilities	(4,402)	(2,837)	(207,444)	(217,520)	(538)	(2,900)
Total net non-current assets	27,137	21,082	59,596	71,155	2,792	2,791
Net assets/(liabilities)	74,216	106,560	(231,743)	(184,649)	(89,570)	(70,667)

9 SUBSIDIARIES (CONTINUED)

(b) Non-controlling interests (Continued)

Summarised income statements

	BNC Children's Hospital Year ended 31 December		Chengdu New Century Year ended 31 December		New Century Healthcare Technology Year ended 31 December	
	2021 *RMB'000*	2020 *RMB'000*	2021 *RMB'000*	2020 *RMB'000*	2021 *RMB'000*	2020 *RMB'000*
Revenue	311,378	217,011	82,814	84,108	18,534	5,809
Profit/(loss) before income tax	115,799	85,031	(48,427)	(47,146)	(18,903)	(42,120)
Income tax expense	(26,380)	(21,650)	1,333	(24,312)	–	673
Profit/(loss) for the year	89,419	63,381	(47,094)	(71,458)	(18,903)	(41,447)
Total comprehensive income/(loss)	89,419	63,381	(47,094)	(71,458)	(18,903)	(41,447)
Total comprehensive income/(loss) attributable to the non-controlling interests	31,297	22,183	(7,064)	(10,719)	(8,034)	(17,615)
Dividends paid to the non-controlling interests	42,639	43,353	–	–	–	–

9 SUBSIDIARIES (CONTINUED)

(b) Non-controlling interests (Continued)

Summarised statements of cash flows

	BNC Children's Hospital Year ended 31 December		Chengdu New Century Year ended 31 December		New Century Healthcare Technology Year ended 31 December	
	2021 *RMB'000*	2020 *RMB'000*	2021 *RMB'000*	2020 *RMB'000*	2021 *RMB'000*	2020 *RMB'000*
Cash flows from operating activities						
Cash generated from/(used in) operations	118,279	73,776	(34,840)	(10,595)	(5,035)	(3,394)
Interest paid	(256)	(141)	(1,037)	(1,084)	(68)	(262)
Interest received	1,327	1,443	25	19	7	8
Income tax paid	(28,638)	(22,294)	–	–	–	–
Net cash generated from/(used in) operating activities	90,712	52,784	(35,852)	(11,660)	(5,096)	(3,648)
Net cash (used in)/generated from investing activities	(6,795)	58,704	(1,031)	(1,463)	(56)	(353)
Net cash (used in)/generated from financing activities	(124,202)	(125,003)	34,513	8,615	4,348	4,743
Net (decrease)/increase in cash and cash equivalents	(40,285)	(13,515)	(2,370)	(4,508)	(804)	742
Cash and cash equivalents at the beginning of the year	137,030	150,545	6,663	11,171	4,158	3,416
Cash and cash equivalents at the end of year	96,745	137,030	4,293	6,663	3,354	4,158

10 INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD

	As at 31 December	
	2021	2020
	RMB'000	*RMB'000*
Associates	1,809	2,575

	As at 31 December	
	2021	2020
	RMB'000	*RMB'000*
At the beginning of the year	2,575	12,985
Share of net (loss)/profit of investments accounted for using the equity method	(703)	54
Impairment loss *(note 27)*	–	(10,306)
Other comprehensive income	(63)	(158)
At the end of the year	1,809	2,575

(i) Interests in an associate

On 7 August 2018, the Group invested 10.1% interest in Chiron Healthcare Holdings Limited ("Chiron Healthcare Group") for a cash consideration of HKD15,000,000. The directors of the Group believe that it is appropriate to account for the investment in Chiron Healthcare Group by using the equity method because the Group can nominate one director in the board of directors of Chiron Healthcare Group which demonstrate that the Group has significant influence in Chiron Healthcare Group. Set out below is the information of the associate.

Name of entity	Place of business/ country of incorporation	% of ownership interest		Nature of relationship	Measurement method	Quoted fair value		Carrying amount	
		2021	2020			2021	2020	2021	2020
		%	%			*RMB'000*	*RMB'000*	*RMB'000*	*RMB'000*
Chiron Healthcare Group	Hong Kong	10.1%	10.1%	Associate	Equity method	–*	–*	1,809	2,575
Total equity account investments								1,809	2,575

* Private entity – no quoted price available.

10 INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD (CONTINUED)

(ii) Summarised financial information for associates

Summarised balance sheet

	Chiron Healthcare Group	
	As at 31 December	
	2021 *RMB'000*	2020 *RMB'000*
Total current assets	27,732	29,078
Total non-current assets	7,386	6,467
Total current liabilities	(18,461)	(10,790)
Non-controlling interest	(1,255)	(744)
Net assets attributable to owners	17,912	25,499
Net assets	16,657	24,755

10 INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD (CONTINUED)

(ii) Summarised financial information for associates (continued)

Reconciliation to carrying amounts

	Chiron Healthcare Group	
	As at 31 December	
	2021	2020
	RMB'000	*RMB'000*
Opening net assets attributable to owners	25,499	26,525
Less: loss for the year	(7,496)	(331)
Add: loss for the year attributable to non-controlling interests of an associate	539	865
Other comprehensive income	(630)	(1,560)
Closing net assets attributable to owners	17,912	25,499
Group's share in %	10.1%	10.1%
Group's share in RMB	1,809	2,575
Carrying amount	1,809	2,575
Revenue	92,901	138,660
Loss for the period	(7,496)	(331)

11 FINANCIAL INSTRUMENTS BY CATEGORY

The Group holds the following financial instruments:

	As at 31 December	
	2021 *RMB'000*	2020 *RMB'000*
Financial assets		
At amortised cost		
Trade receivables *(note 13)*	39,351	28,577
Other receivables excluding prepayments *(note 14)*	19,814	17,989
Amounts due from related parties *(note 15)*	158,925	161,003
Cash and cash equivalents *(note 16)*	223,843	299,211
	441,933	506,780
Financial liabilities		
At amortised cost		
Trade payables *(note 22)*	27,448	25,618
Accruals and other payables (excluding non-financial liabilities) *(note 23)*	152,940	145,704
Amounts due to related parties *(note 15)*	5,314	4,214
Lease liabilities *(note 7)*	280,241	361,095
	465,943	536,631

The Group's exposure to various risks associated with the financial instruments is discussed in note 3. The maximum exposure to credit risk at the end of the reporting period is the carrying amount of each class of financial assets mentioned above.

12 INVENTORIES

	As at 31 December	
	2021	2020
	RMB'000	*RMB'000*
Pharmaceuticals	15,144	14,246
Medical consumables	5,998	5,338
	21,142	19,584

The cost of inventories was recognised as expense and included in cost of revenue amounting to RMB101,222,000 for the year ended 31 December 2021 (2020: RMB78,475,000) (note 25).

13 TRADE RECEIVABLES

	As at 31 December	
	2021	2020
	RMB'000	*RMB'000*
Current assets		
Trade receivables from contracts with customers	39,797	29,033
Less: allowance for impairment of trade receivables	(446)	(456)
Trade receivables – net	39,351	28,577

As at 31 December 2021 and 2020, the aging analysis of the trade receivables based on demand note date was as follows:

	As at 31 December	
	2021	2020
	RMB'000	*RMB'000*
Up to 3 months	31,738	21,383
4 – 6 months	1,604	2,170
7 months – 1 year	904	1,192
Over 1 year	5,551	4,288
	39,797	29,033

13 TRADE RECEIVABLES (CONTINUED)

(i) Fair values of trade receivables

Due to the short-term nature of the current receivables, their carrying amounts approximate their fair value.

(ii) Impairment and risk exposure

The Group applies the HKFRS 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables. Note 3.1.2 provides for details about the calculation of the allowance for impairment of trade receivables.

All of the trade receivables are denominated in RMB. As a result, there is no exposure to foreign currency risk.

14 OTHER RECEIVABLES, DEPOSITS AND PREPAYMENTS

	As at 31 December	
	2021	2020
	RMB'000	*RMB'000*
Current		
Prepayments	4,418	5,246
Deposits	1,428	2,899
Other receivables	10,117	5,221
Others	2,425	3,508
	18,388	16,874
Less: provision for impairment	(218)	–
	18,170	16,874
Non-current		
Prepayments	2,071	7,516
Deposits	6,062	6,361
	8,133	13,877
Less: provision for impairment	–	(3,168)
	8,133	10,709

Due to the short-term nature of the other current receivables and deposits, their carrying amount approximates their fair value. Note 3.1.2 sets out information about the impairment of financial assets and the Group's exposure to credit risk. All of the other current receivables and deposits which is classified as the financial assets at amortised cost are denominated in RMB. As a result, there is no exposure to foreign currency risk.

15 BALANCES WITH RELATED PARTIES

The relationship between related parties is disclosed in below table and the Group is set out in Note 34.

	As at 31 December	
	2021	2020
	RMB'000	*RMB'000*
Amounts due from related parties		
– Trade		
Beijing Jiahua Likang Medical Investment and Management Co., Ltd.	140,446	141,606
Chengdu Yunxi Ge Health Management Co., Ltd.	1,379	–
Tianjin Heping New Century Women's and Children's Hospital Co., Ltd.	79	73
Beijing Children's Hospital, Capital Medical University	–	26
Chengdu Women's and Children's Central Hospital	7	7
	141,911	141,712
Less: provision for impairment	(7,280)	(6,090)
	134,631	135,622
– Non-Trade		
Shanghai New Century Pujin Pediatric Clinic Outpatient Service Co., Ltd.	1,850	1,850
Beijing Bairui Kangchen Technology Development Co., Ltd.	26,522	22,541
Chengdu Yunxi Ge Health Management Co., Ltd.	982	443
Foshan Shunde Yihe Clinic Co., Ltd.	439	439
Chengdu Wuhou New Century Joy City Clinic Outpatient Service Co., Ltd.	636	68
Zhuhai Yunzhong Equity Investment Limited Partnership	49	40
	30,478	25,381
Less: provision for impairment	(6,184)	–
	24,294	25,381
	158,925	161,003

15 BALANCES WITH RELATED PARTIES (CONTINUED)

	As at 31 December	
	2021	2020
	RMB'000	*RMB'000*
Amounts due to related parties		
– Trade		
Beijing Children's Hospital, Capital Medical University	1,572	984
Beijing Muhe Jiaye Property Management Co., Ltd.	978	987
Chengdu Women's and Children's Central Hospital	110	33
	2,660	2,004
– Non-Trade		
Beijing Children's Hospital, Capital Medical University	2,027	1,892
Chengdu Yunxi Ge Health Management Co., Ltd.	251	–
Ms. Zhao Juan	190	190
Zhuhai Yunzhong Equity Investment Limited Partnership	110	110
Mr. Jia Xiaofeng	14	14
Chengdu Wuhou New Century Joy City Clinic Outpatient Service Co., Ltd.	55	2
Tianjin Heping New Century Women's and Children's Hospital Co., Ltd.	3	–
Shenzhen Jardine Yihe Qiaoxiang out-patient department	2	–
Mr. Xu Han	1	1
Ms. Xin Hong	1	1
	2,654	2,210
	5,314	4,214

The amounts due from/to related parties are unsecured, interest-free except those loans to related parties as disclosed in note 34, and repayable on demand and denominated in RMB. Their carrying values as at 31 December 2021 and 2020 approximate their fair values.

15 BALANCES WITH RELATED PARTIES (CONTINUED)

As at 31 December 2021 and 2020, the aging analysis of the amounts due from related parties and amounts due to related parties which are trade in nature based on demand note date is as follows:

	As at 31 December	
	2021	2020
	RMB'000	*RMB'000*
Amounts due from related parties – trade in nature		
Within one year	5,298	8,580
1 year – 2 years	8,482	36,205
Over 2 years	128,131	96,927
	141,911	141,712
Amounts due to related parties – trade in nature		
Within one year	2,660	2,004

16 CASH AND CASH EQUIVALENTS

	As at 31 December	
	2021	2020
	RMB'000	*RMB'000*
Cash at banks	223,089	265,534
Cash on hand	754	1,052
Short term bank deposit	–	32,625
	223,843	299,211

Cash and cash equivalents are denominated in the following currencies:

	As at 31 December	
	2021	2020
	RMB'000	*RMB'000*
RMB	152,039	207,243
USD	66,756	79,043
HKD	5,048	12,925
	223,843	299,211

17 SHARE CAPITAL

	Number of ordinary shares	Nominal value of ordinary share *USD*
Authorized:		
At 31 December 2020 and 2021	500,000,000	50,000

	Number of ordinary shares	Nominal value of ordinary share *USD*	Equivalent nominal value of ordinary shares *RMB'000*
Issued and paid:			
As at 31 December 2020 and 2021	490,025,000	49,003	335

18 SHARES HELD FOR EMPLOYEE SHARE SCHEME

Pursuant to the board resolution on 28 August 2020, the Company repurchased shares of the Company to set up an employee stock incentive plan. As the 31 December 2021,the Company has repurchased 1,923,500 shares (as at 31 December 2020: 1,921,500 shares). These shares are held by the Company's Employee Share Trust (the "Trust") for the purpose of issuing shares under the Company's employee share scheme. Shares issued to employees are recognised on a first-in-first-out basis. As at 31 December 2021, there was no specific plan approved. Up to the date of this report, no shares were granted under the employee share scheme.

	Number of shares	Nominal value of ordinary share	Value of shares
		USD	*RMB'000*
Opening balance 1 January 2021	1,921,500	192	2,826
Acquisition of shares by the Trust	2,000	–*	3
Balance 31 December 2021	1,923,500	192	2,829

* The amount stated above was less than 1,000.

19 SHARE PREMIUM AND RESERVES

	Note	Share premium RMB'000	Reserves: Other reserves RMB'000	Merger reserve RMB'000	Statutory surplus reserve (a) RMB'000	Sub-total RMB'000
At 1 January 2020		2,606,262	(113,187)	(1,417,965)	23,479	(1,507,673)
Appropriation to statutory surplus reserves		–	–	–	5,873	5,873
Shares exercised under restricted share award scheme		233	(168)	–	–	(168)
Share-based payments	20	–	1,566	–	–	1,566
Translation difference		–	406	–	–	406
At 31 December 2020		2,606,495	(111,383)	(1,417,965)	29,352	(1,499,996)
At 1 January 2021		2,606,495	(111,383)	(1,417,965)	29,352	(1,499,996)
Appropriation to statutory surplus reserves		–	–	–	4,756	4,756
Translation difference		–	290	–	–	290
At 31 December 2021		2,606,495	(111,093)	(1,417,965)	34,108	(1,494,950)

(a) Statutory surplus reserve

In accordance with the PRC regulations and the articles of association of the companies now comprising the Group, before distributing the net profit of each year, companies registered in the PRC are required to set aside 10% of its statutory net profit for the year after offsetting any prior year's losses as determined under relevant PRC accounting standards to the statutory surplus reserve fund. When the balance of such reserve reaches 50% of each company's share capital, any further appropriation is optional. The statutory surplus reverse is appropriated for BNC Children's Hospital and Jiahua Yihe. Before 1 January 2014, the balance of the statutory surplus reserve from BNC Children's Hospital had reached 50% of the share capital, no statutory surplus reserve was appropriated in 2021 (2020: Nil). The statutory surplus reserves for Jiahua Yihe was RMB4,756,000 in 2021 (2020: RMB5,873,000).

20 SHARE-BASED PAYMENTS

RSA Scheme

On 29 August 2016, the shareholders of the Company approved a RSA Scheme. In accordance with the shareholders' approval, 9,000,000 ordinary shares (the "Restricted Shares") were allotted and issued at par value each to Talent Wise Investments Limited, a business company incorporated in the British Virgin Islands with limited liability, and the Restricted Shares were held on trust by the two shareholders of Talent Wise Investments Limited as trustee for the RSA Scheme. The two shareholders are the directors of the Company.

The purposes of the RSA Scheme are: (i) to provide any individual, being a director (including executive and non-executive director), employee, officer, agent or consultant of the Company or any other member of the Group, who is selected by the Administration Committee (as defined below) in accordance with the terms of and entitled to receive a grant under the RSA Scheme (the "Selected Participant"), with an opportunity to acquire a proprietary interest in the Company; (ii) to encourage and retain such individuals to work with the Group and provide additional incentive for them to achieve performance goals; and (iii) to attract suitable personnel for further development of the Group.

The RSA Scheme was managed by a sub-committee of the board of the Company, including the Chief Executive Officer, chairman of the remuneration committee and other senior management of the Company, delegated with the power and authority by the board to administer the RSA Scheme (the "Administration Committee") may stipulate at the time of selecting any person as a Selected Participant.

The criteria for determining Selected Participants, number of Restricted Shares and grant consideration and the other terms and conditions of the grants, the Administration Committee shall take into consideration matters including, but without limitation to, the present contribution and expected contribution of the relevant Selected Participants, the Group's general financial condition, overall business objectives and future development plan, the initial issue price of the shares held by the trustee, the net asset value per share as at the end of the financial year immediately before the date of the grant letter.

20 SHARE-BASED PAYMENTS (CONTINUED)

RSA Scheme (continued)

On 25 July 2017, the board of the Company announced that, 2 directors and 265 employees of the Group were granted Restricted Shares in respect of an aggregate of 9,000,000 shares. Subject to certain vesting conditions such as the service condition and non-market performance condition, the Restricted Shares shall be vested as the vesting schedule as follows:

(i) as to 17% of the Restricted Shares on 25 July 2017;

(ii) as to 23% of the Restricted Shares on 25 July 2018;

(iii) as to 30% of the Restricted Shares on 25 July 2019; and

(iv) as to the remaining 30% of the Restricted Shares on 25 July 2020.

Based on the closing price of HKD7.65 per share as quoted on The Stock Exchange of Hong Kong Limited on 25 July 2017, the exercise price of the Restricted Shares granted to the directors of the Company, and its employees was HKD3.825.

Restricted Shares was granted under the scheme are as follows:

	As at 31 December	
	2021	2020
Number of shares granted under the RSA Scheme	9,000,000	9,000,000

The directors have used the Binomial pricing model to determine the fair value of the Restricted Shares as at the grant date. Key assumptions, such as the risk-free interest rate and projections of staff turnover rate, are required to be determined by the directors with best estimates as follows:

	As at 25 July 2017	
	Employee	Executive
Fair market value per share as at valuation date (HKD)	7.65	7.65
Exercise price (HKD per share)	3.83	3.83
Risk free rate of interest	2.37%	2.37%
Dividend Yield	0.65%	0.65%
Life of RSA Scheme (years)	5.0	5.0
Volatility	40.00%	40.00%
Exercise multiple	2.2	2.8
Annual staff turnover rate	10.00%	0.00%

20 SHARE-BASED PAYMENTS (CONTINUED)

Total expenses arising from share-based payments transactions recognised during the period as part of employee benefit expense were as follows:

	Year ended 31 December	
	2021 *RMB'000*	2020 *RMB'000*
Shares issued under RSA Scheme *(note 26)*	–	1,566

Movements in the number of Restricted Shares for the years ended 31 December 2021 and 2020 are as follows:

	Year ended 31 December	
	2021	2020
As at 1 January	–	2,509,500
Exercised during the year	–	(19,500)
Forfeited during the year	–	(2,490,000)
As at 31 December	–	–
Vested and exercisable at 31 December	–	–

21 DIVIDENDS

The board of directors of the Company does not resolve to declare a dividend for the year ended 31 December 2021 (2020: nil).

For the year ended 31 December 2021, a dividend of RMB42,639,000 (2020: RMB43,353,000) was paid to BCH, a non-controlling shareholder of BNC Children's Hospital, a subsidiary of the Group.

22 TRADE PAYABLES

The ageing analysis, based on demand note date, of the trade payables is as follows:

	As at 31 December	
	2021 *RMB'000*	2020 *RMB'000*
Up to 3 months	20,138	17,909
4 – 6 months	5,099	3,941
7 months – 1 year	957	1,473
Over 1 year	1,254	2,295
	27,448	25,618

The carrying amounts of trade payables are denominated in RMB. The carrying amounts approximate their fair values due to their short-term maturities.

23 ACCRUALS, OTHER PAYABLES AND PROVISIONS

	As at 31 December	
	2021 *RMB'000*	2020 *RMB'000*
Accrued employee benefits	29,557	23,167
Refund liabilities (i)	103,531	98,164
Accrued operating expenses	21,144	19,509
Other payables to suppliers of plant and equipment	13,141	15,634
Dividend payable	2,642	2,642
Duty and tax payable other than corporate income tax	2,924	2,312
Others	12,482	9,755
	185,421	171,183

(i) Refund liabilities

When a customer has a right to obtain refundable prepayment for unused service package within a given period and their advanced deposit in relation to prepaid cards, the Group recognises a refund liability for the amount of consideration received. See note 2.22 regarding the accounting policy of refund liabilities.

24 DEFERRED INCOME TAX

The analysis of deferred income tax is as follows:

	As at 31 December	
	2021	2020
	RMB'000	*RMB'000*
Deferred tax assets:		
– Deferred tax assets to be recovered after more than 12 months	8,530	8,620
– Deferred tax assets to be recovered within 12 months	3,148	2,743
	11,678	11,363
Deferred tax liabilities:		
– Deferred tax liabilities to be recovered after more than 12 months	60,922	63,319
– Deferred tax liabilities to be recovered within 12 months	2,141	3,335
	63,063	66,654
Set-off of deferred tax assets pursuant to set-off provisions	(11,080)	(10,864)
Net deferred tax assets	598	499
Net deferred tax liabilities	51,983	55,790

24 DEFERRED INCOME TAX (CONTINUED)

The movement in deferred tax assets and liabilities during the year, without taking into consideration the offsetting of balances within the same tax jurisdiction, is as follows:

Deferred tax assets	Provision for receivables	Tax losses	Leases	Total
	RMB'000	*RMB'000*	*RMB'000*	*RMB'000*
At 1 January 2020	89	43,226	927	44,242
Credited/(charged) to the statement of comprehensive income	10	(32,423)	(466)	(32,879)
At 31 December 2020	99	10,803	461	11,363
At 1 January 2021	99	10,803	461	11,363
Credited/(charged) to the statement of comprehensive income	77	(132)	370	315
At 31 December 2021	176	10,671	831	11,678

The expiry date of tax losses is as follow:

	As at 31 December	
	2021	2020
	RMB'000	*RMB'000*
As at 31 December 2021	–	57,995
As at 31 December 2022	71,533	71,533
As at 31 December 2023	87,992	87,992
As at 31 December 2024	92,242	92,242
As at 31 December 2025	96,823	96,823
As at 31 December 2026	112,173	–
As at 31 December 2029	15,718	15,718
As at 31 December 2030	31,842	31,842
As at 31 December 2031	23,665	–
	531,988	454,145

24 DEFERRED INCOME TAX (CONTINUED)

The Group did not recognise deferred tax assets of RMB112,499,000 in 2021 (2020: RMB94,977,000) in respect of tax losses amounting to RMB489,305,000 (2020: RMB410,933,000) which can be carried forward against future taxable income.

The movement in deferred tax liabilities during the year, without taking into consideration the offsetting of balances within the same tax jurisdiction, is as follows:

Deferred tax liabilities	Intangible Assets *RMB'000*	Leases *RMB'000*	Total *RMB'000*
Balance at 1 January 2020	74,028	–	74,028
(Credited)/charged to the statement of comprehensive income	(7,632)	187	(7,445)
Acquisition of subsidiaries	71	–	71
Balance at 31 December 2020	66,467	187	66,654
Balance at 1 January 2021	66,467	187	66,654
Credited to the statement of comprehensive income	(3,473)	(118)	(3,591)
Balance at 31 December 2021	62,994	69	63,063

The tax rate for the recognition of deferred tax assets and deferred tax liabilities is 25% for the year ended 31 December 2021 (2020: 25%).

25 EXPENSES BY NATURE

	Year ended 31 December	
	2021	2020
	RMB'000	*RMB'000*
Employee benefits expenses *(note 26)*	322,489	263,789
Cost of inventories and consumables	101,222	78,475
Consultation fees	48,346	35,100
Depreciation and amortisation	86,621	94,788
Utilities, maintenance fee and office expenses	36,545	34,471
Outsourced examination and inspection fees	7,492	5,517
Rental expenses	3,095	2,421
Auditors' remuneration		
– Audit services	3,200	3,200
Other expenses	52,634	41,064
	661,644	558,825

26 EMPLOYEE BENEFIT EXPENSES

	Year ended 31 December	
	2021	2020
	RMB'000	*RMB'000*
Wages, salaries and bonuses	249,332	212,013
Welfare and other expenses	45,344	42,010
Pension costs – defined contribution plan	27,813	8,200
Share-based payments to directors and employees	–	1,566
	322,489	263,789

26 EMPLOYEE BENEFIT EXPENSES (CONTINUED)

(a) Contribution to a pension plan

The employees of the Group in the PRC are members of a state-managed pension scheme operated by the PRC Government. The Group is required to contribute a specified percentage of payroll costs as determined by local government authority to the pension obligations to fund the benefits. The only obligation of the Group with respect to the retirement benefits scheme is to make the specified contribution under the scheme. The Group did not have any forfeited contribution for the year ended 31 December 2021 and 2020 in connection with the defined contribution plan operated by local governments.

(b) Five highest paid individuals

The five individuals whose remunerations were the highest in the Group for the year include three (2020: three) directors whose emoluments are reflected in the analysis shown in note 38. The emoluments payable to the remaining two (2020: two) individuals during the year are as follows:

	Year ended 31 December	
	2021 *RMB'000*	2020 *RMB'000*
Basic salaries, housing allowance, share options, other allowance and benefits in kind	2,787	2,325
Contribution to pension scheme	53	8
Discretionary bonuses	424	429
	3,264	2,762

The number of highest paid non-director individuals whose remunerations fell within the following band is as follows:

	Number of individuals Year ended 31 December	
	2021	2020
Emolument bands (in HK dollar)		
HK$1,000,000 to HK$1,500,000	–	1
HK$1,500,000 to HK$2,000,000	1	1
HK$2,000,000 to HK$2,500,000	1	–
	2	2

During the years ended 31 December 2021 and 2020, no emoluments were paid by the Group to the five highest paid individuals as an inducement to join or upon joining the Group or as compensation for loss of office.

27 IMPAIRMENT LOSSES ON NON-CURRENT ASSETS

	Year ended 31 December	
	2021 *RMB'000*	2020 *RMB'000*
Impairment losses on property, plant and equipment *(note 6)*	15,010	–
Impairment losses on goodwill *(note 8)*	–	234,486
Impairment losses on other intangible assets *(note 8)*	–	19,479
Impairment losses on investments accounted for using the equity method *(note 10)*	–	10,306
	15,010	264,271

28 OTHER GAINS — NET

	Year ended 31 December	
	2021 *RMB'000*	2020 *RMB'000*
Gains on disposal of right-of-use assets	3,859	2,444
Gains on financial assets at FVPL	–	1,132
Bargain purchase of a subsidiary	–	744
Losses on disposal of intangible assets	(115)	–
Losses on disposal of property, plant and equipment	(584)	(341)
	3,160	3,979

29 FINANCE COSTS — NET

	Year ended 31 December	
	2021	2020
	RMB'000	*RMB'000*
Finance income		
Interest income	3,059	3,287
Finance costs		
Interest and finance charges paid/payable for lease liabilities	(13,902)	(15,787)
Interest expense on related party borrowings	(402)	–
Net foreign exchange losses	(2,349)	(7,540)
	(16,653)	(23,327)
Finance costs – net	(13,594)	(20,040)

30 INCOME TAX EXPENSE

	Year ended 31 December	
	2021	2020
	RMB'000	*RMB'000*
Current income taxation:		
– PRC corporate income tax	30,021	23,353
Deferred income tax *(note 24)*	(3,906)	25,434
	26,115	48,787

30 INCOME TAX EXPENSE (CONTINUED)

The taxation on the Group's profit before income tax differs from the theoretical amount that would arise using the standard taxation rate of the PRC, the principal place of the Group's operations, as follows:

	Year ended 31 December	
	2021 *RMB'000*	2020 *RMB'000*
Loss before income tax	(59,147)	(328,747)
Calculated at a taxation rate of 25%	(14,787)	(82,187)
Effects of different tax rates or income tax exemption applicable to different entities of the Group	5,726	7,046
Tax super deduction for research and development expenses	(1,190)	(2,713)
Income not subject to tax	–	(185)
Expenses not tax deductible	12	59,529
Tax effect of tax losses or temporary differences not recognised	34,080	35,853
Adjustment of deferred income tax arising in prior years	2,274	31,444
Income tax expense	26,115	48,787

(a) Cayman Islands income tax

The Company is incorporated in the Cayman Islands as an exempted company with limited liability under the Companies Law of Cayman Islands and accordingly, is exempted from Cayman Islands income tax.

(b) PRC Corporate Income Tax

Subsidiaries established and operating in Mainland China are subject to PRC corporate income tax at the rate of 25% except for New Century Healthcare Technology which has been eligible as a High and New Technology Enterprise since December 2019 with preferential tax rate of 15% as set out in PRC Corporate Income Tax Law.

(c) Hong Kong profits tax

Hong Kong profits tax rate is 16.5% for the years ended 31 December 2021 and 2020. No Hong Kong profit tax was provided for as there was no estimated assessable profit that was subject to Hong Kong profits tax during the years ended 31 December 2021 and 2020.

30 INCOME TAX EXPENSE (CONTINUED)

(d) Withholding tax

As at 31 December 2021, deferred tax liabilities of RMB26,543,400 (2020: RMB24,365,200) have not been recognised for the withholding tax that would be payable on the unremitted earnings of the PRC subsidiaries. Management expects to reinvest such amount in these subsidiaries in the foreseeable future. Unremitted earnings of these subsidiaries as at 31 December 2021 amounted to RMB265,434,000 (2020: RMB243,652,000).

31 LOSS PER SHARE

(a) Basic

Basic loss per share is calculated by dividing the loss attributable to owners of the Company by the weighted average number of ordinary shares in issue adjusted for bonus elements in ordinary shares issued during the year and excluding shares held for RSA scheme.

	Year ended 31 December	
	2021	2020
Loss attributable to owners of the Company (RMB'000)	(101,461)	(371,383)
Weighted average number of ordinary shares in issue (in thousands) (i)	483,334	485,126
Basic loss per share *(in RMB)*	(0.21)	(0.77)

The loss per share presented above is calculated by using the weighted average number of ordinary shares during the year ended 31 December 2021.

(i) On 25 July 2017, the Company granted 9,000,000 Restricted Shares to certain employees pursuant to a restricted share award scheme. As at 31 December 2021, except for 4,767,000 shares that were forfeited, all the other shares were vested. Those forfeited shares were excluded from the calculation of basic losses per share.

As at 31 December 2021, the Company held 1,923,500 (2020: 1,921,500) shares for employee share scheme of the Company to set up an employee stock incentive plan. These shares were not included in the calculation of basic loss per share as they are not outstanding.

(b) Diluted

For the years ended 31 December 2021 and 2020, diluted loss per share is equivalent to the basic loss per share due to the Group's negative financial results attributable to owners of the Company. There were no dilutive shares in 2021 while the Restricted Shares was anti-dilutive in 2020.

32 CASH FLOW INFORMATION

(a) Cash generated from operation

	Year ended 31 December	
	2021	2020
	RMB'000	*RMB'000*
Loss before income tax	(59,147)	(328,747)
Adjustments for:		
– Depreciation of property, plant and equipment *(note 6)*	30,173	34,618
– Amortisation *(note 8)*	15,067	16,320
– Depreciation of right-of-use assets *(note 7)*	41,381	43,850
– Share-based payments *(note 20)*	–	1,566
– Other gains – net *(note 28)*	(3,160)	(3,979)
– Finance costs — net *(note 29)*	13,594	20,040
– Impairment losses on investments accounted for using the equity method *(note 10)*	–	10,306
– Share of net loss/(profit) of investments accounted for using the equity method *(note 10)*	703	(54)
– Impairment losses on intangible assets *(note 8)*	–	253,965
– Provision for impairment of property, plant and equipment *(note 6)*	15,010	–
– Net impairment losses on financial assets	7,582	6,211
– Inventories	(1,558)	(3,888)
– Trade and other receivables	(11,979)	1,090
– Balances with related parties	(215)	(2,513)
– Trade and other payables	18,030	(10,750)
– Contract liabilities	(140)	(14,621)
– Deferred income	(2,641)	2,641
Cash generated from operations	62,700	26,055

32 CASH FLOW INFORMATION (CONTINUED)

(a) Cash generated from operation (Continued)

In the statements of cash flows, proceeds from sale of property, plant and equipment comprise:

	Year ended 31 December	
	2021 *RMB'000*	2020 *RMB'000*
Net book amount *(note 6)*	846	475
Loss on disposal of property, plant and equipment	(584)	(341)
Proceeds from disposal of property, plant and equipment	262	134

(b) Non-cash investing and financing activities.

Non-cash investing and financing activities include acquisition of right-of-use assets is disclosed in note 7.

32 CASH FLOW INFORMATION (CONTINUED)

(c) Reconciliation of financial liabilities arising from financing activities

	Amounts due to related parties RMB'000	Dividends payable RMB'000	Leases RMB'000	Total RMB'000
Financial liabilities as at 1 January 2020	(4,492)	(2,642)	(356,401)	(363,535)
Cash flows				
– net cash flows from financing activities	–	–	40,359	40,359
– net cash flows from operating activities	278	–	9,663	9,941
Acquisition of subsidiaries	–	–	(8,477)	(8,477)
Other changes (i)	–	–	(46,239)	(46,239)
Financial liabilities as at 31 December 2020	(4,214)	(2,642)	(361,095)	(367,951)
Cash flows				
– net cash flows from financing activities	–	–	37,201	37,201
– net cash flows from operating activities	(1,100)	–	10,220	9,120
Other changes (i)	–	–	33,433	33,433
Financial liabilities as at 31 December 2021	(5,314)	(2,642)	(280,241)	(288,197)

(i) For the year ended as at 31 December 2021, other changes also include addition, modification and foreign exchange differences to leases.

33 COMMITMENTS

(a) Capital commitments

The following is the details of capital expenditure contracted for but not recognised in the consolidated financial statements.

	As at 31 December	
	2021	2020
	RMB'000	*RMB'000*
Contracted but not provided for		
– Property, plant and equipment	446	3,290
– Intangible assets	–	1,433
	446	4,723

(b) Operating lease commitments

The Group leases certain office buildings under non-cancellable operating lease agreements.

The future minimum lease payables under non-cancellable operating leases contracted but not provided for at each year-end date are as follows:

	As at 31 December	
	2021	2020
	RMB'000	*RMB'000*
No later than 1 year	227	478

34 SIGNIFICANT RELATED PARTY TRANSACTIONS

(a) Parent entities

The Company is controlled by the following entities:

Name	Type	Place of incorporation	Ownership interest	
			2021	2020
JoeCare Investment Co., Ltd ("JoeCare")	Immediate parent entity	British Virgin Islands	30.78%	30.78%
Century Star Investment Co., Ltd ("Century Star")	Immediate parent entity	British Virgin Islands	1.84%	1.84%

Mr. Jason ZHOU directly held the interests of the Company through JoeCare and Century Star.

As at 31 December 2021, Ms. LIANG Yanqing held 11.78% (2020: 11.78%) interests of the Company through Victor Gains Limited, a company incorporated in the British Virgin Islands. Pursuant to the voting agreement signed on 18 February 2016, Ms. LIANG Yanqing irrevocably agreed to follow Mr. Jason ZHOU's voting directions when exercising the voting rights attached to the shares beneficially owned by her during the term of the voting agreement. Accordingly, Mr. Jason ZHOU was deemed as controlling shareholder of the Company through the power to control 44.40% of interest in the Company including the shares repurchased by Jason ZHOU from open capital market.

(b) Subsidiaries

Interest in subsidiaries are set out in note 9.

(c) Key management compensation

Key management includes directors and senior managements. The compensation paid or payable to key management for employee services is shown below:

	Year ended 31 December	
	2021 *RMB'000*	2020 *RMB'000*
Salaries and bonus	11,475	10,690
Share-based payments	–	479
Contribution to pension plans	263	168
Welfare and other expenses	585	867
Total	12,323	12,204

34 SIGNIFICANT RELATED PARTY TRANSACTIONS (CONTINUED)

(d) Transactions with related parties

Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Other parties are also considered to be related if they are subject to common control, common significant influence or joint control, controlling shareholder, members of key management and their close family member of the Group are also considered as related parties. The directors of the Company are of the view that the following parties that had transactions or balances with the Group are related parties:

Name	Relationship with the Group
Beijing Jiahua Likang Medical Investment and Management Co., Ltd. (北京嘉華麗康醫療投資管理有限公司)	The controlling shareholder of the Company has significant influence
Beijing Children's Hospital, Capital Medical University (首都醫科大學附屬北京兒童醫院)	Significant influence on the subsidiary of the Company
Beijing Muhe Jiaye Property Management Co., Ltd. (北京睦合嘉業物業管理有限公司)	Controlled by Ms. ZHAO Juan, the spouse of the controlling shareholder of the Company
Beijing Bairui Kangchen Technology Development Co., Ltd. (北京柏瑞康辰科技發展有限公司)	Controlled by a shareholder of the Company
Shanghai New Century Pujin Pediatric Clinic Outpatient Service Co., Ltd. (上海新世紀浦錦兒科門診部有限公司)	Controlled by a shareholder of the Company
Zhuhai Yunzhong Equity Investment Limited Partnership (珠海雲眾股權投資企業(有限合夥))	The general partner is key management of the Company
Chengdu Women's and Children's Central Hospital (成都市婦女兒童中心醫院)	Significant influence on the subsidiary of the Company
Chengdu Yunxi Ge Health Management Co., Ltd. (成都雲禧閣健康管理有限公司)	Significant influenced by the controlling shareholder of the Company
Tianjin Heping New Century Women's and Children's Hospital Co., Ltd. (天津和平新世紀婦兒醫院有限公司)	Significant influenced by the controlling shareholder of the Company
Foshan Shunde Yihe Clinic Co., Ltd. (佛山市順德怡和門診部有限公司)	Significant influenced by the controlling shareholder of the Company
Chengdu Wuhou New Century Joy City Clinic Outpatient Service Co., Ltd.(成都武侯新世紀大悦城門診部)	The controlling shareholder of the Company has significant influence
Shenzhen Jardine Yihe Qiaoxiang out-patient department(深圳市怡和僑香門診部)	Controlled by a shareholder of the Company

34 SIGNIFICANT RELATED PARTY TRANSACTIONS (CONTINUED)

(d) Transactions with related parties (Continued)

The following significant transactions were carried out between the Group and its related parties. In the opinion of the directors of the Company, the related party transactions were carried out in the normal course of business and at terms negotiated between the Group and the respective related parties.

	Year ended 31 December	
	2021 *RMB'000*	2020 *RMB'000*
Hospital consulting services provided to		
– Beijing Jiahua Likang Medical Investment and Management Co., Ltd.(i)	3,623	8,002
– Tianjin Heping New Century Women's and Children's Hospital Co., Ltd.	891	529
Medical services to		
– Chengdu Yunxi Ge Health Management Co., Ltd.	28	–
	4,542	8,531
Examination and laboratory test services received from		
– Beijing Children's Hospital, Capital Medical University	1,729	1,037
– Chengdu Women's and Children's Central Hospital	33	65
Purchase of goods from		
– Beijing Children's Hospital, Capital Medical University	1	290
Cleaning services received from		
– Beijing Muhe Jiaye Property Management Co., Ltd.	8,934	8,409
Confinement services received from		
– Chengdu Yunxi Ge Health Management Co., Ltd.	807	–
Lease of hospital premises		
– Chengdu Women's and Children's Central Hospital(ii)	10,000	8,500
	21,504	18,301

(i) Jiahua Yihe provided hospital consulting services to Jiahua Likang for its for-profit private hospitals outside Beijing. Under the arrangement, the hospital consulting services that Jiahua Yihe provides relate to brand licensing and authorizing use of management know-how, best practices for medical services and operations and the relevant know-how, professional development training systems and clinical experience exchange platform, procurement and supplier services support and information technology systems and support. Under the agreement, Jiahua Likang agrees to pay Jiahua Yihe a monthly base fix fee for each of its hospitals that receives Jiahua Yihe's specified services in the agreement. In addition, Jiahua Yihe provides other additional business operational and financial consultancy services upon request by Jiahua Likang from time to time at specified hourly rates.

(ii) Lease of hospital premises include the rental fee paid to Chengdu Women's and Children's Central Hospital.

34 SIGNIFICANT RELATED PARTY TRANSACTIONS (CONTINUED)

(e) Loans to related parties

	Year ended 31 December	
	2021 *RMB'000*	2020 *RMB'000*
Loans to other related parties		
Beginning of the period	24,830	20,289
Loans advanced	2,850	3,400
Interest expense	1,131	1,141
End of the period	28,811	24,830
Less: provision for impairment	(6,184)	–
	22,627	24,830

On 30 April 2019, Jiahua Yihe entered into a credit facility agreement with Beijing Bairui Kangchen Technology Development Co., Ltd. ("Bairui Kangchen"), a related party controlled by a shareholder of the Company. Pursuant to the agreement, Jiahua Yihe agreed to provide a loan credit line amounting to RMB20,000,000 to Bairui Kangchen with an annual interest rate at 4.75%. Bairui Kangchen has pledged its share interests in Shanghai New Century Pujin Pediatric Clinic Outpatient Service Co., Ltd. and Shenzhen New Century Healthcare Investment Co., Ltd. to Jiahua Yihe as collateral for the loans.

On 1 August 2020, Jiahua Yihe entered into a supplementary agreement with Bairui Kangchen to increase the loan credit line to RMB24,250,000 and Bairui Kangchen committed to repay all the loans before 1 September 2022.

(f) Year-end balances arising from sales/purchases of services

Balances with related parties as at 31 December 2021 and 2020 were disclosed in note 15.

(g) Provision of premises by a related party

The Group has established BNC Children's Hospital based on a public-private-partnership arrangement with BCH, a public hospital in Beijing, the PRC. Pursuant to the cooperation agreement in 2002, BCH has agreed to provide premises on its allocated land for the business operation of BNC Children's Hospital without extra payments to each other. The term of the cooperation with BCH lasts until 12 December 2022.

35 CONTINGENCIES

The Group has been named defendants in a number of lawsuits arising in the ordinary course of business. Provision will be made for the probable losses to the Group on those claims when management can reasonably estimate the outcome of the lawsuits taking into account of the legal advice.

36 EVENT OCCURRING AFTER REPORTING PERIOD

Acquisition of 12.47% of equity interest of Beijing Jiahua Yongsheng Medical Investment Management Co.,Ltd. ("Jiahua Yongsheng")

On 29 January 2022, the Company's wholly-owned subsidiary, Jiahua Yihe has entered into a sale and purchase agreement with Jiahua Likang and Jiahua Yongsheng (the "Sale and Purchase Agreement"), pursuant to which Jiahua Yihe has conditionally agreed to purchase, and Jiahua Likang has conditionally agreed to sell, the 12.47% of equity interest of Jiahua Yongsheng for a cash consideration of RMB18,700,000.

The consideration of RMB18,700,000 was determined after arm's length negotiation between Jiahua Yihe and Jiahua Likang and on normal commercial terms with reference to the valuation of the entire equity interest of Qingdao New Century Women's and Children's Hospital Co., Ltd. ("Qingdao New Century") as appraised by a reputable qualified independent valuer. Qingdao New Century is wholly owned by the Jiahua Yongsheng.

The completion of this acquisition is conditional upon the satisfaction of certain conditions precedent: the shareholders' meeting of Jiahua Yongsheng having passed a resolution to approve the acquisition; and the change of industrial and commercial registration having been completed pursuant to the laws, regulations, and other relevant provisions of the PRC, while Jiahua Yongsheng continuing to operate normally after the change.

Upon the completion of this acquisition, the Company will indirectly hold 12.47% of equity interest in the Jiahua Yongsheng, which will become an affiliate of the Group. As at the reporting date, the registration for the acquisition with the relevant Administration for Market Regulation in the PRC has not been completed.

37 BALANCE SHEET AND RESERVE MOVEMENT OF THE COMPANY

Balance sheet of the Company

	Note	As at 31 December 2021 RMB'000	2020 RMB'000
ASSETS			
Non-current assets			
Investment in subsidiaries		1,766,431	1,766,431
Investments accounted for using the equity method		1,809	2,575
Total non-current assets		1,768,240	1,769,006
Current assets			
Cash and cash equivalents		1,529	6,542
Other receivables, deposits and prepayments		639	707
Amounts due from subsidiaries		748,382	750,855
Total current assets		750,550	758,104
Total assets		2,518,790	2,527,110
EQUITY			
Equity attributable to owners of the Company			
Share capital		335	335
Shares held for employee share scheme		(2,829)	(2,826)
Share premium		2,606,495	2,606,495
Reserves	37(a)	(85,526)	(85,463)
Accumulated losses	37(a)	(30,102)	(20,487)
Total equity		2,488,373	2,498,054
LIABILITIES			
Current liabilities			
Amounts due to subsidiaries		26,828	26,508
Accruals, other payables and provisions		3,589	2,548
Total current liabilities		30,417	29,056
Total liabilities		30,417	29,056
Total equity and liabilities		2,518,790	2,527,110

The balance sheet of the Company was approved by the Board of Directors on 28 March 2022 and signed on its behalf:

Jason ZHOU *XU Han*

37 BALANCE SHEET AND RESERVE MOVEMENT OF THE COMPANY (CONTINUED)

(a) Accumulated losses and reserve movement of the Company

	Accumulated losses *RMB'000*	Reserves *RMB'000*
At 1 January 2020	(3,081)	(86,702)
Total comprehensive loss		
– Loss for the year	(17,406)	–
– Other comprehensive loss	–	(159)
Shares exercised under share awards scheme	–	(168)
Share-based payments	–	1,566
At 31 December 2020	(20,487)	(85,463)
Total comprehensive loss		
– Loss for the year	(9,615)	–
– Other comprehensive loss	–	(63)
At 31 December 2021	(30,102)	(85,526)

38 BENEFITS AND INTERESTS OF DIRECTORS

(a) Directors and chief executive emoluments

The remuneration of each director and the chief executive is set out below:

For the year ended 31 December 2021	Fees RMB'000	Salaries RMB'000	Share-based payments RMB'000	Discretionary bonuses RMB'000	Housing allowance RMB'000	Welfare and other expenses RMB'000	Contribution to a pension plan RMB'000	Total RMB'000
Executive directors								
Mr. Jason ZHOU (i)	–	1,990	–	–	–	–	–	1,990
Mr. XU Han	–	1,044	–	416	40	37	53	1,590
Ms. XIN Hong	–	1,044	–	416	40	37	53	1,590
	–	4,078	–	832	80	74	106	5,170
Independent non-executive directors								
Mr. WU Guanxiong	100	–	–	–	–	–	–	100
Mr. SUN Hongbin	100	–	–	–	–	–	–	100
Mr. JIANG Yanfu	100	–	–	–	–	–	–	100
Dr. MA Jing	100	–	–	–	–	–	–	100
	400	–	–	–	–	–	–	400
	400	4,078	–	832	80	74	106	5,570

38 BENEFITS AND INTERESTS OF DIRECTORS (CONTINUED)

(a) Directors and chief executive emoluments (Continued)

For the year ended 31 December 2020	Fees RMB'000	Salaries RMB'000	Share-based payments RMB'000	Discretionary bonuses RMB'000	Housing allowance RMB'000	Welfare and other expenses RMB'000	Contribution to a pension plan RMB'000	Total RMB'000
Executive directors								
Mr. Jason ZHOU (i)	–	1,791	–	–	–	–	–	1,791
Mr. XU Han	–	975	100	429	40	61	32	1,637
Ms. XIN Hong	–	972	100	429	40	61	32	1,634
	–	3,738	200	858	80	122	64	5,062
Independent non-executive directors								
Mr. WU Guanxiong	100	–	–	–	–	–	–	100
Mr. SUN Hongbin	100	–	–	–	–	–	–	100
Mr. JIANG Yanfu	100	–	–	–	–	–	–	100
Dr. MA Jing	100	–	–	–	–	–	–	100
	400	–	–	–	–	–	–	400
	400	3,738	200	858	80	122	64	5,462

(i) Jason ZHOU is also the chief executive.

On 31 July 2015, the Company appointed Mr. Jason ZHOU as the directors. On 18 February 2016, the Company appointed Mr. XU Han and Ms. XIN Hong as the directors.

As at 31 December 2021, Mr. WANG Siye, Mr. GUO Qizhi, Mr. YANG Yuelin, Dr. CHENG Chi-Kong and Mr. XIE Qiang were the non-executive directors ("NED") of the Company. During the year ended 31 December 2021, neither emoluments were paid by the Group to the NED nor consideration were paid to the third parties for making available directors' services.

During the years ended 31 December 2021 and 2020, no emoluments were paid by the Group to directors as an inducement to join or upon joining the Group or as compensation for loss of office.

38 BENEFITS AND INTERESTS OF DIRECTORS (CONTINUED)

(b) Directors' retirement and termination benefits

None of directors received any retirement and termination benefits during the year ended 31 December 2021 (2020: nil).

(c) Consideration provided to third parties for making available directors' services

The Group did not pay consideration to any third parties for making available directors' services during the year ended 31 December 2021 (2020: nil).

(d) Information about loans, quasi-loans and other dealings in favour of directors, controlled bodies corporate by and connected entities with such directors

There is no other loans, quasi-loans and other dealings in favour of directors, controlled bodies corporate by and connected entities with such directors during the year ended 31 December 2021 (2020: nil).

(e) Directors' material interests in transactions, arrangements or contracts

No significant transactions, arrangements and contracts in relation to the Group's business to which the Company was a party and in which a director of the Company had a material interest, whether directly or indirectly, subsisted at the end of the year or at any time for the year ended 31 December 2021 (2020: nil).

Financial Summary

	For the year ended December 31,				
	2021	2020	2019	2018	2017
	RMB'000	*RMB'000*	*RMB'000*	*RMB'000*	*RMB'000*
Revenue	632,565	512,785	729,369	615,984	536,460
Profit before income tax	(59,147)	(328,747)	48,065	119,276	159,918
Income tax expense	(26,115)	(48,787)	(43,572)	(45,838)	(45,031)
Total comprehensive income	(84,972)	(377,128)	4,493	73,438	114,887
Total comprehensive income attributable to:					
– Owners of the Company	(101,171)	(370,977)	(26,556)	41,514	73,493
– Non-controlling interests	16,199	(6,151)	31,049	31,924	41,394

	As of December 31,				
	2021	2020	2019	2018	2017
	RMB'000	*RMB'000*	*RMB'000*	*RMB'000*	*RMB'000*
Total assets	1,270,896	1,471,045	1,876,668	1,611,024	1,441,935
Total liability	586,658	659,193	643,140	339,680	203,498
Total equity	684,238	811,852	1,233,528	1,271,344	1,238,437
Equity attributable to:					
– Owners of the Company	737,459	838,633	1,210,805	1,237,508	1,193,645
– Non-controlling interests	(53,221)	(26,781)	22,723	33,836	44,792

Definitions

"2016 Management Consulting Services Agreement"	the management consulting services agreement entered into between Jiahua Yihe and Jiahua Likang on June 1, 2016;
"AGM"	annual general meeting of the Company;
"Articles of Association"	the articles of association of the Company adopted on December 22, 2016 which became effective on the Listing Date, as amended from time to time;
"Audit Committee"	the audit committee of the Board;
"BCH"	Beijing Children's Hospital, Capital Medical University (首都醫科大學附屬北京兒童醫院), a connected person of the Company on the subsidiary level only due to its 35.0% interest in BNC Children's Hospital;
"BNC Ao-dong Clinic"	Beijing New Century Ao-dong Clinic Outpatient Service Co., Ltd. (北京新世紀奧東門診部有限公司), formerly known as Beijing Meihua Women and Children Clinic Co., Ltd. (北京美華婦兒門診部有限公司), a company incorporated in the PRC with limited liability on May 15, 2014, which is a wholly-owned subsidiary of the Company;
"BNC Chaowai Clinic"	The First Branch of Beijing New Century Yide Consultancy Co. Ltd. (北京新世紀怡德諮詢有限公司第一分公司), formerly known as Beijing New Century Yide Chaowai Clinic of Beijing New Century Yide Consultancy Co., Ltd. (北京新世紀怡德諮詢有限公司新世紀怡德朝外診所). Beijing New Century Yide Consultancy Co., Ltd. (北京新世紀怡德諮詢有限公司), formerly known as Renze (Beijing) International Corporation Management and Service Co., Ltd. (仁澤(北京)國際企業管理服務有限責任公司), is a company incorporated in the PRC with limited liability on October 27, 2014, which is a wholly-owned subsidiary of the Company;
"BNC Children's Hospital"	Beijing New Century Children's Hospital Co., Ltd. (北京新世紀兒童醫院有限公司), a company incorporated in the PRC with limited liability on December 13, 2002, which is a non-wholly-owned subsidiary of the Company;
"BNC Harmony Clinic"	Beijing New Century Ronghe Outpatient Service Co., Ltd. (北京新世紀榮和門診部有限公司), a company incorporated in the PRC with limited liability on May 30, 2012, which is a wholly-owned subsidiary of the Company;
"BNC Qingnian Road Clinic"	Beijing New Century Qingnian Road Pediatric Clinic Co., Ltd. (北京新世紀青年路兒科診所有限公司), a company incorporated in the PRC with limited liability, which is a wholly-owned subsidiary of the Company;

"BNC Wenyu Clinic"	Beijing New Century Wenyu Clinic Outpatient Service Co., Ltd. (北京新世紀溫榆門診部有限公司), a company incorporated in the PRC with limited liability, which is a wholly-owned subsidiary of the Company;
"BNC Women's and Children's Hospital"	Beijing New Century Women's and Children's Hospital Co., Ltd. (北京新世紀婦兒醫院有限公司), a company incorporated in the PRC with limited liability on January 4, 2012, which is a wholly-owned subsidiary of the Company;
"Board" or "Board of Directors"	the board of Directors of the Company;
"BVI"	the British Virgin Islands;
"Century Star"	Century Star Investment Co., Ltd., a company incorporated in the BVI with limited liability on August 14, 2015 and is wholly-owned by Mr. Zhou;
"CG Code"	Corporate Governance Code as set out in Appendix 14 to the Listing Rules;
"Chengdu New Century Women's and Children's Hospital"	Chengdu New Century Women's and Children's Hospital Co., Ltd. (成都新世紀婦女兒童醫院有限公司), a company incorporated in the PRC with limited liability, which is a non-wholly-owned subsidiary of the Company;
"Chengdu Women's and Children's Central Hospital"	Chengdu Women's and Children's Central Hospital (成都市婦女兒童中心醫院), a not-for-profit public hospital owned and managed by Chengdu Bureau of Hospital Administration;
"China" or "PRC"	the People's Republic of China; for the purpose of this annual report only, references to "China" or the "PRC" do not include Taiwan, the Macau Special Administrative Region and Hong Kong;
"Company"	New Century Healthcare Holding Co. Limited (新世紀醫療控股有限公司), a company incorporated in the Cayman Islands with limited liability on July 31, 2015, the Shares of which are listed on the Main Board of the Stock Exchange;
"Controlling Shareholder(s)"	Mr. Zhou, JoeCare and Century Star;
"Director(s)"	director(s) of the Company;

Definitions (Continued)

"Economic Benefits"	all the economic rights and benefits and other similar rights attaching or accruing to (i) the 100% equity interest in Jiahua Kangming held by Ms. Zhao and Ms. ZHOU Jie, and (ii) the 30% equity interest in each of BNC Women's and Children's Hospital and BNC Harmony Clinic held by Jiahua Kangming, on or after the completion of the transactions contemplated under the VIE Acquisition Agreement, to the extent permitted under the applicable laws and regulations;
"Employee Share Scheme"	the restricted share award scheme approved and adopted by the Company on August 28, 2020;
"GMP Certificate"	Certificate of Good Manufacturing Practices for Pharmaceutical Products;
"Group", "our Group", "we" or "us"	the Company and its subsidiaries;
"GSP Certificate"	The Good Supply Practices for Pharmaceutical Products Certificate;
"HKEx"	Hong Kong Exchanges and Clearing Limited;
"Hong Kong" or "HK"	the Hong Kong Special Administrative Region of the PRC;
"HKFRS"	Hong Kong Financial Reporting Standards;
"HK$" or "HKD"	Hong Kong dollars, the lawful currency of Hong Kong;
"Independent Third Party(ies)"	any individual(s) or entity(ies) who, as far as our Directors are aware, is/are not connected with the Company or the connected persons of the Company within the meaning ascribed under the Listing Rules;
"IPO"	initial public offering of Shares and listing of the Group on the Stock Exchange on the Listing Date;
"Jiahua Kangming"	Beijing Jiahua Kangming Medical Investment and Management Co., Ltd. (北京嘉華康銘醫療投資管理有限公司), a company incorporated in the PRC with limited liability on December 18, 2015 and is a connected person of the Company;
"Jiahua Likang"	Beijing Jiahua Likang Medical Investment and Management Co., Ltd. (北京嘉華麗康醫療投資管理有限公司), a company incorporated in the PRC with limited liability on April 16, 2009, and is a connected person of the Company;

Definitions (Continued)

"Jiahua Yihe"	Beijing Jiahua Yihe Management and Consulting Co., Ltd. (北京嘉華怡和管理諮詢有限公司), a company incorporated in the PRC with limited liability on June 15, 2015 and wholly-owned by the Company;
"Jiahua Yihe Hospitals"	Hospitals, clinics and/or other medical institutions owned, operated, invested and/or managed by Jiahua Yihe at the relevant time (including any future time during the term of the Framework Property Management and Cleaning Services Agreement) or, where the context so requires, any of them;
"Likang Hospitals"	Hospitals, clinics and/or other medical institutions owned, operated, invested, and/or managed by Jiahua Likang at the relevant time (including any future time during the term of the Framework Management Consulting Services Agreement) or, where the context so requires, any of them;
"JoeCare"	JoeCare Investment Co., Ltd., a company incorporated in the BVI with limited liability on July 16, 2015 and wholly-owned by Mr. Zhou. JoeCare is one of our Controlling Shareholders;
"Latest Practicable Date"	March 28, 2022
"Listing"	the listing of the Shares on the Main Board of the Stock Exchange;
"Listing Date"	the date on which dealings in the Shares first commenced on the Stock Exchange, i.e. January 18, 2017;
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange, as amended and supplemented from time to time;
"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers contained in Appendix 10 to the Listing Rules;
"Mr. Zhou"	Mr. Jason ZHOU, Chairman of the Board, chief executive officer, an executive Director and one of our Controlling Shareholders;
"Ms. Liang"	Ms. LIANG Yanqing (梁艷清), one of our substantial Shareholders;
"Ms. Zhao"	Ms. ZHAO Juan (趙娟), the spouse of Mr. Zhou;
"Muhe Jiaye"	Beijing Muhe Jiaye Property Management Co., Ltd. (北京睦合嘉業物業管理有限公司), a company incorporated in the PRC with limited liability, a connected person of the Company;

Definitions (Continued)

"Nomination Committee"	the nomination committee of the Board;
"Operating Medical Institutions"	BNC Children's Hospital, BNC Women's and Children's Hospital, BNC Harmony Clinic, BNC Wenyu Clinic, BNC Ao-dong Clinic and Chengdu New Century Women's and Children's Hospital;
"Prospectus"	the prospectus dated December 30, 2016 issued by the Company;
"Remuneration Committee"	the remuneration committee of the Board;
"RMB"	Renminbi, the lawful currency of the PRC;
"RSA Scheme"	the restricted share award scheme approved and adopted by the Company on August 29, 2016;
"SFO"	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time;
"Shares(s)"	ordinary share(s) of US$0.0001 each in the issued capital of the Company or if there has been a subsequent sub-division, consolidation, reclassification or reconstruction of the share capital of the Company, shares forming part of the ordinary equity share capital of the Company;
"Shareholder(s)"	holder(s) of the Share(s);
"State Council"	State Council of the PRC (中華人民共和國國務院);
"Stock Exchange"	The Stock Exchange of Hong Kong Limited;
"Subsidiaries"	has the meaning ascribed to it in section 2 of the Companies (Winding Up and Miscellaneous Provisions) Ordinance;
"Tier 1 Cities"	Beijing, Shanghai, Guangzhou and Shenzhen or, where the context so requires, any of them;
"Victor Gains"	Victor Gains Limited, a company incorporated in the BVI with limited liability on February 2, 2010 and wholly-owned by Ms. Liang, and one of our substantial shareholders;

Definitions (Continued)

"Voting Agreement"	an agreement entered into between Mr. Zhou and Ms. Liang on February 18, 2016 and renewed on February 17, 2019 and subsequently automatically renewed on February 17, 2022 (pursuant to a renewal agreement entered into between the same parties on March 23, 2022) for a renewed term of three years until February 17, 2025, pursuant to which Ms. Liang irrevocably agreed to follow Mr. Zhou's voting directions when exercising the voting rights attached to the Shares beneficially owned by her during the term of such agreement;
"YoY"	year-on-year; and
"%"	percent.

In this annual report, the terms "associate", "connected person", "connected transaction", "controlling shareholder", "subsidiary" and "substantial shareholder" shall have the meanings given to such terms in the Listing Rules, unless the context otherwise requires.